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ABSTRACT 
EPIGENETIC MODIFICATION OF VITAMIN D-INDUCED GENE 
EXPRESSION IN HUMAN COLORECTAL AND BREAST CANCER CELL 
LINES 
MAY 2018 
 
SHARMIN HOSSAIN, B.S., UNIVERSITY OF DHAKA 
 
M.S., UNIVERSITY OF DHAKA 
 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Professor Richard J. Wood 
 
Epigenetics is the study of the regulation of genes that is not dependent on 
nucleotide sequence. This may include heritable changes in gene activity and expression 
but also those that are not heritable. In recent years, epigenetic researchers have made great 
strides in understanding the molecular mechanisms behind cellular functions in response 
to diet, exercise, and other lifestyle modifications, like methylation, histone modification 
etc. It is now known that the epigenome is critical to healthy human development in 
addition to genetics, and dietary factors can modulate epigenetic alterations in cells.  
The classic view of cancer etiology is that genetic alterations damage DNA 
structure and induce mutated proteins (oncogenes) that lead to disease progression. More 
recently, the role of epigenetic alterations during development and chronic disease 
development has gained increasing attention. This caused a paradigm shift in our 
understanding of possible mechanisms leading to disease susceptibility. Epidemiological 
studies have revealed an inverse correlation between the intake of cruciferous vegetables 
and the risk of certain types of cancer [1]. There has also been evidence, from various 
epidemiological studies, of higher intake or blood levels of vitamin D and its association 
with a reduced risk of colorectal and breast cancer [2]. Thus, there is evidence that both 
higher intake of cruciferous vegetable and better vitamin D status are associated with a 
reduced risk of cancer. The primary focus of my dissertation is the manipulation of histone 
modification via dietary agents like vitamin D and sulforaphane in human colorectal and 
breast cancer cell lines with a review of current literature focusing on vitamin D and breast 
cancer.   
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CHAPTER 1 
 
 INTRODUCTION 
1.1 Overview 
Although there is some evidence that vitamin D may have a protective role in 
preventing colorectal cancer, existing literature marginally supports the preventive 
potential of vitamin D in other malignancies, like breast cancer, with the exception of 
possible benefits of vitamin D supported by genetic data in bladder and prostate cancer [3]. 
Epidemiological studies have shown that a high level of consumption of cruciferous 
vegetables such as broccoli, Brussel sprouts etc. is associated with a reduced risk of certain 
human cancers [4] and is attributable to certain bioactive phytochemicals, such as, 
isothiocyanates (ITCs) found at relatively high levels in these vegetables. Sulforaphane 
(SFN), derived from glucosinolates in cruciferous vegetables, is an ITC found to be more 
potent than other major glucosinolates and ITCs with proposed anticancer effects [5].  
1.2 Statement of Problem 
 
The question if vitamin D has a role in cancer incidence, progression, and mortality 
has been studied in detail for over two decades. Specific focus has been on colorectal, 
breast, and prostate cancers since these three malignancies account for approximately 35% 
of total cancer cases and 20% of cancer deaths in the United States. While vitamin D status 
has been reported to have an inverse association with colorectal cancer (CRC) incidence 
and mortality; findings in breast cancer (BC) patients suggested a lower risk for progression 
and mortality with higher serum 25- hydroxyvitamin D3 [25(OH)D3], a biomarker of 
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vitamin D status [3]. 25(OH) D3 is a pro-hormone form of vitamin D produced in the liver 
and is considered the most reliable indicator of vitamin D status. 25(OH) D3 is then 
converted to 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], the hormonally active form of 
vitamin D, in the kidneys. There are several enzymes involved in this process and will be 
discussed in greater detail to elucidate D action in the subsequent chapters.  
Although, observational studies show positive outcomes between vitamin D and 
BC, randomized clinical trials have generally failed to support these associations, to date. 
The current literature provides conflicting findings regarding the vitamin D action in 
cancer. Due to these inconsistencies, it is difficult to ascertain if vitamin D (the active form) 
is related to a direct reduction in cancer risk, or to what extent higher concentrations of 
vitamin D status biomarker, serum 25(OH) D3 serve as a surrogate for an overall healthier 
lifestyle and lower cancer risk in population studies [6]. 
The important role of active vitamin D compounds in various cancer cell types, 
including malignant breast cells, by inducing cellular differentiation, inhibition of cell 
growth and cell death via apoptosis is well-established [7-10]. While, dietary intake of 
vitamin D has been inconsistently linked to breast cancer risk, studies considering the 
association of breast cancer risk and sun exposure as a proxy of endogenous vitamin D 
synthesis, have observed inverse associations[11, 12].  
Isothiocyanates (ITCs) are naturally occurring secondary metabolites of cruciferous 
vegetables. Glucosinolates in cruciferous vegetables are converted to ITCs upon hydrolysis 
by the enzyme myrosinase [13]. These ITCs, predominantly sulforaphane, have been 
reported to possess chemopreventive and chemotherapeutic effects both in vitro and in vivo 
[14]. Rigorous SFN research is now focused on its anti-carcinogenic roles considering the 
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growing body of evidence, although it was first identified as a potent inducer of phase 2 
detoxification enzyme[15, 16].  
 Epigenetic changes, which can be triggered by various dietary components can 
cause heritable changes in the DNA structure and chromatin complex without disrupting 
the actual coding sequence of the DNA. In other words, epigenetics focuses on modifying 
the DNA (gene expression) via external agents, such as vitamins, minerals, phytochemicals 
etc. that do not change the primary DNA sequence. Histone protein modification in the 
chromatin structure and DNA methylation are two key epigenetic mechanisms studied in 
cancer. Epigenetic effects of SFN has been linked predominantly to post-translational 
histone modification processes. Histone deacetylase (HDAC) inhibition by SFN in human 
colon and prostate cancer cells in vitro were supported by in vivo experiments in humans, 
and was similar in preclinical models of gastrointestinal and prostate cancer [17]. HDACs 
remove acetyl groups from DNA and affect transcription which can result in silencing 
numerous important tumor suppressor genes. SFN has several known biochemical 
properties, including activation of antioxidant enzymes via Nrf2 transcription factor 
activation, altering phase I and II detoxification enzymes, and inhibition of HDAC activity 
[16, 18-21]. By inhibiting the HDAC action, sulforaphane can reverse epigenetically 
silenced genes in cancer cells, resulting in cell cycle arrest and/or apoptosis [18, 22].  
  Despite numerous studies demonstrating the anti-cancer effects of various ITCs, 
the exact mechanism of SFN action is still unclear and requires further attention. There is 
also not enough information on how sulforaphane works particularly in colorectal and 
breast cancers on a molecular level.
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CHAPTER 2 
 
LITERATURE REVIEW 
 
Vitamin D deficiency is considered a pandemic because of its widespread presence 
in  all age groups and in nearly all geographical regions [3]. It is a culmination of lifestyle 
changes in the modern societies that involve a decrease in time spent outdoors, widespread 
use of sunscreens, and air pollution which contribute to insufficient exposure to sunlight, 
and thus reduced skin synthesis of vitamin D. Other factors that notably increase the risk 
of vitamin D deficiency are: aging of populations and the resulting decline of vitamin D 
synthesis in the skin, low intake of vitamin D with the diet, and the obesity epidemic. In 
the absence of sufficient sun exposure to maintain adequate vitamin D status, an alternative 
way to get adequate vitamin D is through certain foods or vitamin D supplements.  
Historically speaking, vitamin D recommendation for adults of 5 μg/d (200 IU/d) 
vitamin D was considered adequate to prevent osteomalacia (adult vitamin D deficiency) 
in the absence of sunlight. But more was needed to help prevent osteoporosis and secondary 
hyperparathyroidism. Later on, other health benefits of vitamin D supplementation were 
suggested to accrue based on observations from epidemiological studies, such as: 
prevention of some cancers and reduced risks of multiple sclerosis and hypertension [23]. 
In 2011, the US Institute of Medicine (IOM) established a Dietary Reference Intake (DRI) 
for vitamin D across all age groups, considering newer research findings since 1997, the 
previous estimate of vitamin D needs of the population. Based on this review of the 
evidence, the IOM has tripled the recommended daily intakes of vitamin D to 15 µg (600 
IU) per day for people aged 1-70 years, and increased to 20 µg (800 IU) per day for those 
older than 70 years [24]. The recommendation for dietary Vitamin D is based on how much 
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is needed to achieve a serum 25(OH)D of 20 ng/ml (50 nmol/L) in 97.5% of the population. 
A serum 25(OH)D concentration of 20 ng/mL to 50 ng/mL (50nM- 125nM) is considered 
adequate for healthy people. A level less than 20 ng/mL indicates vitamin D deficiency. 
However, some researchers recommend maintaining serum 25(OH)D3 levels of 30 ng/mL 
(75 nmol/L) may be needed to prevent chronic diseases like cancer, but this has not been 
sanctioned by the IOM due to lack of sufficient evidence. In the 2000–2004 NHANES 
cycle, 78% of Americans had a serum 25(OH)D3 less than 30ng/ml [25]. 
2.1 Synthesis and Metabolism of Vitamin D 
The metabolism of vitamin D is complex and involves several different enzymes 
and organs. In humans with adequate sun exposure, vitamin D3 (cholecalciferol) is formed 
from cutaneous 7-dehydrocholesterol (7-DHC) synthesized in the basal layer of the 
epidermis. Initially, the β-ring of 7-DHC undergoes photolysis upon the exposure of skin 
to UV-B radiation, leading to the formation of pre-vitamin D3 that non-enzymatically is 
converted to vitamin D and then transferred into the blood[26]. Subsequent activation of 
vitamin D3 involves sequential 25- and 1-α-hydroxylations of vitamin D3 in the liver and 
kidney, respectively. In the liver, vitamin D3 is hydroxylated by 25-hydroxylase to 25-
hydroxyvitamin D3 also known as 25-hydroxycholecalciferol or abbreviated as 25(OH)D3 
[27]. 25(OH)D3 is then hydroxylated a second time in the kidneys by mitochondrial 1α-
hydroxylase (CYP27B1) producing 1,25(OH)2D3 (calcitriol), the hormonal  form of 
vitamin D, that can activate the vitamin D receptor [27]. Several tissues and organs, such 
as the intestines and skin, can also activate vitamin D through these two-sequential 
enzymatic hydroxylations [28], but liver and kidney are the primary sites of regulation. The 
activity of 25(OH)D3 and 1,25(OH)2D3 is counteracted by the enzyme 24-hydroxylase 
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(CYP24A1), which transforms them to the inactive vitamin D metabolites 
24,25(OH)2D3 and 1,24,25(OH)3D3, respectively, prior to further oxidation and cleavage 
of the side chain resulting in complete inactivation and eventual elimination from the 
body[29]. Both 24,25(OH)2D3 and 1,24,25(OH)3D3 possess significantly lower affinity for 
the vitamin D receptor (VDR) than 1,25(OH)2D3 [30]. This property is important when 
considering molecular functions of vitamin D.  
2.2 Dietary sources of Vitamin D 
A well-balanced diet with a high vitamin D content can help maintain adequate 
vitamin D in our system in the absence of cutaneous sunlight exposure. However, only a 
relatively few foods naturally provide substantial amounts of vitamin D. There are a couple 
of dietary products that are rich in vitamin D, e.g.: fish oils, sea fish etc. Fortified products 
are an important dietary source of vitamin D in the US. One cup of milk contains 
approximately 50 IU of vitamin D, and the average American consumes about 1¼ c of 
milk/day, with adults consuming less[31]. It is assumed that a well-balanced diet should 
provide all the essential nutrients, minerals and vitamins. However, there are groups of 
people who are particularly vulnerable to deficiency of vitamin D, e.g. children, 
adolescents, pregnant and nursing women and the elderly. Vitamin D supplements should 
be used when sun exposure and the diet are unable to fulfill vitamin D needs. 
Currently, the recommended dietary allowance (RDA) for vitamin D3 is 600 IU/day 
(age 1 yr. to 69 yr.) and the upper limit tolerance is 4000 IU/day [32]. Due to the high 
prevalence of vitamin D deficiency and the risk of the related deficiency diseases, 
fortification of certain products, especially milk, orange juice, margarine, butter etc. are 
becoming increasingly common. Vitamin D is relatively stable and does not decompose in 
9 
 
heat or during long-term storage. However, it may be destroyed by ultraviolet radiation. 
Under aerobic conditions in aqueous medium it may undergo autoxidation and lose its 
functional properties. 
While national surveys in both the United States and Canada show the average total 
intake of vitamin D among North Americans to be below the median requirement, they 
also show that average blood levels of 25(OH)D3 are above 20 ng/mL, which is equivalent 
to 50 nmol/L, what the IOM found necessary for good bone health for all individuals [24]. 
The IOM interpreted the seemingly inconsistent observations of low dietary vitamin D 
intake but adequate vitamin D status to suggest that sun exposure currently contributes 
meaningful amounts of sunlight for vitamin D synthesis in North Americans and that most 
of the population is meeting its needs for vitamin D. Table 2.1 lists the average daily 
recommended amounts from the Food and Nutrition Board (a national group of experts) 
for different ages.  
 Table 2.1: Recommended Dietary Allowances (RDAs) for Vitamin D [2] 
 
Age Male Female 
0–12 
months* 
400IU (10 mcg) 400IU (10 mcg) 
1–70 years 600IU (15 mcg) 600IU (15 mcg) 
>70 years 800IU (20 mcg) 800IU (20 mcg) 
                              * Adequate Intake (AI). 1 mcg vitamin D= 40 IU 
Since most Americans will only receive a small amount of vitamin D from dietary 
sources, the more logical source for vitamin D is through sun exposure. Spending 
approximately thirty minutes outside at noon will produce approximately 10,000 IU of 
vitamin D [33].  
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2.3 What is Sulforaphane (SFN)? 
Sulforaphane belongs to a broad class of phytochemicals called isothiocyanates 
(ITCs). ITCs are a chemical class of compounds that are not naturally present in cruciferous 
vegetables, such as broccoli, Brussel sprouts, cabbage, radish, kale, cauliflower etc. 
However, it can be generated from hydrolysis of secondary metabolites, known as 
glucosinolates, by action of the enzyme myrosinase, released from plant cells during the 
process of crushing or mastication (chewing) [34]. ITCs may also be produced in the 
intestines where the resident microflora can promote hydrolysis of glucosinolates to 
isothiocyanates. Sulforaphane is especially high in broccoli and broccoli sprouts [14].  It is 
well known as a potent inducer of phase-2 detoxification enzymes [35] which inhibits 
tumorigenesis in animal models. Indeed, sulforaphane has been implicated in a variety of 
anticarcinogenic mechanisms including effects on cell cycle checkpoint controls and cell 
survival and apoptosis in various cancer cells [36-43]. The protective effects of 
sulforaphane in humans, however, may be influenced by individual genetic variation 
(polymorphisms) in the metabolism and elimination of isothiocyanates from the body [21]. 
2.4 Bioavailability of SFN  
It is important to understand the bioavailability and function of nutrient and non-
nutrient compounds found in various foods with health-promoting properties. Human 
intestinal perfusion studies showed that 74 ± 29% of sulforaphane from broccoli extracts 
can be absorbed in the jejunum [44]. Pharmacokinetic studies in both rats and humans also 
support the notion that sulforaphane can be distributed in the body and reach micromolar 
concentrations in the blood. For example, in rats, following a 50 μmol gavage, detectable 
sulforaphane was evident in the plasma after 1 h and peaked at ∼20 μmol/L at 4 h, with a 
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half-life of ∼2.2 h [45]. We know that different nutrients (macro and micro) have varying 
degrees of absorbability that can affect their bio efficacy. Broccoli sprouts contain up to 50 
times higher concentrations of the sulforaphane precursor glucoraphanin than mature 
broccoli. Thus, in humans, most studies have used broccoli sprouts as a particularly rich 
dietary source of glucoraphanin/sulforaphane. In human subjects, given single doses of 
200 μmol ITC preparation from broccoli sprouts, ITC plasma concentrations peaked 
between 0.943 and 2.27 μmol/L 1 h after feeding (half-life =1.77 ± 0.13 h) [46]. However, 
it is important to note that the glucosinolate dose per unit body weight given to rats in the 
Hu et al. study cited above were much higher (4-fold less ITC with markedly lower body 
weight in the rat) than given to human subjects. The primary aim of this literature review 
is to present our current understanding of the role of vitamin D and SFN and breast and 
colon cancer - what is known and established, what is still missing and where does that 
lead us.  
2.5 Vitamin D & CRC Epidemiological Studies 
Dietary intake, dietary supplementation, latitude and sun exposure, all predictors of 
serum of 25(OH)D3 levels, have been associated with differences in cancer incidence and 
mortality. This association is particularly strong for CRC [47].   
2.5.1 Vitamin D & CRC Meta-Analyses and Systematic Reviews 
To date, meta-analyses of the association between serum 25(OH)D3 and CRC have 
consistently demonstrated a statistically significant inverse relationship for incidence, but 
not recurrence, though data for the latter outcome are comparatively sparse [48, 49]. Since 
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the results of these meta-analyses were reported in 2008 and 2015 respectively, a third 
study of adenoma recurrence was published, which again showed no statistically 
significant association between 25(OH)D3 and odds of adenoma recurrence [50]. 
Underlying mechanisms for the observed differences in the association for 25(OH)D3 by 
incident vs. recurrent adenomas are currently only speculative. Differences in methylation 
patterns during adenoma growth and development [51] and variation in expression of key 
vitamin D pathway enzymes during different stages of development [52, 53] could be two 
potential mechanisms through which differential effects of vitamin D are seen on CRC 
incidence vs. recurrence. It is also possible that individuals included in recurrent lesions 
studies have different risk factor profiles and the carcinogenic pathway is not affected by 
vitamin D the same way as individuals without recurring lesions. Taken together, these 
observational studies indicate that vitamin D may have a role in reducing the risk of 
incident colorectal adenomas, but after removal of these lesions, there is no evidence that 
it will prevent the formation of another.  
Several meta-analyses of serum 25(OH)D3 concentrations and CRC incidence have 
been conducted, and all have shown a statistically significant inverse association. The 
results are summarized in Table 2.2.  
Table 2.2: Vitamin D and CRC Meta Analyses and Systematic Review Summary 
 
    Serum 25 (OH)D3 Outcome 
measure 
Statistic Effect size       
Citations 
 55ng/mL RRpooled 0.62  38% decrease [54] 
50ng/mL OR 0.4 60% decrease [55] 
Every 25ng/mL      
increase 
OR 0.92 8% decrease [56] 
<44nM or >72nM RR 0.66 34% decrease [3] 
High vs. Low OR 0.68 32% decrease [57] 
        High vs. Low RR           0.67 
       vs. 66  
33% decrease 
vs. 34% decrease 
[6] 
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        High vs. Low ORpooled           0.66    34% decrease [58] 
        High vs. Low RR 0.96 4% decrease [59] 
Every 20ng/mL 
increase 
OR 0.82 18% decrease [48] 
High vs. Low RRpooled 0.67 33% decrease [60] 
Every 10ng/mL 
increase 
RR 0.85 15% decrease [61] 
High vs. Low OR 0.70 30% decrease [49] 
≥33 ng/mL, ORpooled 0.49 50% decrease [62] 
 
2.5.2 Vitamin D & CRC Randomized Clinical Trials 
Randomized clinical trials provide the best evidence if an exposure (e.g. vitamin 
D) reduces the risk of any cancer, and to date, only four have been published on vitamin D 
with data specific to CRC [63-66].  The Women's Health Initiative (WHI) randomized 
women to 400 IU vitamin D and 1000 mg of calcium vs. placebo. No differences in risk 
for CRC by treatment group were observed, although some limitations of the trial were 
noted, including the relatively healthy study population, the timing of the intervention, and 
the comparatively short follow-up time [65]. In addition, it has been suggested that the dose 
of vitamin D used in WHI was too low to elicit protective effects [64]. Another clinical 
trial conducted in the United Kingdom, randomized men and women to receive 100,000 
IU of vitamin D every four months for five years [66]. No reduction in risk of either CRC 
incidence or mortality was observed. Results from the ongoing Vitamin D and Omega-3 
Trial (VITAL) trial [67], will likely provide more definitive evidence regarding the efficacy 
of vitamin D in  CRC prevention. In this study, participants are supplemented with 2000 
IU/d of vitamin D with and without an omega-3 fatty acid supplement to ascertain whether 
the intervention can prevent the development of cancer or cardiovascular disease. 
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Four large-scale clinical trials on vitamin D supplementation are currently 
underway and summarized in Table 2.3.  
Table 2.3: Ongoing Large-Scale Randomized Trials of Vitamin D Supplementation 
Worldwide[67] 
 
Trial, Location Treatment  
Duration 
Vitamin D 
intervention 
Primary 
endpoints 
        VITAL, USA 5y 2000IU/d Cancer, CVD 
D-Health, Australia1 5y 60,000 IU/month 
(bolus) 
Total mortality, 
Cancer 
        FIND, Finland2 5y 1600 IU/d or 
3200IU/d 
   Cancer CVD 
        VIDAL, UK3 5y 100,000 IU/month 
(bolus) 
Total mortality, 
Cancer 
 
 
 
 
 
 
 
                                                 
1Neale R. [11.09.14]; D-Health Trial Australian New Zealand Clinical Trials Registry 
identifier: ACTRN12613000743763. Available 
at: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364534&isClinical
Trial=False  
 
2 Toumainen T-P. [11.09.14];Finnish Vitamin D Trial 
(FIND) ClinicalTrials.gov identifier: NCT01463813. Available 
at: http://www.clinicaltrials.gov/ct2/show/NCT01463813?intr=vitamin+D&outc=cancer
&rank=10  
3 Peto J. [11.09.14];Vitamin D and Longevity (VIDAL) Trial: Randomized Feasibility 
Study. ISRCTN46328341. Available at: http://www.controlled-
trials.com/ISRCTN46328341  
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2.5.3 Vitamin D & CRC Case-Control Studies 
Numerous case-control studies analyzed the effect of vitamin D and the risk of 
CRC. Some of them are nested within large prospective cohorts. While some studies 
focused only on serum 25(OH)D3, others were interested in vitamin D intake, 
supplementation and in some cases, sun exposure, to reach their conclusions.  Majority of 
these studies confirm that vitamin D as measured by serum 25(OH)D3 has a protective role 
against CRC. A summary of relevant vitamin D case-control studies is provided in Table 
2.4.  
Table 2.4: Vitamin D and CRC Case-Control Studies Summary 
  
Serum 25 (OH)D3/ 
   Vitamin D intake 
Outcome 
measure 
Statistic Effect size       
Citations 
101.5 nM 25(OH)D3 OR 0.51 49% decrease               
[68] 
21.9 vs. 23.9 ng/mL 
      Of 25(OH)D3 
OR 0.45 55% decrease [69] 
High vs. Low OR 0.60 40% decrease [70] 
Every 50nM increase    
in 25(OH)D3 
OR 0.57 43% decrease [71] 
<20ng/mL RR 1.80 (men) 
0.22 
(women) 
18% increase in 
men 
78% decrease in 
women 
[57] 
D intake OR 0.77 23% decrease [72] 
High vs. Low serum  
25(OH)D3 
OR 0.52 48% decrease [73] 
High vs. Low serum              
25(OH)D3 
ORpooled 0.59 41% decrease 
 
[74] 
>100 nM of 
25(OH)D3 
OR 0.77 23% decrease [75] 
High vs. Low OR 0.68 32% decrease [1] 
        D intake OR 0.69 31% decrease [76] 
        D intake  OR 0.69 31% decrease [77] 
High vs. Low serum  
25(OH)D3 
ORpooled 0.66 34% decrease [78] 
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D intake RR  No effect [79] 
High vs. Low 
25(OH)D3 
OR 0.53 47% decrease [80] 
D intake OR 0.82 18% decrease [81] 
23- 24 ng/ml of  
25(OH)D3 
OR  No effect [82] 
D intake OR 0.5 50% decrease [83] 
 
2.5.4 Vitamin D & CRC Cohort Studies 
Higher vitamin D status has been found to be protective against CRC from a few 
cohort studies (Table 2.5). A recent retrospective analysis looked at the association 
between vitamin D status of advanced CRC patients at the time of diagnosis and subsequent 
outcomes [84]. They measured serum 25(OH)D3 levels in patients with new diagnosis of 
stage IV CRC and compared it with survival.  They defined adequate level of vitamin D as 
>30ng/mL of serum 25(OH)D3 and found a 61% reduced risk (HR=0.61; 95% CI 0.38-
0.98).   Two prospective cohort studies have specifically assessed the association between 
serum 25(OH)D3 concentrations and CRC progression [85, 86]. Mezawa and colleagues 
measured blood levels of 25(OH)D3 in Stage I-IV patients and found that although 
25(OH)D3 levels were significantly related to overall survival, they were not associated 
with disease-free survival [85]. In another study conducted among Stage IV CRC patients 
undergoing chemotherapy, concentrations of 25(OH)D3 were not significantly associated 
with time to progression of disease [86]. Table 2.5 lists studies of interest that are 
prospective in design have a mean follow-up of ±10 years to incident CRC and survival.  
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Table 2.5: Vitamin D and CRC Prospective Cohort Studies Summary 
 
    Serum 25 (OH)D3 Outcome 
measure 
Statistic Effect size       
Citations 
Low vs. High OR 4.6 in men 
2.7 in women 
460% increase 
270% increase 
[87] 
80 nM OR 0.38 72% decrease           
[88] 
Every 10nM      
increase 
HR 0.95 95% decrease           
[89] 
High vs. Low OR 0.77 23% decrease           
[90] 
Every 25nM      
increase 
RR 0.63 37% decrease           
[91] 
 
2.6 Vitamin D & Breast Cancer Epidemiological Studies 
Research on BC and vitamin D association have been inconsistent. A high 
concentration of plasma 25(OH)D3 was associated with a significantly reduced risk of 
premenopausal BC [92]. Reduction in risk of BC is affected by amount of vitamin D 
(intake, supplementation, seasonal variation, and race) and differs by menopause status. A 
serum 25(OH)D3 level of 50 ng/ml was associated with 50% reduction in incident BC, 
compared to a baseline of <10 ng/ml [93]. Every 1 ng/ml increment of plasma 25(OH)D3 
level decrease BC risk by 16%. However, some studies have found opposite effects of 
vitamin D in BC incidence, development, progression and survival. We present the most 
recent epidemiological evidence regarding vitamin D and BC in the following sections. 
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2.6.1 Vitamin D and Breast Cancer Meta Analyses and Systematic Reviews 
Current breast cancer meta analyses and systematic reviews considered both intake 
and supplementation of vitamin D and used breast cancer prognosis, survival, recurrence 
and death as possible outcomes. Four meta-analyses identified a significant inverse 
relationship between the circulating concentrations of 25(OH)D3 and BC [94-97]. Two 
meta-analyses on vitamin D and BC survival have recently been published, and both 
reported that higher concentrations of 25(OH)D3 were related to better survival among 
women clinically diagnosed with BC [97, 98]. Low vitamin D levels were associated with 
a pooled hazard ratio (HRpooled) of 2.13 (95 % CI 1.64–2.78) and 1.76 (95 % CIs 1.35–
2.30) for recurrence and death respectively, in a recent meta-analysis[99].  
Another study looked at vitamin D supplementation and BC risk [100] and found 
no significant association with a reduced risk of BC development in postmenopausal 
women. Due to several reported inconsistencies in the relationship between vitamin D and 
BC risk and most of these meta-analyses and systematic reviews recommended further 
studies i.e. clinical trials for further clarification.  A summary of the most current literature 
is listed below. 
Table 2.6: Vitamin D and BC Meta Analyses and Systematic Review Summary 
 
Serum 25 (OH)D3 Outcome 
measure 
Statistic Effect size       
Citations 
High vs. Low RRpooled 0.92 8% decrease [97] 
High vs. Low RR 0.63 37% decrease [101] 
>75nM HRpooled 0.58 42% decrease [102] 
<15 to >30 ng/mL OR 0.10   90% decrease [96] 
High vs. Low RR 0.84 16% decrease [103] 
Every 5ng/mL      
increase 
RR 0.88 12% decrease [104] 
Every 25ng/mL      
increase 
OR 0.92 8% decrease [95] 
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40 ng/mL RR 0.80 20% decrease [105] 
High vs. Low HRpooled 0.63 37% decrease [106] 
High vs. Low RR           0.55     45% decrease [107] 
Every 10ng/mL 
increase 
ORpooled 0.99 1% decrease [108] 
Every 20ng/mL 
increase 
RR 0.73 27% decrease [109] 
78 nM OR 0.50 50% decrease [110] 
52 ng/ml ORpooled 0.50 50% decrease [93] 
2.6.2 Vitamin D and BC Clinical Trials 
Randomized clinical trials for BC and vitamin D association have also presented 
mixed results to date, and the inconsistencies persisted though pre- and post-menopausal 
sub-group analyses. One study considering the Women’s Health Initiative (WHI) clinical 
trial of calcium and vitamin D (CaD) supplements (average intervention period of 7.0 
years), found that a relationship between CaD and BC risk was only suggestive [111]. 
Subjects were vitamin D sufficient for all endpoint analyses. A deficiency of vitamin D, on 
the other hand, in BC patients, was found to be unresponsive to standard low-dose D 
supplementation [112].  
A more recent study focused on a small group of early BC (EBC) patients treated 
with adjuvant or neoadjuvant chemotherapy and effects of a tailored, high-dose, oral 
vitamin D supplementation in a randomized phase III trial [113]. Their objective was to 
restore a normal serum 25(OH)D3 level in this population which would reflect on the 
suggested beneficial role of vitamin D. At the end of the trial, 44% of these patients 
achieved vitamin D normalization.  
Another population-based, double-blind, randomized placebo-controlled trial 
looked at supplemental calcium and vitamin D and associated risk of common cancers and 
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found that improving calcium and vitamin D nutritional status substantially reduces all-
cancer risk in postmenopausal women only [64].  
2.6.3 Vitamin D and BC Case-Control Studies 
Case-control studies examining vitamin D and BC association have produced 
mixed results despite controlling for potential confounders. A Mendelian randomization 
study analyzing the effects of circulating concentrations of vitamin D and subsequent 
cancer risks found that there was a 11% decrease in BC risk with every 25ng/mL increase 
in circulating 25(OH)D3 [56]. BC is a heterogeneous disease and it is possible that vitamin 
D only affects certain BC subtypes. e.g. based on tumor type, histological grade or hormone 
receptors. One study looked at this particular aspect and found the lowest risk of aggressive 
BC in patients from the second tertile compared to the lowest tertile where they used serum 
25(OH)D3 ≥75 nM to indicate vitamin D sufficiency [114].  
BC is prevalent throughout the world, in varying degrees, due to the substantial 
differences in the overall population, landscape, exposure to sun, diet, race, age 
distribution, and cultural influences). Considering the rising incidence of BC and high 
prevalence of vitamin D deficiency in Iran, a recent case-control study assessing BC risk 
and vitamin D status, found three times lower the risk of BC incidence in the highest 
quartile of serum 25(OH)3 group (OR = 0.269; 95% CI, 0.122-0.593), as well as highest 
intake of vitamin D (OR=0.39; 95% CI, 0.196-0.784)[115]. This association was 
significant only in the premenopausal women (OR = 0.25; 95% CI, 0.094-0.687) when 
stratified by menopause status.  
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Another study from India, with similar objectives, found that low serum 25(OH)D3 
levels were associated with a high risk of BC (OR=2.5; 95% CI, 0.9-7.4) [116]. Although 
seasonal variation in vitamin D association studies are important, exclusive research on 
this topic is rather limited. Majority of the case-control studies regarding BC and vitamin 
D link have been nested within large prospective cohorts and a few of them are highlighted 
below.  
One recent nested case-control study in the Nurses' Health Study cohort found that, 
although not related to overall BC risk, serum 25(OH)D3 significantly inversed BC risk in 
summer (RR = 0.66; 95% CI, 0.46-0.94) only [117]. A nested case–control study within 
the Multiethnic Cohort Study of five race/ethnic groups (white, African-American, Native 
Hawaiian, Japanese, and Latino) found BC risk was inversely associated with serum 
25(OH)D among white (OR=0.43; 95% CI,0.23-0.80) but not in other race/ethnic groups 
[118]. However, another nested case-control study within a large prospective cohort with 
10 years of follow-up, studying the same association failed to establish a connection 
between serum 25(OH)D levels and BC risk, although women with relatively high levels 
in summer months were at reduced risk [119]. 
A Korean study on serum 25(OH)D3 and BC risk [120] showed significant 
association with serum 25(OH)D3 highest quartile (OR=1.27; 95 %CI, 1.15-1.39) and 
remained significant when stratified by menopausal status: pre-menopause (OR=1.26; 95 
% CI ,1.09-1.45) and post-menopause (OR=1.25; 95 % CI, 1.10-1.41).  
There have been several other studies regarding BC risk and serum 25(OH)D3 and 
they’re summarized in Table 2.7.  
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Table 2.7: Vitamin D and BC Case-Control Studies Summary 
 
Serum 25 (OH)D3 Outcome 
measure 
Statistic Effect size       
Citations 
<19.8 to >27 ng/mL RR 0.80 20% decrease [121] 
  18.1 to 29.5 ng/mL RR 0.84 16% decrease [122] 
<12.0 to >24.0 ng/mL RR 0.45 55% decrease [92] 
<20 to >40 ng/mL RR 0.56  44% decrease [123] 
<24.0 to >33.7 ng/mL RR 0.52 48% decrease [124] 
<14.7 to >29.2 ng/mL RR 1.09 10% increase [125] 
<12 to >30 ng/mL RR 0.31 69% decrease [126] 
9.44 to 32.8 ng/mL RR 0.93 7% decrease [127] 
<18.3 to >33.7 ng/mL RR 1.13 11% increase [128] 
<22 to >41.7 ng/mL RR           0.73     27% decrease [129] 
<20 to >60 ng/mL RR 0.20 80% decrease [130] 
 
2.6.4 Vitamin D and BC Cohort Studies  
A recent study used a 25(OH)D3 prediction model to assess the relationship 
between vitamin D and incident BC risk was conducted by Palmer and colleagues [131]. 
Participants were part of the Black Women’s Health Study who have been followed by 
biennial mail questionnaires since 1995. The 25(OH)D3 prediction model is based on 
measured 25(OH)D3 in plasma specimens obtained from 2856 participants (between 2013 
and 2015) by using questionnaire-based variables from the same time frame. They found 
that, when compared to the highest quartile, women in the lowest quartile of predicted 
25(OH)D3 were estimated to have a 23 % increased risk of BC. The Pathways Study is a 
prospective cohort that looked at serum 25(OH)D3 association with BC prognosis[132] and 
found that 25(OH)D3 was significantly associated with BC-specific survival (HR=0.37; 
95% CI, 0.15-0.93) in premenopausal women and supports the idea that vitamin lowers the 
risk of BC morbidity and mortality. 
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There aren’t a lot of retrospective studies in BC association with vitamin D and 
even less in Latin American women. A recent retrospective case-cohort study examined 
serum 25(OH)D3 levels in Chilean BC patients before endocrine therapy and its association 
to clinical parameters at the time of diagnosis [133]. Using serum 25(OH)D3 ≥ 30 ng/ml 
(75 nM) as sufficient vitamin D status [33], they found no significant association between 
weight, BMI, tumor stage, tumor ER expression and changes in serum 25(OH)D3 levels. 
This observation may be due to a small number of subjects studied, although the results 
were like studies of season–dependence of 25(OH)D3 levels. 
A recent European study that analyzed the effects of serum 25(OH)D3 on BC risk 
in three ongoing, large, prospective cohort studies from the CHNACES consortium 
presented a comprehensive finding on the association of serum 25(OH)D3 and site-specific 
cancer incidence [134]. They found a 27% reduction in BC incidence (high vs. low) 
although this difference was not significant. Their cutoff for vitamin D sufficiency was a 
serum 25(OH)D3 levels >50nM and <30 nM as deficient. 
2.7 Sulforaphane and Colorectal Cancer 
Sulforaphane (SFN) is an isothiocyanate (ITC) that can be formed from its 
precursor molecules present in cruciferous vegetables, such as broccoli, cabbage, broccoli 
sprouts etc. SFN was first identified as a potent inducer of phase II detoxification enzymes, 
and growing evidence indicates that SFN might have some chemoprotective 
properties[17]. Some dietary compounds have been known to de-repress epigenetically 
silenced genes in various cancer cells that could have important implications in cancer 
prevention and therapy.  
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One epigenetic mechanism that affects this process of de-repression is histone 
deacetylation inhibition. HDACs affect histone acetylation status by removing acetyl 
groups from the nuclear histone proteins which can cause epigenetic silencing of important 
genes in cancer cells. Inhibition of this process will have an opposite effect, reducing the 
net removal of histone acetyl groups (histone deacetylase or HDAC enzymes) and 
potentially de-repressing silenced genes. This could result in cell cycle arrest and/or 
apoptosis reducing carcinogenesis. SFN is one phytochemical that demonstrates HDAC 
inhibitor action [135].  
For example, one study investigated the antiproliferative and pro-apoptotic effects 
of SFN on the SW620 colon cancer cell line and found that SFN at concentrations of 10–
50 μM reduces cell viability and inhibits cell proliferation in a time- and dose-dependent 
manner. DNA damage was also inhibited after 24 h and 48 h in the same cell line [37]. 
Another study on LS-174 and Caco-2 cells (both human colon cancer cell lines) found that 
a combination of SFN and mixed isothiocyanates (ITCs) reduced colon carcinogenesis by 
both stimulating apoptosis and enhancing intracellular defenses against genotoxic agents 
[136]. A more recent study analyzed 5 different colon cancer cell lines- HCT116, HT-29, 
KM12, SNU-1040, and DLD-1 and found that SFN (5µM and 25µM) inhibited growth via 
G2/M phase cell cycle arrest and increased apoptosis while exhibiting negligible toxicity 
in normal (nonmalignant) cells [5]. Another study isolated different hydrolysates of 
broccoli and found that the crude extract (80% alcohol extract) of broccoli florets had high 
cytotoxic activity against different human cancer cell lines, particularly, colon cancer (IC50 
3.88 µg/mL)[137].  
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In a study examining the anti-proliferative effect of SFN on an array of human 
colon cancer cell lines- DLD-1, HCT116 and LoVo, SFN exhibited anti-proliferative 
effects demonstrated by colony formation assays. Colony formation was reduced by SFN 
in a dose-dependent manner, especially at 20 µM [138]. In HT-29 colon cancer cells, one 
study found a significant reduction in cell proliferation (≥20 µM) [139] while another found 
that SFN induced cell cycle arrest in a dose-dependent manner, followed by cell death [34]. 
SFN also showed dose-dependent cytotoxicity and proapoptotic activity in HCT-116 cells 
in another study[41].    
A phase I placebo controlled, double-blind, randomized clinical trial to assess 
toxicities of either glucosinolate (300 μmol/day) or isothiocyanate (75 μmol/day) showed 
no toxicities or abnormal events occurred with any of the test extracts [140]. In another 
study comparing natural SFN vs. SFN supplements, with subjects consuming >300 μmol 
of glucosinolates every day for 7 days, consumption of SFN precursor (glucoraphanin) had 
no adverse effects, indicating that a high dose of glucosinolates was well tolerated in the 
subjects [141]. 
2.8 Sulforaphane and Breast Cancer 
SFN is a chemoprotective agent used in cell culture, animal cancer models 
(carcinogen-induced and genetic) as well as in xenograft models of cancer. In humans, a 
key factor in determining the efficacy of SFN as a chemoprevention agent is gaining an 
understanding of the metabolism, distribution and bioavailability of SFN and the factors 
that alter these parameters [39]. The importance of epigenetics in the initiation and 
progression of breast cancer has become more appreciated and has led many investigators 
to incorporate epigenetics-based treatments in breast cancer drug development [142].  
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One study investigating bulk histone acetylation and DNA methylation 
modifications in a large cohort of breast tumors found that the occurrence of certain histone 
marks correlates with tumor morphology and biological subtype. In other words, tumors 
with adverse traditional prognostic or phenotypic characteristics were found to have 
reduced levels of detectable histone acetylation marks and vice versa [143].  
Effects of histone deacetylase inhibitor compounds have been studied both in vivo 
and in vitro. Most of these studies used various extracts from cruciferous vegetables and in 
different combinations. One study analyzed potential estrogen receptor (ER) ligands acting 
as agonists or antagonists, when bound to extracts from cabbage, fermented cabbage, and 
acidified Brussels Sprouts. These extracts were evaluated for their estrogenic and 
antiestrogenic activities in estrogen-dependent human breast cancer (MCF-7) cells using 
as endpoints proliferation and induction of estrogen-responsive pS2 gene expression. At 
low concentrations (5-25 ng/mL) all the extracts reduced 1 nM estradiol-induced MCF-7 
cell proliferation [144]. Another study found that SFN treatment (30μM) along with 
autophagy inhibition in MCF-7 and MDA-MB-231 breast cancer cells might be a 
promising strategy for breast cancer control [145]. Sulforaphane (1-5 μmol/L) decreased 
aldehyde dehydrogenase–positive cell population by 65% to 80% and reduced the size and 
number of primary mammospheres by 8- to 125-fold and 45% to 75%, respectively in a 
recent breast cancer stem cell study [146]. A combination of HDAC inhibitors with 
demethylating agents was suggested as a promising strategy for the effective treatment of 
hormonal refractory BC, mainly in triple negative BC cells (TNBC) [147]. Another study 
also found that SFN significantly inhibits cell proliferation in multiple TNBC cell lines 
through inducing G2/M phase arrest and apoptosis [148].  
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A single oral dose of 150 μmol SFN in rats resulted in mammary tissue levels of 
SFN which presented with metabolites at concentrations known to alter gene expression in 
vitro[149]. In a follow-up study, similar results were found in human breast tissue when 
eight healthy women undergoing reduction mammoplasty were given a single dose of a 
broccoli sprout preparation containing 200 μmol of SFN [149].  
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CHAPTER 3 
 
PURPOSE OF THE STUDY 
Colorectal cancer is the second most invasive and third most common cancer in 
both men and women in the US. Prevention of colorectal cancer is an ongoing challenge, 
part of which is attributable to the constantly changing environmental factors that influence 
the development of colorectal cancer like- diet, exercise, smoking, alcohol intake, obesity 
etc. [1]. The most significant risk factors for breast cancer are gender (being a woman) and 
age (growing older) while other factors include- radiation to chest before the age of 30, 
genetics, race, overweight/obesity, alcohol intake, smoking and lack of exercise. Research 
shows that women with high levels of the vitamin in their blood are more likely to survive 
breast cancer than patients with low levels [2].   
Both higher vitamin D status [3] and cruciferous vegetable intake [4] have been 
linked to reduced risk of cancers. However, little is known about how these two factors 
may work synergistically with each other to augment the anti-proliferative activity of 
vitamin D. It has also been found that, enzymes involved in autocrine metabolism of 
vitamin D in breast tissue may provide important targets for both the prevention and 
treatment of breast cancer [5]. However, not much is known about the role of vitamin D in 
normal breast cell development and specific cell cycle events such as proliferation. This is 
a problem because the therapeutic window for the active vitamin D metabolite is quite 
small, and has an increased risk of developing toxicity from hypercalcemia and 
hypercalciuria at therapeutically effective, anti-proliferative doses of vitamin D. A 
selective downregulation of the vitamin D receptor (VDR) in colon and breast cancer cells, 
or alterations in the relative activity of the cellular enzymes involved in 1,25(OH)2D3 
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activation (CYP27B1) and inactivation (CYP24A1) can significantly alter the availability 
of intracellular concentrations of 1,25(OH)2D3. It can also alter the sensitivity of the cell to 
the active D metabolite by manipulating VDR activity.  We hypothesized that 1,25(OH)2D3 
treatment will decrease the rate of cell proliferation in colon and breast cancer cells by 
modulating D responsive genes. We also hypothesized that treatment of colon and breast 
cancer cells with SFN or TSA will further support vitamin D action. We anticipate the 
study findings will shed new light on potential anti-cancer mechanisms related to vitamin 
D anti-proliferative effects via increased inhibition of HDAC activity through dietary 
bioactive components, like SFN.  
We will discuss the specific aims and hypotheses of our three papers in the 
following order: epidemiological evidence from a systematic review and meta-analysis on 
vitamin D and breast cancer followed by in vitro primary studies on human breast cancer 
(MCF-7 cells) and colorectal cancer (Caco-2 cells) respectively.  
3.1 Paper 1: A Systematic Review and Meta-Analysis of Vitamin D and Breast Cancer 
Vitamin D is well known for its role in bone health primarily. However, recent 
epidemiologic studies have linked vitamin D deficiency with adverse cardiovascular and 
cancer-related outcomes [6]. Although vitamin D can be found in a limited number of 
foods, the major source of vitamin D is the endogenous production. Plasma concentrations 
of 25(OH)D3 have been used as a stable indicator of vitamin D status in humans [7]. 
Epidemiologic evidence for an association between plasma 25(OH)D3 and BC incidence 
and/or prevalence is inconsistent [8].  
             Moreover, there aren’t enough clinical trials with vitamin D mostly due to lack of 
adequate power. Although, certain longitudinal studies have assessed the relationship 
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between plasma 25(OH)D3 concentrations and inverse CRC risk, [9-13], there are not 
enough studies associated with prostate or BC incidence [11, 14-16]. Vitamin D 
supplementation studies with or without calcium [17-20] reported inconclusive or 
nonsignificant results for cancer [21]. The mixed results suggest that the relationship of 
vitamin D status and BC risk is still incompletely understood [22] and drove our systematic 
review and meta-analysis.  
The primary objective of the systematic review and meta-analysis is to gather 
evidence over the past ~18 years linking vitamin D status and intakes (food and 
supplements) with the occurrence of breast cancer.  
This study aims at reaching the objective by pooling data from the existing 
literature, interpreting and evaluating the results in both pre- and post-menopausal women. 
We also discussed potential biological mechanisms behind those putative associations.  
The final selected 18 studies were first reviewed in a systematic way, stratifying by 
study design and type of exposure with measures of association compared across studies. 
We used the PRISMA guidelines in summarizing the article search. The study-specific RRs 
for each exposure of interest were examined in pooled models, after testing for 
heterogeneity using the I2 test. As such, a summary or pooled RR was provided using forest 
plots and estimated using inverse variance weighting [23].  Random effects models that 
further incorporated between-study variability were conducted using DerSimonian and 
Laird’s methodology.  
A pre-defined quality score (QS) was used to assess the quality of each included 
study and the key findings of studies for each exposure of interest were presented using a 
harvest plot. Finally, Begg’s funnel plots were used to examine publication bias; each OR 
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point estimate was plotted against corresponding standard errors (SE) for each study on a 
logarithmic scale [24, 25] combining all exposures (e.g. serum and dietary vitamin D 
exposures).  
3.2 Paper 2: Histone Deacetylase activity and Vitamin D-Dependent Gene 
Expressions in Relation to Sulforaphane in Human Breast Cancer (MCF-7) Cells 
Vitamin D has been found to be protective against BC [26]. Numerous studies tried 
to prove the association although the findings are not consistent. However, there are limited 
studies about histone deacetylation (HDAC) inhibition patterns in BC tumors. There is a 
strong lack of evidence regarding BC risk and vitamin D-HDAC inhibitor combination 
therapy.  
The primary objective of this study is to determine how HDAC inhibition 
influences vitamin D-induced gene expression in BC. The rationale is that the chosen 
epigenetic modifiers (SFN and TSA) will alter the acetylation status of histone proteins, 
which will loosen the histone protein complex allowing increased transcription of vitamin 
D-inducible genes. 
Hypothesis a: Expression of vitamin D-dependent genes will be increased by HDAC 
inhibitors  
Our working hypothesis for this specific aim is that the expression of vitamin D-
inducible genes will be increased by concomitant treatment of cells with histone 
deacetylase (HDAC) inhibitors SFN and TSA. To test this working hypothesis, we have 
measured, with and without HDAC inhibitors, the mRNA expressions of VDR (vitamin D 
receptor), CYP24A1, CYP27B1 and TRPV6 by real time quantitative polymerase chain 
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reaction (RT-qPCR) in MCF-7 cells. Treatments were 100 nM vitamin D with and without 
SFN (20µM) and TSA (1µM). Our expectation was that vitamin D treatment will increase 
the expression of these selected genes and that concomitant treatment with SFN or TSA 
will further augment the association.  
Hypothesis b. Histone protein acetylation status will be increased by SFN and TSA 
treatments  
To test the relative HDAC inhibition by SFN and TSA, we measured changes in 
histone protein acetylation following our chosen treatments of 100 nM vitamin D with and 
without SFN (20µM) and TSA (1µM). Cells were incubated for 24 hours once 70% 
confluent after being seeded onto a 96-Well plate at 10,000 cells/well. HDAC I/II reagents 
(HDAC I/II Assay, Promega, 2017) were added at equal volumes to each well and 
incubated for 1 hour at room temperature. Relative luminescence (RLu) were recorded 
using OptiMax Luminometer and results were analyzed.   
We hypothesized that, SFN and TSA will increase histone deacetylase inhibition in 
MCF-7 cells and co-treatment with vitamin D would enhance D effects.  
Hypothesis c: Cell proliferation will be decreased by 1,25-dihydroxyvitamin D3 
treatment and will be further decreased by concomitant HDAC Inhibitor action 
We hypothesized that treatment of MCF-7 cells with the HDAC inhibitors will alter 
the acetylation status of histone proteins, thereby increase cellular vitamin D 
responsiveness.  
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We conducted colony formation (colonogenic) and migration assay to 
physiologically demonstrate an increase in the anti-proliferative effects of vitamin D 
combined with HDAC inhibitors SFN and TSA. Clonogenic assays demonstrate the 
effectiveness of a treatment by visually examining the number of colonies formed. 
Migration assay tests the ability of cells to migrate a scratch wound after treatment. 
Efficacy of the treatments are inversely proportional to the distance migrated i.e. if the 
distance migrated after the treatment is more than initial scratch, the test compound is less 
effective in preventing migration and vice versa. We also performed a cell viability assay 
that measured ATP which is directly proportional to the number of live cells in the system 
post-incubation (24Hrs).  
Our expectation was that vitamin D will decrease cell proliferation, which would 
be further decreased by epigenetic modifiers affecting histone acetylation status.  
3.3 Paper 3: Association Between Histone Deacetylase activity and Vitamin D-
Dependent Gene Expressions in Relation to Sulforaphane in Human Colorectal 
Cancer Cells 
Vitamin D, despite its known functions in bone metabolism, has been in the 
spotlight for its anti-carcinogenic properties for the past two decades. One study found that 
colon cancer mortality in the USA was highest in places with the least amount of sunlight 
[27], suggesting a protective role of Vitamin D. The development of many cancers (i.e. 
prostate, lungs, colon, etc.) have been associated with a reduced expression of the vitamin 
D receptor (VDR). Low VDR expression in cancer cells decreases cellular sensitivity to 
vitamin D, reducing its uptake resulting in decreased anti-proliferative action in these cells 
[28, 29]. Epigenomic alterations in CRC is behind the existing knowledge on gene 
mutations [30] and cell-specific mechanisms are yet to be explored. To the best of our 
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knowledge, this study is the first to demonstrate vitamin D- dependent key gene 
expressions in relation to histone modification in human colorectal cancer using both 
proliferating and differentiated Caco-2 cells as the experimental model.  
The primary objective of this study is to determine to what extent treatment with 
HDAC inhibitors influence vitamin D-induced transcriptional activity in Caco-2 cells.  
We hypothesized that treatment of cells with vitamin D would increase the 
sensitivity of Caco-2 cells which, in turn, will increase the action of HDAC inhibitors. We 
also hypothesized that, an increase in HDAC inhibition preceded by adequate vitamin D 
uptake will decrease progression of colorectal cancer in vitro. 
Hypothesis a: Expression of vitamin D-dependent genes will be increased by HDAC 
inhibitors  
Our working hypothesis for this specific aim is that the expression of vitamin D-
inducible genes will be increased by concomitant treatment of cells with histone 
deacetylase (HDAC) inhibitors SFN and TSA. To test this working hypothesis, we have 
measured, with and without HDAC inhibitors, the mRNA expressions of VDR (vitamin D 
receptor), CYP24A1, CYP27B1 and TRPV6 by real time quantitative polymerase chain 
reaction (RT-qPCR) in Caco-2 cells. Treatments were 100 nM vitamin D with and without 
SFN (20µM) and TSA (1µM). Our expectation was that vitamin D treatment will increase 
the expression of these selected genes and that concomitant treatment with SFN or TSA 
will further augment the association.  
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Hypothesis b. Histone protein acetylation status will be increased by SFN and TSA 
treatments  
To test the relative HDAC inhibition by SFN and TSA, we measured changes in 
histone protein acetylation following our chosen treatments of 100 nM vitamin D with and 
without SFN (20µM) and TSA (1µM). Cells were incubated for 24 hours once 70% 
confluent after being seeded onto a 96-Well plate at 10,000 cells/well. HDAC I/II reagents 
(HDAC I/II Assay, Promega, 2017) were added at equal volumes to each well and 
incubated for 1 hour at room temperature. Relative luminescence (RLu) were recorded 
using OptiMax Luminometer and results were analyzed.   
We hypothesized that, SFN and TSA will increase histone deacetylase inhibition in 
Caco-2 cells and co-treatment with vitamin D would enhance D effects.  
Hypothesis c: Cell proliferation will be decreased by 1,25-dihydroxyvitamin D3 
treatment and will be further decreased by concomitant HDAC Inhibitor action 
We hypothesized that treatment of Caco-2 cells with the HDAC inhibitors will alter 
the acetylation status of histone proteins, thereby increase cellular vitamin D 
responsiveness.  
We conducted migration assay to physiologically demonstrate an increase in the 
anti-proliferative effects of vitamin D combined with HDAC inhibitors SFN and TSA. 
Migration assay tests the ability of cells to migrate a scratch wound after treatment. 
Efficacy of the treatments are inversely proportional to the distance migrated i.e. if the 
distance migrated after the treatment is more than initial scratch, the test compound is less 
effective in preventing migration and vice versa. We also performed a cell viability assay 
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that measured ATP which is directly proportional to the number of live cells in the system 
post-incubation (24Hrs).  
Our expectation was that vitamin D will decrease cell proliferation, which would 
be further decreased by epigenetic modifiers affecting histone acetylation status.  
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4.1 Abstract   
Background: In this systematic review and meta-analysis, we pooled and evaluated 
evidence linking serum vitamin D (both in serum and diet) with breast cancer (BC) 
occurrence.  
Methods: Searching PubMed and Cochrane databases (January 1st  2000 through August 
31st , 2017), only observational studies were included. Publication bias and consistency upon 
replication were assessed, while harmonizing risk ratios (RR, 95% CI) of BC, per fixed 
increment of 5 exposures [10 ng/mL of 25(OH)D; 100 IU/d for total/dietary vitamin D 
intakes; vitamin D deficiency; supplement use). RRs were pooled using random effect 
models.  
Results: Pooled findings from 18 studies suggested a net direct association between 
25(OH)D deficiency and BC, with RRpooled=1.73, 95% CI: 1.28-2.34, p<0.001).  Total 
vitamin D intake was also inversely related to BC (RRpooled=0.98, 95% CI: 0.96-1.00, 
P=0.029, per 100 IU/d). No evidence of publication bias was found and consistency upon 
replication was shown for all 5 exposures of interest.  
Conclusions: Our study indicated that serum vitamin D deficiency and total vitamin D 
intake were associated with BC occurrence. 
Impact: Thus, pending future randomized controlled trials, vitamin D may be protective 
against BC occurrence.   
 
Key words: Vitamin D, breast cancer, meta-analysis 
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4.2 Abbreviations 
1,25(OH)2D=1,25 di-hydroxyvitamin D 
25(OH)D=25-hydroxyvitamin D 
BC=Breast cancer 
CI=Confidence Interval 
CVD=Cardiovascular Disease 
HR=Hazard Ratio 
IU=International Units 
OR=Odds ratio 
RR=Risk Ratio 
SD=Standard Deviation 
SE=Standard Error 
QS=Quality score 
 
4.3 Introduction 
         Breast  cancer is the most common malignancy among women in the US that has 
substantial medical and economic costs associated with it [1]. In 2017, an estimated 
252,710 new cases of invasive BC will be diagnosed among women (BC report 2017-18) 
and approximately 40,610 women and 460 men are expected to die from BC in 2017. 
Although there has been an overall increase in BC death rates between 1975 and 1989, a 
steady decline attributed to advanced healthcare and screening has been observed from 
2006 to 2015. However, this decline has not been the same among different racial and 
ethnic groups. The relative survival rates based on the most recent data as published on the 
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American Cancer Society report are: 91% at 5 years after diagnosis, 86% after 10 years 
and 80% after 15 years BC report 2017-18.   According to a recent retrospective study that 
looked at the stage-dependent average per capita cost of BC treatment, costs were higher 
in patients whose cancer were more advanced at diagnoses. For example, there is 
approximately a $10,000 difference in surgical costs during the first 12 months of 
diagnoses between a stage 0 and IV cancer screening. [1] 
            Vitamin D is known to play a major role in bone health and calcium homeostasis. 
In recent years, epidemiologic studies have linked vitamin D deficiency with several 
adverse outcomes, including cardiovascular and cancer-related morbidity and mortality.[2] 
Vitamin D is limited to certain foods (fatty fish, cod liver oil, egg yolk, some mushrooms, 
meat etc.) or supplements. The major contribution to vitamin D status is the endogenous 
production of vitamin D in the skin. Plasma concentrations of 25-hydroxyvitamin D 
[25(OH)D] has a half-life of 1-2 months and can reflect vitamin D  production, absorption, 
and storage.[3] Epidemiologic evidence for an association between plasma 25-
hydroxyvitamin D [25(OH)D] and breast cancer (BC) incidence and/or prevalence is 
inconsistent.[4]  
      Vitamin D deficiency is present throughout the world.[5] Increased awareness of the 
association of vitamin D deficiency with various health outcomes in recent years has 
contributed to an increase in vitamin D supplement use as well as the prescription of high 
dose vitamin D in treating vitamin D deficiency. [6]     
       The results from numerous epidemiological studies that studied circulating vitamin D 
concentrations and risk of various cancers have proven to be inconsistent. Moreover, there 
is a lack of definitive clinical trials with vitamin D supplementation and risk of cancer 
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mostly due to lack of adequate power. A recent Mendelian randomization study showed 
that a multi-single nucleotide polymorphism score for circulating 25(OH)D concentration 
was not directly associated with risk of several cancers including BC [7]. However, a cross 
sectional study in Brazilian postmenopausal women showed that low serum 25 (OH)2 
vitamin D level is a risk factor for ER negative tumors, with positive axilla and a higher 
rate of cell proliferation. [8]  
      Several longitudinal studies have assessed the relationship between plasma 25-
hydroxyvitamin D [25(OH)D] concentrations and cancer risk. The results have been 
summarized in several meta-analyses, which concluded that 25(OH)D concentrations are 
inversely associated with colorectal cancer incidence [9-13] but are not associated with 
prostate or BC incidence [11, 14-16]. Interventional studies that assessed the influence of 
vitamin D supplementation with or without calcium and cancer [17-20] reported 
inconclusive or nonsignificant results. [21] The mixed results from observational and 
interventional studies suggest that the relationship of vitamin D status and cancer risk is 
still incompletely understood.[22] 
     This systematic review and meta-analysis attempts to pool, interpret and evaluate 
research evidence over the past ~18 years linking vitamin D status and intakes (food and 
supplements) with the occurrence of BC among both pre- and post-menopausal women. 
Finally, this study discusses potential biological mechanisms behind those putative 
associations.  
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4.4 Methods   
4.4.1 Search strategy 
We conducted a systematic review of the literature on BC using primarily PubMed 
and Cochrane library as a secondary search. We focused on serum and dietary vitamin D 
as specific exposures. We searched systematically by combining the keywords "vitamin 
D" and "BC." Synonymous keywords were not included in the search to avoid 
heterogeneity in defining the concepts. We restricted the literature search to human studies 
published in English between January 1st, 2000 and August 31st, 2017. Figure 4.1 shows 
the search result, inclusion and exclusion criteria and the final number of studies. We 
considered original research published between 2000 and 2017 because the association of 
vitamin D with BC was studied rarely before 2000. We assessed the papers by reviewing 
titles and abstracts yielded by an initial search using relevant keywords combinations in 
abstracts (i.e. vitamin D and BC). We conducted a systematic review of the literature on 
BC focusing on specific exposures, namely serum and dietary vitamin D, (See Appendix 
C for search details). Among those that were selected for review, we retrieved further key 
information such as study design, contextual setting, sample size, main outcome and key 
findings. We used EndNote (X8.1) to create a reference database and we summarized 
extracted summary data in an Excel spreadsheet. 
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Fig. 4.1: Study Selection.*N=496 excluded based on study subject (non-human); N= 
1,769 excluded based on full text availability; N=26 non-English language (excluded); 
N=191 studies with male participants (excluded); N=164 participants younger than 19 
years(excluded); N=787 studies with irrelevant parameters (excluded).  
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-
Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097 
 
For more information, visit www.prisma-statement.org. 
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4.4.2 Study Identification and Selection 
Two independent reviewers (Sharmin Hossain and May Beydoun) determined 
whether studies were selected for review and meta-analysis. We initiated study inclusion 
and exclusion by examining titles and abstracts. We retained only studies with direct 
relevance to our research question. We obtained full text for the selected papers, which we 
then screened for potential inclusion in the systematic review and meta-analysis. The 
studies that were included assessed any type of association between vitamin D status and 
BC incidence or prevalence. Included studies presented findings as risk ratios (RR), hazard 
ratios (HR) or odds ratios (OR). They used a binary outcome for BC and categorical 
assessment of vitamin D status (usually binary). Primary reasons for excluding studies were 
“No relevant data available,” “Study is a randomized controlled trial,” “Study subjects are 
not adult women,” “Outcome is not incident or prevalent BC,” or “Exposure is not serum 
25(OH)D or dietary intake of vitamin D”. The meta-analysis was carried out on all 
observational study designs including cross-sectional, prospective and retrospective cohort 
studies. 
4.4.3 Data extraction 
   Detailed study-level characteristics were summarized in APPENDIX B (e.g. age, 
gender, country), study design (e.g. case-control, cross-sectional, cohort), sample size (e.g. 
number of cases and controls, or total sample size), type of exposures measured, type of 
population and quality score (described later). Selected studies were sorted by year of 
publication and first author’s last time. Type of exposure was identified as serum 25(OH)D 
(per 10ng/mL), serum 25(OH)D (deficient vs. not), dietary vitamin D (per 100 IU/d), 
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supplemental vitamin D (yes vs. no), and total vitamin D intake (per 100 IU/d). Further 
data extraction for use in the meta-analysis was conducted using a series Excel sheets (1 
per study) in which the final effect size and its 95% CI were estimated.   
4.4.4 Qualitative review and meta-analysis     
   The final selected 18 studies were first reviewed in a systematic way, stratifying 
by study design and type of exposure. The original measures of association are presented 
and compared across studies. Using the same 18 studies, we conducted a meta-analysis to 
assess the strength of the association of BC outcomes with vitamin D exposures among 
pre- and post-menopausal women combined. This analysis was thus restricted to case-
control, cross-sectional, and prospective cohort studies with available data that had 
comparable measurements for each risk/protective factor, thus allowing the estimation of 
a pooled measure of association across those data and studies, namely a risk ratio (RR) 
with its 95% CI. Modifications to the reported RR were made when measured on different 
scales of exposure [e.g. per 1 SD vs. quartiles vs. tertile vs. per 1-unit (e.g. 10 ng/mL) 
increase]. All RRs were converted into a single measure of association that closely 
represents the effect of a fixed incremental linear increase in the exposure on the risk of 
BC. After converting the RR with their 95% CI to LogeRR with its SE, both parameters 
(i.e. the point estimate and its SE) were divided by a conversion factor. In fact, in a normal 
distribution, the means of the highest and lowest tertile lie 2.18 SD apart; therefore, the log 
RRs were divided by 2.18 to obtain log RR per SD. Similarly, extreme quintiles effects 
were divided by 2.8, while extreme quartile effects were divided by 2.54. This approach 
was adopted elsewhere.[23] The value of SD was estimated using descriptive data from 
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cases and controls (or total population in the case of cross-sectional or cohort studies) or 
by approximating the differences between extreme quantiles and then dividing them by the 
conversion factors above.[24] From this, RR per 10 ng/mL for serum 25(OH)D, or per 100 
IU dietary or total vitamin D was estimated by dividing the LogeRRZ with its Standard 
Error (SE)z by the estimated SD value (either reported in the study or estimated from 
extreme quantiles) and multiplying it by 10 and 100, respectively. The Log-transformed 
RR is then exponentiated to obtain the point estimate of RR per 10 ng/mL increase in 
25(OH)D or 100 IU/d of dietary/total vitamin D intake. To obtain the 95% CI, the LogeRR 
point estimate is used along with its SE to obtain the lower and upper confidence limits on 
the Loge scale. These values are then exponentiated to obtain RR’s 95% CI. A similar 
approach was adopted when vitamin D exposure in a specific study was reported into non-
quantile categories (i.e. exposure groups with varying sample sizes). However, in this case, 
each contrast with a referent category is transformed into per 10 ng/mL or100 IU/d and 
then pooled into a common measure of association using random effects models within that 
study. Moreover, in the latter instance, median exposure value in each category is estimated 
and subtracted from the referent to obtain average increment in vitamin D exposure 
corresponding to each contrast. This is then used to ensure the measure of association 
corresponded to 10 ng/mL or 100 IU/d increase, for 25(OH)D and dietary/total vitamin D, 
respectively. Varying units and conversion factors in the measurement of serum 25(OH)D 
were also considered in these calculations. In studies with stratified analyses (e.g. by age 
group), incremental RR were estimated per strata and then pooled into one estimate with 
associated 95% CI, using random effects models within the study.    
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 The study-specific RRs for each exposure of interest were then examined in pooled 
models, after testing for heterogeneity using the I2 test. As such, a summary or pooled RR 
was provided using forest plots  and estimated using inverse variance weighting.[25] 
Random effects models that further incorporated between-study variability were conducted 
using DerSimonian and Laird’s methodology.[25]  
4.4.5 Harvest and funnel plots 
  A pre-defined quality score (QS) was used to assess the quality of each included 
study. This QS is a modified version of previously used scoring systems[26] and was 
applied in a previous meta-analysis.[23] In our meta-analysis, the QS scale included 4 
items, namely study design, study size, outcome assessment, and adjustment for potential 
confounders, each of which can be scored from 0 to 2 in ascending order of quality. Thus, 
the total QS score could range from 0 to 8. Since only one outcome was studied (i.e. BC), 
only one QS was linked to each study. Three independent assessments of QS items/study 
were made by three co-authors (May Beydoun, Hind Beydoun and Xiaoli Chen) and the 
average QS was determined. A consensus was then achieved by the 3 co-authors after 
initial rating.  To represent graphically the key findings of studies for each exposure of 
interest, a harvest plot was used. This plot shows the exposure-outcome associations of 
interest in each study, whether they were significant and in which direction (-1= “inverse 
association”, 0= “null association”, 1= “positive association”) for each exposure against 
QS which is presented on the y-axis. At least 3 studies were needed to create a harvest plot 
per hypothesized exposure-outcome association.  
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 Finally, in order to examine publication bias, we used Begg’s funnel plots 
(APPENDIX E); each OR point estimate was  plotted against their corresponding standard 
errors (SE) for each study on a logarithmic scale,[27,28] combining all exposures (e.g. 
serum and dietary vitamin D exposures). This type of bias was also formally tested using 
the Begg-adjusted rank correlation tests[29] and the Egger’s regression asymmetry 
test.[30] All analyses were conducted with STATA 15.0 (StataCorp, College Station, TX) 
.[31] Type I error was set at 0.05 for all measures of association. 
4.5 Results 
4.5.1 Study Selection, Characteristics and Quality Score 
 Out of 3,451 un-duplicated titles and abstracts between 2000 and 2017, 18 
published original epidemiologic studies were considered for review and/or meta-analysis. 
Those selected studies were published between 2005 and 2014 (Mean±SD: 2010±3), with 
11 being US studies, 1 Canadian, 4 European and 2 from Asia (APPENDIX D). Moreover, 
most studies had a case-control or nested case-control design (n=16), with only 2 being 
prospective cohort studies. Eight studies comprised adult women of varying age ranges, 
while 4 included only pre-menopausal women and 6 were restricted to post-menopausal 
women. Overall, mean age was 54.2 with a SD of 10.3y.  The cumulative sample of studies 
included in our meta-analysis consisted of 125,291 subjects, with a Mean±SD: 
6,690±17,245 subjects per study. Finally, mean QS with its SD was 4.56±1.69 (range:2-8), 
indicating a relatively above average quality set of studies, given that the maximum score 
is 8.  
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4.5.2 Qualitative Review of Studies  
Of 16 case-control studies included in this paper, 9 studies (56.3%) showed that a 
reduced risk of BC was associated with high levels of 25(OH)D [19, 21, 24, 29, 32, 33] or 
the use of vitamin D or multivitamin supplements [34-39].  The other 7 case-control studies 
(43.7%), however, showed no associations of BC risk with 25(OH)D levels or vitamin D 
intake [30, 32, 33, 40-43]. 
Of two prospective cohort studies included in this current study, both showed that 
dietary calcium could reduce the risk of BC among postmenopausal women [44,45]. For 
example, in the Cancer Prevention Study II Nutrition Cohort (QS=8), McCullough et al 
(2005) studied dairy, calcium, and vitamin D intake and BC risk among 68,567 
postmenopausal women aged 50-74 years in the US (QS=8). [46-49] Their results 
supported the hypothesis that dietary calcium may modestly reduce the risk of 
postmenopausal BC. In the Iowa Women's Health Study of 34,321 postmenopausal women 
aged 55-69 years with 18 years of follow-up (QS=8), [42] reported that vitamin D intake 
appeared to be associated with a small decrease in BC risk among postmenopausal women 
in the US.  
4.5.3 Meta-Analysis: Findings for Serum Vitamin D  
  In total, measures of the association from 12 case-control studies on serum 25(OH) 
D in relation to BC were pooled, with a total number of 8,156 cases matched with 11,336 
controls. Our pooled findings indicated that there was no detectable association between 
serum 25(OH)D concentration and BC occurrence (RR=0.99, 95% CI: 0.98-1.00, P=0.12, 
per 10 ng/mL), while based on 3 case-control studies (1,021 cases matched with 1,021 
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controls), serum 25(OH)D deficiency was shown to have a direct relationship with the risk 
of BC  (RR=1.73, 95% CI: 1.28-2.34, P<0.001) (Fig 4.2).  
 
Figure 4.2: Study Summary. Heterogeneity chi-squared =  58.61 (d.f. = 11) p = 
0.0001. I-squared (variation in ES attributable to heterogeneity) =  81.2%. Test of ES=1: 
z=  1.30 p = 0.195 
4.5.4 Meta-analysis: Findings for Dietary Vitamin D (foods and supplements)  
 In total, measures of association from 4 studies on total dietary vitamin D (foods 
and supplements) relation to BC occurrence were pooled. We demonstrate a clear net 
inverse association between total vitamin D intake and BC, with a pooled RR=0.98, 95% 
CI: 0.96-1.00, P=0.029, per 100 IU/d. This small inverse association was observed for 
67 
 
dietary vitamin D and supplemental vitamin D usage (yes vs. no), though did not attain 
statistical significance.  
4.5.5 Bias Assessment: Funnel and Harvest Plots  
    Begg’s funnel plot indicated that most of the 22 data-points fell within the 
expected confidence limits when plotting Loge(RR) against its SE. Begg’s test indicated 
no publication bias, with z=0.99 and associated p-value of 0.32, and Egger’s test indicated 
there was no asymmetry whereby Loge(RR) was not associated with its SE in terms of 
slope. In addition, there was no bias in terms of the directionality of Loge(RR) that were 
published in the literature.  
    Examining each individual exposure, harvest plots are presented in APPENDIX 
F, plotting qualitative findings (-1=”inverse association”, 0=”null association” and 
1=”positive association”) against study-level QS.[50,51] Based on the clustering of 
findings, 6 of 11 studies that examined 25(OH)D in relation to BC, reported a null overall 
finding. Noteworthy is that those studies had a slightly higher QS compared with those that 
reported an inverse association, though the difference was not statistically significant (QS 
4.4 vs. 4.0). In contrast, all studies with 25(OH)D deficiency, total/dietary vitamin D and 
supplemental vitamin D reported a finding that follows the hypothesized direction of 
association. The latter finding suggests consistency upon replication whereby an overall 
pooled finding trending towards the hypothesized direction was consistent with the overall 
finding of each individual study included in the meta-analysis.  
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4.6 Discussion 
    This study is to our knowledge, the most up to date among very few meta-
analyses conducted to synthesize the literature on vitamin D exposure and BC occurrence. 
Pooled findings indicated that there was a net direct association between 25(OH)D 
deficiency and BC occurrence, with a pooled RR=1.73, 95% CI: 1.28-2.34, p<0.001).  An 
inverse association was also observed for total vitamin D intake from foods and 
supplements (RR=0.98, 95% CI: 0.96-1.00, P=0.029, per 100 IU/d) and BC. No net 
association was detected between BC and serum 25(OH)D (per 10 ng/mL) or between BC 
and dietary/supplemental vitamin D. There was no evidence of publication bias. Harvest 
plots suggested consistency upon replication was found for all 5 exposures of interest.     
   In recent years, there has been considerable interest in whether vitamin D inhibits 
BC development.[42] The anticarcinogenic potential of vitamin D comes from the active, 
hormonal form of vitamin D, 1,25-dihydroxyvitamin D [1,25(OH)2D], which is the 
product of a second hydroxylation of 25-hydroxyvitamin D [25(OH)D] in the kidneys. 
Experimental studies indicate that 1,25(OH)2D can also be synthesized from 25(OH)D in 
other tissues, possibly including breast tissue. [52, 53]The vitamin D receptor is activated 
by 1,25-dihydroxyvitamin D [1,25(OH)D], and is found in nearly all tissues and organs in 
the human body. It is responsible for the transcription of numerous genes related to cell-
cycle control and apoptosis. Therefore, it is of considerable interest in relation to many 
cancers, including BC. [54] While the circulatory levels of the biologically active 
metabolite 1,25-dihydroxyvitamin D [1,25(OH)2D] is tightly regulated, the precursor 25-
hydroxyvitamin D [25(OH)D] serves as an indicator of vitamin D status from other sources 
i.e. vitamin D from cutaneous synthesis and diet. Since circulating 25(OH) is related to 
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1,25-dihydroxyvitamin D [1,25(OH)2D] in breast tissue and circulating 1,25-
dihydroxyvitamin D [1,25(OH)2D] is homeostatically controlled, circulating 25-
hydroxyvitamin D [25(OH)D] is thought to be potentially relevant to breast 
carcinogenesis.[42] 
This study has many strengths. First, this systematic review of the literature is, to 
our knowledge, one of the few to have examined a wide range of vitamin D exposures and 
their relationships to with BC occurrence through meta-analysis. Second, we used a 
validated quality scoring system as a tool to examine heterogeneity of study results based 
on quality of data. However, our study results should to be interpreted with caution 
considering several limitations. First, our literature search was restricted to the PubMed 
and Cochrane databases, and did not include other electronic databases such as Embase or 
Web of Science. Second, we used specific key terms to perform the literature search but 
did not search for cross-references or unpublished studies (abstracts, conference papers, 
theses and dissertations). Third, while exposures included dietary and supplemental 
vitamin D in addition to serum 25(OH)D, some meta-analyses were low-powered given 
the limited number of data-points available. Fourth, evidence was mostly generated from 
observational studies, namely, cross-sectional, retrospective cohort and prospective cohort 
studies, which precludes our ability to confirm causality. Thus, a separate meta-analysis of 
randomized controlled trials is needed, once enough trials are made available for such 
analysis. Fifth, the associations reported in this study may be confounded by other micro – 
and macro-nutrients, as well as lifestyle factors that have been shown to affect the risk of 
BC. Finally, publication bias cannot be ruled out as an explanation for these study results. 
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        Our review and meta-analysis indicated that serum vitamin D deficiency, as well as 
total vitamin D intake, were associated with BC occurrence in the general population, 
suggesting a putative protective effect of vitamin D pending future randomized controlled 
trials.   
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     5.1 Abstract  
It is relatively unknown how dietary bioactive compound, sulforaphane, in 
partnership with vitamin D, regulate vitamin D-dependent gene expression in breast 
cancer. It has been suggested that the combination of various bioactive components 
with vitamins is crucial for their potential anticancer activities. METHODS: This study 
employed a combinatorial chemo preventive strategy to investigate the impact of 
dietary histone deacetylase inhibitor i.e. sulforaphane on chromatin remodeling in 
breast cancer. To understand the epigenetics-mediated changes in gene expression, 
MCF-7 cells were exposed for 24 hours to vitamin D (100nM) either alone or in 
combination with L-sulforaphane and TSA (20μM and 1μM respectively) at 70% 
confluency. Changes to VDR, CYP24A1, CYP27B1 and TRPV6 gene expressions 
were quantified using real-time PCR-based assays. Histone deacetylase inhibitor 
activity was assessed using HDAC I/II assay that measured global changes in 
acetylation status. Cell viability was measured using ATP and MT assays. Clonogenic 
and migration assays were performed to analyze the ability of single cells to grow into 
colonies and % closure (migration ability) upon treatments respectively. Results were 
expressed as ΔCT± standard error of means (SEM) from One-way ANOVA analyses 
for mRNA expressions and mean± SEM for all other assays. RESULTS: In MCF-7 
cells, treatment with 1,25 (OH)2 D3 tended to decrease VDR (13±0.4) and CYP27B1 
(12±0.96) while significantly increasing TRPV6 (p=0.02, 14±0.1) and CYP24B1 
(p<0.0001, 0.38±0.12) expression.  D alone and D+TSA group had the opposite effects 
on HDAC inhibition from SFN alone, D+SFN and TSA alone. The clonogenic assay 
showed a significant decrease in colony formation with no colonies for D+TSA 
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(p<0.03) and TSA alone group (p<0.03). Cell viability tended to decrease with D alone 
and in combination with TSA. CONCLUSION: These data suggest that the effects of 
vitamin D and sulforaphane are selective and gene-specific in MCF-7 cells.  
Key words: HAT, histone acetyltransferase; HDAC, histone deacetylase; SFN, 
sulforaphane; TSA, Trichostatin A; VDRE, vitamin-D response elements. 
5.2 Introduction 
Breast cancer is the most common cancer among women worldwide and the 
incidence has continued to rise over time. [1] Nutrition influences cancer etiology in about 
35% of cancer cases. [2] General preventive dietary advice often includes reducing intake 
of alcohol, red meat, and saturated fat while increasing the intake of fiber, vitamin D and 
phytoestrogens from various food sources. [3] Breast cancer is a heterogeneous disease and 
vitamin D might only affect certain breast cancer subtypes. However, a protective effect of 
vitamin D against breast cancer has been suggested in several studies, which has been 
related to sunlight, dietary intake, vitamin D supplement and ethnic background. [4] 
Potentially important factors associated with increased breast cancer are listed below: 
Table 5.1: Factors Influencing BC Risk [5] 
 
Factors Modifiable Factors 
 
 
 
 
Modifiable 
Weight gain after the age of 18 and/or being 
overweight or obese (for postmenopausal breast 
cancer) 
Use of menopausal hormone therapy (combined 
estrogen and progestin) 
Physical inactivity 
Alcohol consumption  
Heavy smoking 
Shift work at night (i.e., that disrupts sleep patterns) 
 
 
Age 
Personal of Family History 
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Non-modifiable 
Inherited Mutations in BRCA1, BRCA2 of other 
susceptibility genes 
Atypical Hyperplasia 
High dose radiation to the chest at a younger age 
(e.g., for cancer treatment) 
High Breast Tissue density 
High BMD (bone mineral density) 
 
 
Reproductive 
Long Menstrual History 
Inability to have children 
Use of Oral contraceptives 
Having first child after age 30 
High natural levels of sex hormones 
 
Many in vitro and pre-clinical studies have examined the use of 1,25-
dihydroxyvitamin D3 to treat breast cancer. Four meta-analyses identified a significant 
inverse relationship between the circulating concentrations of 25-hydroxyvitamin D3 and 
breast cancer [6-8]. By contrast, a large randomized clinical trial, Women’s Health 
Initiative (WHI), showed that administering 400 IU vitamin D and 1000 mg of calcium 
versus placebo to women did not reduce the risk of breast cancer. The finding from WHI 
does not support the use of vitamin D as a prophylactic agent for breast cancer. However, 
better survival among woman diagnosed with breast cancer has been reported to be related 
to vitamin D intake leading to higher concentrations of 25-hydroxyvitamin D3 [8, 9]. A 
high concentration of plasma 25(OH)D3 is associated with a significantly reduced risk of 
premenopausal breast cancer [10]. A serum 25-hydroxyvitamin D (25(OH)D3) level of 50 
ng/ml was associated with 50% lower incidence of breast cancer, compared to a baseline 
of < 10 ng/ml [11]. 
It has been hypothesized that 1,25-dihydroxyvitamin D3 can reduce the risk of 
breast cancer. Several studies have examined the effects of 1,25-dihydroxyvitamin D3 on 
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mammary carcinogenesis in various cell lines and animal models and found a protective 
role of 1,25-dihydroxyvitamin D3 in breast cancer development.  
In breast cancer, investigations carried out on histone modifications are relatively 
newer than DNA methylation studies. Post-translational histone modifications have a 
critical role in breast tumorigenesis and aggressiveness of prognosis. Since different breast 
cancer subtypes represent distinct gene expression profiles, it is important to clarify the 
effect of histone modification on gene expression levels in breast tumors. However, there 
are limited studies on histone modification patterns in breast cancer tumors, though the 
numbers of investigations are increasing. There are several bioactive compounds present 
naturally in food that are known to modify genetic and epigenetic profiles in various 
cancers. Sulforaphane is one such compound that can be extracted from its precursor 
molecules present in cruciferous vegetables e.g. broccoli, Brussel sprouts etc. It is known 
to be a potent natural source of histone deacetylase (HDAC) inhibitor activity. [12] We 
used Trichostatin A (TSA) as our positive control. TSA is a fungal metabolite with well-
established, strong histone deacetylase inhibitor activity. 
The objective of this study is to determine how histone modification using 
sulforaphane or Trichostatin A (TSA), influences vitamin D-induced gene transcription in 
breast cancer. There are not enough studies that examined this specific association and in 
MCF-7 cells as a model of breast cancer. The rationale is that the chosen epigenetic 
modifiers will alter the acetylation status of histone proteins, which will loosen the DNA-
histone protein complex and allow increased transcriptional activity at the vitamin D 
response element (VDRE) found in the promoter region of vitamin D-inducible genes. 
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5.3 Methods  
5.3.1 Cell Culture 
Cells were treated on day 7 from the date of seeding into 6-well plates. The 
experiment included six different treatment groups namely- DMSO control (0.1%), 1,25 
(OH)2D3 (100nM), SFN (20 µM), TSA (1µM), 1,25 (OH)2D3 + SFN and 1,25 (OH)2D3 + 
TSA (APPENDIX G). After treatment, the cells were incubated for 24 hours before 
harvesting. MCF-7 cells were obtained from Arcaro lab. 1, 25 (OH)2D3 was purchased from 
Enzo Life Sciences, Plymouth Meeting, PA. Trichostatin A and SFN were purchased from 
Sigma-Aldrich, St. Louis, MO. Real-time PCR materials, including all primers and master 
mix were purchased from Applied Biosystems, Foster City, CA. Cell culture dishes were 
bought from Costar, Cambridge, MA. All other cell culture materials and materials for 
RNA isolation and cDNA synthesis were purchased from Life Technologies, Grand Island, 
NY.  
5.3.2 RNA Isolation and Reverse Transcription 
At the completion of the treatment period, cells were washed with saline, then 
treated with 1 mL Trizol per well of a 6-well plate, and cells were scraped to be harvested 
for subsequent RNA extraction.  Cells were frozen at -80°C until RNA was ready to be 
isolated in collection tubes. To isolate the RNA, 200 µL chloroform was added to each 
homogenate for phase separation. Isopropanol (500 µL) was then used to precipitate the 
RNA. Washing three times with 1 mL of 75% ethanol was followed by the addition of 40 
µL of Diethyl pyrocarbonate (DEPC) water. The samples were then incubated for 10 
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minutes at 56°C to ensure maximum RNA solubility. RNA samples were then quantified 
using a Nanodrop machine (λ260/280). cDNA was prepared using the SuperScript III First 
Strand Synthesis System for RT-PCR (Life Technologies, Grand Island, NY). Details of 
the protocol are listed in APPENDIX H. 
5.3.3 Real Time PCR 
For all experiments, mRNA expressions of GAPDH, VDR, CYP24A1, CYP27B1, 
and TRPV6, were measured by ViiA™ 7 Real-Time PCR System (Applied Biosystems, 
Foster City, CA). Reactions consisted of 10 µL of SYBR GREEN Gene Expression Master 
Mix (Applied Biosystems, Foster City, CA) with forward and reverse primers (10nM each) 
and 10 µL of DNAse/RNAse Free Water with 100 ng of cDNA. Duplicates were set up for 
each sample. The levels of VDR, CYP24A1, CYP27B1, and TRPV6 were measured by 
the comparative ΔΔCT method (ThermoFisher Scientific, 2016). For each sample, the 
relative abundance of GAPDH and the target genes were obtained. The difference between 
those two abundances (target gene- GAPDH) is the ΔCT for that sample which were the 
values used for statistical analysis. The mean ΔCT values were then normalized against the 
mean ΔCT values of the control sample, Dimethyl Sulfoxide (DMSO), resulting in a ΔΔCT 
value. 2 was raised to the – ΔΔCT to produce a relative quotient (RQ) for each sample, 
with the RQ of the control being one. RQ values were used to create the mRNA expression 
curves for each gene. Primer sequences are available on APPENDIX A. 
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5.3.4 Histone Deacetylase (HDAC) Assay 
We used a luminescent HDAC-Glo™ I/II Assay (Promega, 2017). The assay uses 
an acetylated, live-cell-permeant, luminogenic peptide substrate that can be deacetylated 
by HDAC activities. Deacetylation of the peptide substrate is measured using a coupled 
enzymatic system in which a protease in the Developer Reagent cleaves the peptide from 
aminoluciferin, which is quantified in a reaction using Ultra-Glo™ Recombinant 
Luciferase. The HDAC-mediated luminescent signal is persistent and proportional to 
deacetylase activity.  
Cells were harvested 24 h after treatment with SFN (20 µM) and TSA exposure (1 
µM), and cell lysates were analyzed for HDAC activity, as reported [13].  
5.3.5 ATP Assay 
We used the CellTiter-Glo® 2.0 Assay (Promega, 2017). This assay provides a 
homogeneous method to determine the number of viable cells in culture by quantitating 
the amount of ATP present, which indicates the presence of metabolically active cells. 
Luminescence readout is directly proportional to the number of viable cells in culture. Cells 
were harvested 24 h after co-treatment with SFN (20 µM) and TSA (1 µM), and cell lysates 
were analyzed for ATP activity. 
5.3.6 MT Assay 
We used the RealTime-Glo™ MT Cell Viability Assay (Promega, 2017), and 
measured cell viability in MCF-7 cells continually in the same sample well up to 48 hours. 
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This gave us more information about the mode of action of our treatments about time 
dependence. The nonlytic nature and rapid response of the assay made it possible to 
monitor cell viability over time in the same well. The assay measures the reducing potential 
of viable cells, and is ATP-independent, providing an orthogonal method for viability or 
cytotoxicity determination. 
Luminescence readout is proportional to the number of viable cells in culture. Cells 
were harvested 24 h after co-treatment with SFN (20 µM) and TSA (1 µM), and cell lysates 
were analyzed for ATP activity. 
5.3.7 Caspase 3/7 Assay 
We used the Caspase-Glo® 3/7 Assay (Promega, 2017) to measure apoptosis in 
MCF-7 cells. The assay provides a pro luminescent caspase-3/7 DEVD-aminoluciferin 
substrate and a proprietary thermostable luciferase in a reagent optimized for caspase-3/7 
activity, luciferase activity and cell lysis. Adding the single Caspase-Glo® 3/7 Reagent in 
an "add-mix-measure" format results in cell lysis, followed by caspase cleavage of the 
substrate. This liberates free aminoluciferin, which is consumed by the luciferase, 
generating a "glow-type" luminescent signal that is proportional to caspase-3/7 activity in 
the system. Cells were harvested 24 h after co-treatment with SFN (20 µM) and TSA (1 
µM), and cell lysates were analyzed for caspase 3/7 activity.  
5.3.8 Clonogenic Assay 
We used the “plating before treatment” setup for this assay[14]. MCF-7 cells were 
harvested and re-plated (500/well) in a 6-well plate and allowed overnight to attach (day 
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0). Cells were treated (in duplicates) the next day using DMSO as the vehicle control, D 
(100nM), SFN (20µM) and TSA (1µM) as primary treatments and in combinations 
(D+SFN) and (D+TSA) (day 1). The plates were then incubated for three weeks at 37˚C. 
After the desired incubation period, the cells were fixed using 70% EtOH followed by 
Crystal violet (0.5%) staining. Colonies were counted using a standard colony counter. 
Plating efficiency (PE) and Surviving fractions (SF) were calculated as per protocol 
described by Franken et al. [14]. This entire experiment was repeated two more times for 
an N=3.  
5.3.9 Migration Assay 
A simple scratch test was used to determine the rates of closure following 
treatments to assess their efficacy. MCF-7 cells were seeded in 6-well plates at a density 
of 325,000 cells/well and allowed to attach overnight. Once the cells were 70% confluent, 
wounds were created using the etching at the bottom of the wells as guide, using a p-200 
pipet tip. The wells were then washed with 1X sterile PBS and treated as designed. 
Photographs were taken on day 0 at four reference points (4 quadrants) and marked as the 
“0Hr”. Each wound was then followed over the course of 24 hours to determine the rate of 
closure in response to the treatments. Photographs were taken again and marked as “24Hr”. 
This entire experiment was repeated for an N=3. Percent closure is calculated as below: 
% closure= (0Hr avg. wound size- 24Hr avg. wound size)/ 0Hr avg. wound size 
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5.3.10 Statistical Analyses 
Results from real-time PCR were analyzed using one-way ANOVA with a p-value 
of <0.05 used as the cut-off for statistical significance. The analysis was setup as a 
randomized block design with each experiment as a block. Dunnett’s Multiple Comparison 
Tests was also used to find which means of the treatment groups differed significantly from 
the control (DMSO) and used a P-value of <0.05 as a cut-off for statistical significance. 
All statistical analyses and figures were generated using GraphPad Prism (v 7.04). Tukey’s 
post-test was conducted to determine significant multiple comparison differences. 
5.4 Results 
5.4.1 D-responsive gene expression 
We hypothesized that the expression of vitamin D-inducible genes will be increased 
by concomitant treatment of MCF-7 cells with HDAC inhibitors (SFN and TSA). We 
measured, with and without the HDAC inhibitors, the mRNA expressions of genes known 
to be involved in vitamin D action: namely, VDR (vitamin D receptor), CYP24A1 (24 
hydroxylase), CYP27B1 (1α hydroxylase) and TRPV6 (transient receptor potential, 
vanilloid family, member 6 calcium-specific channel protein) by real time quantitative 
polymerase chain reaction (RT-PCR); results are expressed as ΔCT±SEM and the graphs 
represent the RQ values (2^-ΔΔCT). Although, VDR expression (N=4) in MCF-7 cells was 
not statistically significant from the one-way ANOVA test, Browne- Forsythe test showed 
a significant association (p=0.0009). When compared to the control, D alone group (-
0.47±0.11), D+SFN group (-0.28±0.32), and D+TSA group (-0.20±0.29) tended to 
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decrease its expression while SFN alone (0.003±0.23) and TSA alone (0.05±0.41) showed 
minimal increase. There was no statistical difference observed from the Wilcoxon Signed 
Rank test. 
TRPV6 (N=3) expression, was overall significant (p=0.04) from the One-way 
ANOVA test. D alone (3.56±2.5), D+TSA (1.21±0.69) and SFN alone (4.34±2.3) groups 
tended to increase TRPV6 expression. TSA alone (19.14±9.4, p=0.04) showed a moderate 
increase after D+SFN group (47.88±35.00, p=0.02) and were statistically significant. There 
was no statistical difference observed from the Wilcoxon Signed Rank test. 
CYP24A1 expression (N=2) was statistically significant (p<0.0001) from both the 
One- way ANOVA and the Brown-Forsythe test (p<0.0001). As expected, D alone group 
(36.16±8.66) demonstrated statistically significant response. SFN alone (2.69±0.90, 
p<0.0001), D+SFN group (2.00±2.8, p=0.0009) and TSA alone (0.29±0.34, p=0.0002) 
showed smaller change in CYP24A1. When combined with D, TSA showed the second 
highest response in CYP24A1 (13.24±2.31,p<0.0001) and was statistically significant. 
No treatment showed statistical significance in CYP27B1 (N=3) expression. 
Results summary compared to control:  D alone (-0.16±0.41), SFN alone (-0.16±0.34), 
D+SFN (-0.67±0.06) and D+TSA (-0.67±0.06) decreased CYP27B1 expression while TSA 
alone (0.66±0.60) tended to increase its expression. There was no statistical difference 
observed from the Wilcoxon Signed Rank test. The results for RT-PCR experiments are 
presented in Fig 5.1. 
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Fig 5.1: mRNA Expressions of Vitamin D Responsive Genes in MCF-7 Cells. (a) 
Cyp24a1 showed the highest response in D only group; (b) TRPV6 showed the highest 
response in D+SFN group. Treatments had no effect on (c) Vitamin D receptor (VDR) and 
(d) Cyp27b1 when compared to control. The data were analyzed by One-way ANOVA with 
*p <0.05, **p<0.01, ***p<0.001 and **p<0.0001 as significant.  
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5.4.2 Histone Acetylation Status  
Both epigenetic modifiers used in our experiments are known to have well-
demonstrated HDAC inhibitor properties. However, SFN has a more diverse biochemical 
effect, including triggering increased expression of many cytoprotective proteins in the cell 
than TSA (positive control). To test the relative HDAC inhibition by SFN and TSA, we 
measured nuclear HDAC I/II enzyme activity and changes in histone protein acetylation to 
measure the extent of alteration in histone acetylation status. MCF-7 cells were seeded at 
10,000 cells/well in a 96-well, opaque walled plate. Cells were treated at 70% confluency 
with the desired treatments and incubated for 24 hours before the assay was conducted. 
Our expectation was that the selected dosages of SFN (20 μM) and TSA (1 μM), are 
sufficient to provide significant changes in histone acetylation in MCF-7 cells. The HDAC 
assay results are presented in Fig 5.2.  
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Fig 5.2: HDAC Activity in MCF-7 cells. No significant difference was observed among 
the treatments. Each data point represents mean± SEM (N=3).  
The overall HDAC activity (N=3) was insignificant from One-way ANOVA 
analysis and the treatments showed minimal to no HDAC inhibitor activity. TSA alone 
group (-107.31±43.3) and SFN alone (-45.67±29.46) demonstrated the expected response 
to HDAC inhibition, albeit insignificant. D alone group (194±194) showed no inhibition 
and so did D+TSA group (260±185.6). D+SFN group (-45.67±66.11) showed similar 
effects as SFN alone group.  
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5.4.3 ATP-dependent Cell Viability Assay 
To determine cell viability, we measured cellular ATP activity. MCF-7 cells were 
seeded at 10,000 cells/well in a 96-well, opaque walled plate. Cells were treated at 70% 
confluency with the desired treatments and incubated for 24 hours before the assay was 
conducted. Our expectation was that the selected dosages of SFN (20 μM) and TSA (1 μM) 
with vitamin D (100 nM), are sufficient to decrease viability in MCF-7 cells. The results 
are presented as percent (%) control in Fig 5.3. 
           
 
 
 
 
 
 
 
 
 
 Fig 5.3: ATP-dependent Cell Viability in MCF-7 cells. No effect of treatments was 
observed on ATP-dependent viability. Values are representative of three independent 
experiments (N=3) and are expressed as percent (%) control.  
 
 93 
 
5.4.4 ATP-independent Cell Viability Assay 
     To determine cell viability in an ATP-independent manner, we measured 
cellular MT Cell Viability Substrate activity. MCF-7 cells were seeded at 10,000 cells/well 
in a 96-well, opaque walled plate. Cells were treated at 70% confluency with the desired 
treatments and incubated for 24 hours before the assay was conducted. Our expectation 
was that the selected dosages of SFN (20 μM) and TSA (1 μM) with vitamin D (100 nM) 
would be sufficient to decrease viability in MCF-7 cells. Two- way ANOVA test was 
performed to test for time X treatment interaction. 
    Compared to control, all treatments were significant different at all time points 
(p<0.0001) with an overall significant interaction(p<0.0001). Tukey’s post test showed 
significant difference in D+SFN (p<0.0001) and D+TSA (p<0.0001) at 0 and 48 hours, 
with an increase in cytotoxicity by SFN and TSA at 48 hours. There was no significant 
difference among the treatments at 6, 12 and 24 hours. The results are presented as relative 
luminescence in Fig 5.4. 
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Fig 5.4: ATP-independent Cell Viability in MCF-7 cells. Maximum decrease in cell 
viability was observed at 48H. Each data point represents 4 replicates and results are 
expressed as (Mean±SEM).  
5.4.5 Apoptosis in MCF-7 cells 
           We used Caspase-Glo® 3/7 lytic assay and measured the degree of caspase cleavage 
of the substrate. The cleavage liberates free aminoluciferin, which is consumed by the 
luciferase enzyme, generating signals proportional to caspase-3/7 activity (used as a proxy 
measure of apoptosis). In other words, the higher the activity of the enzyme, the higher the 
luminescent signal. MCF-7 cells were seeded at 10,000 cells/well in a 96-well, opaque 
walled plate. Cells were treated at 70% confluency with the desired treatments and 
incubated for 24 hours before the assay was conducted. Our expectation was that the 
selected dosages of SFN (20 μM) and TSA (1 μM) with vitamin D (100 nM) would be 
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sufficient to induce apoptosis in MCF-7 cells. The results are presented as relative 
luminescence in Fig 5.5. 
 
 
 
 
 
 
 
 
 
 
Fig 5.5: Apoptosis in MCF-7 cells. All treatments demonstrated significant decrease in 
caspase 3/7 activity in MCF-7 cells. Values are representative of four independent 
experiments (N=3) and represented as percent (%) control (Mean±SEM). Tukey’s post test 
showed no significant difference between D+SFN when compared to D alone.   
5.4.6 Clonogenic Assay 
Clonogenic assays, first tested in 1956 and later modified to fit several mammalian 
cell types, including stem cells, essentially test every cell in a population for its ability to 
undergo “unlimited” cell division [14]. This assay is especially suitable to determine cell 
reproductive death post-treatment with ionizing radiation as well as other choice of 
cytotoxic compounds. The general principle is, only a fraction of the cells will retain the 
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capacity to produce colonies. We treated MCF-7 cells as per protocol (described in the 
methods section) for three weeks with desired treatments. We then counted the cell 
colonies (Fig 5.6) formed and the calculated the surviving fraction (SF). There seems to be 
a trend of decreased colony formation when compared to control after three weeks (N=3). 
Summary of treatment vs control: DMSO (0.15±0.07), D alone (0.02±0.005), SFN alone 
(0.024±0.005), D+SFN group (0.024±0.0005), D+TSA (p=0.03, 0.0015±0.0015) and TSA 
(p=0.03). Data is represented in the form of a surviving fraction (SF) curve in Fig.5.7.  
   DMSO                    D                      SFN                  D+SFN            D+TSA               TSA 
 
Fig 5.6: Clonogenic Assay in MCF-7 Cells. Untreated controls (DMSO) with 60 and 56 
clones, respectively, formed after seeding 1000 cells per well. D treatment group had 30 
and 26 clones per well, respectively, while SFN group had 11 and 30. D+SFN group had 
33 and 22 clones respectively, while neither D+TSA or TSA showed any colony formation.  
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(A)                                                                                             
(B)                                                                           
Fig 5.7: (A) Surviving Fraction Curve from Clonogenic Assay in MCF-7 Cells. (A) 
D+TSA group (p< 0.03) and TSA group (p<0.03) significantly reduced colony formation 
in MCF-7 cells. (B) Sample control (DMSO) cell picture on day 0.  
5.4.7 Migration Assay 
MCF-7 cells were plated and treated as per protocol described above. We then 
calculated the % closure for each treatment compared to the control per the formula shown 
in the methods section. Compared to control (N=3) the combination groups D+SFN 
(0.87±0.09) and D+TSA (0.86±0.07), showed no difference in migration (Fig 5.8). D alone 
(0.89±0.09) and TSA alone (0.90±0.10) groups showed moderate reduction in migration 
while SFN alone (0.80±0.07) demonstrated the opposite effect in MCF-7 cells.    
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Fig 5.8: Percent (%) Closure in MCF-7 cells. No significant difference was observed in 
MCF-7 cells when compared to control.  
5.5 Discussion 
Breast cancer is the most frequently diagnosed cancer in women [15]. Breast cancer 
ranks second as a cause of cancer death in women. Overall, breast cancer death rates 
declined by 36% from 1989 to 2012 due to improvements in early detection and treatment, 
translating to the avoidance of approximately 249,000 breast cancer deaths [5].  
A large proportion of breast cancer cells contain the VDR protein. However, the 
level of expression is variable within individual cells and, therefore, the biological response 
to 1,25-dihydroxyvitamin D3 varies for an individual patient’s cells as well as between 
patients. One of the key factors regarding the activity of 1,25-dihydroxyvitamin D3 is its 
availability in the breast cancer environment. This is maintained by the balance between 
synthesis and catabolism of vitamin D. Many epidemiological studies have reported 
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positive associations between gene polymorphisms and risk of breast cancer; these include 
vitamin D related genes such as polymorphisms in VDR, vitamin D-binding protein, as 
well as the CYP24A1 gene [3]. In the present study, our chosen treatments had no effect 
on VDR expression in MCF-7 cells. 
Intracellular calcium plays a critical role in many fundamental cellular processes 
such as proliferation, apoptosis, and secretion. Therefore, calcium levels are tightly 
controlled in cells and any disruptions in intracellular calcium homeostasis play a critical 
role in tumor progression in all cancer types. Studies have been conducted to analyze how 
intracellular calcium homeostasis and the associated calcium signaling pathways are 
altered in breast cancer cells compared with normal mammary gland cells. Calcium 
channels are either upregulated or downregulated depending on the types of cancer. One 
such example is the altered expression of TRPV6 in prostate, pancreatic, thyroid, colon, 
ovary, and breast cancer [16]. TRPV6 mRNA was first shown to be regulated by 
1,25(OH)2D3 [17] in Caco-2 cells, a human intestinal cell line. The epithelial calcium 
channel TRPV6 is upregulated in breast carcinoma compared with normal mammary gland 
tissue [18] and TRPV6 overexpression is strongly associated with the invasive status. It 
regulates both breast cancer cell migration and invasion [19]. Although studies have shown 
TRPV6 to be increased in breast carcinoma [20], one study found TRPV6 mRNA to be 
expressed at very low levels in MCF-7 cells[18]. Although we did not find any significant 
association of vitamin D with TRPV6 expression, D+SFN significantly increased its 
expression, which is along the line of what we hypothesized. 
The primary effect of exposure of breast cancer cells to 1,25-dihydroxyvitamin D3 
is cell cycle arrest due to changes in the functional status of the proteins that regulate cell 
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cycle [21]. 1,25(OH)2D can also induce morphological changes associated with apoptosis 
in breast cancer cells [22]. 1,25-dihydroxyvitamin D3 can inhibit the invasion and 
metastasis of cancer cell 1,25(OH)2D and has potent anti-angiogenic properties that can 
inhibit tumor cell invasion [23]. Effect of 1,25-dihydroxyvitamin D3 on cell proliferation 
can also be mediated in an indirect way, via interference to the function of estrogen 
receptors (ER) [24]. 1,25-dihydroxyvitamin D3 and its analogues reduce the expression of 
ERα, which in turn reduces the level of mitogenic signals to breast cancer cells from 
estrogens.  
CYP27B1 is present in some breast cancer cells and may lead to the autocrine 
synthesis of 1,25-dihydroxyvitamin D3 from 25(OH)D3. It has been shown that breast 
adipocytes also express CYP27B1 and could bio-activate 25(OH)D3 to 1,25-
dihydroxyvitamin D3 and in a paracrine fashion deliver 1,25-dihydroxyvitamin D3 to the 
breast epithelium. The expression of CYP27B1 can be considered a central mechanism in 
the association between active vitamin D and its antitumor effects [25]. In a recent study, 
a targeted ablation of CYP27B1 was accompanied by significant acceleration in initiation 
of spontaneous mammary tumorigenesis where cell proliferation, angiogenesis, cell cycle 
progression, and survival markers were up-regulated in tumors, and apoptosis was down-
regulated [26]. In the present study, we found that CYP27B1 expression was not affected 
by the treatment groups. 
The availability of 1,25-dihydroxyvitamin D3 is also determined by its degradation, 
along with its activation. This process is initiated by the 24-hydroxylation of 1,25-
dihydroxyvitamin D3 by the enzyme, CYP24A1. In normal tissues, this enzyme is induced 
in response to 1,25-dihydroxyvitamin D3 exposure, providing a regulatory mechanism that 
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maintains the concentration of 1,25-dihydroxyvitamin D3 at a non-toxic level. Genome 
hybridization studies have revealed that in certain human breast cancers the CYP24A1 
gene is amplified and this may cause a reduction in the level of 25(OH)D3 and 1,25-
dihydroxyvitamin D3 level and could allow cells to proliferate unduly [27]. We found that 
CYP24A1 expression was significantly decreased when added SFN to vitamin D, which is 
the opposite of what we hypothesized. However, in advanced cancers, this role might prove 
to be very beneficial. 
Phytochemicals have been studied extensively for the treatment of various diseases 
and disorders [28]. They exhibit a wide range of safety and target multiple pathways and 
targets in breast cancer cells [29]. Current evidence suggests that naturally occurring 
phytochemicals can target breast cancer stem cells (CSCs) [1, 30]. Hence, phytochemicals 
are proposed to be useful in the treatment of cancer. Consumption of cruciferous vegetables 
such as broccoli, correlates with decreased risk of cancer induction. This protective effect 
has been shown to be in part due to the presence of an isothiocyanate (ITC)- glucoraphanin 
[31, 32]. The four important ITCs formed from glucosinolates by the activity of myrosinase 
are benzyl-ITC, allyl-ITC, phenylethyl-ITC (PEITC) and methylsulphinylbutyl-ITC 
(sulforaphane). PEITC [33] and sulforaphane [34] are two well-studied ITCs for their 
anticancer activities. Sulforaphane has been found to inhibit proliferation, angiogenesis, 
and metastasis as well as induce cell cycle arrest and apoptosis in breast cancer cells. It 
reactivated expression of ER-α in MDA-MB-231 cells, whereas, in combination with 
tamoxifen, reduced proliferation in MDA-MB-231 cells. Sulforaphane treatment caused 
cell cycle arrest and decreased cyclin A, cyclin B1 and CDC2 expression in breast cancer 
(MDA-MB-231) cells [35]. Finally, sulforaphane decreased the production of IL-1β, IL-6, 
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TNF-α, interferon-γ, IL-4, platelet-derived growth factor and VEGF in MDA-MB-231 
cells [36]. Although more cited for its antioxidative and anti-inflammatory defense 
mechanisms, the induction of proliferation arrest and apoptotic cell death primarily 
contribute to its anticancer functions. [37-39] However, the precise molecular mechanisms 
of sulforaphane-elicited anticancer effect are not thoroughly elucidated. [40] 
Modified histones have gained importance as biomarkers of breast cancer 
prognosis. The investigations carried out on mechanisms of histone modifications are also 
promising for the development of efficient HDAC inhibitor therapies. 
It is not clear from the results as to how the HDAC inhibitors work when combined 
with vitamin D. We did observe some predicted response to D in genes such as CYP24A1, 
and TRPV6. However, SFN and TSA had opposing effects in most cases. Clonogenic assay 
findings confirmed that D+SFN group was more effective than D alone group even though 
we did not reach statistical significance. Overall, we demonstrated significant association 
between vitamin D and the HDAC inhibitors as we hypothesized but merits further 
exploration due to the opposing effects of SFN and TSA. 
Insights into the biology of breast cancers have been gained from the identification 
of genes commonly mutated in these cells signaling pathways and have led to paradigms 
that have informed the study of epigenetic alterations in cancer. These insights are also 
currently being used to develop new diagnostic and prognostic assays and potential 
therapies for breast cancer. 
In summary, we state that the components of the vitamin D pathway can potentially 
be used both as treatment and preventive strategies for breast cancer. In cancers with low 
VDR expression, it may be possible that future treatments could target the genomic and 
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epigenomic level alterations to increase VDR expression by modulating expression of 
transcription factors or utilizing HDAC inhibitors, respectively.  
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    6.1 Abstract  
It is relatively unknown how dietary bioactive compound, sulforaphane, in 
partnership with vitamin D, regulate gene expression linked to colorectal cancer. It has 
been suggested that the combination of various bioactive components with vitamins is 
crucial for their potential anticancer activities. METHODS: This study employed a 
combinatorial chemo preventive strategy to investigate the impact of dietary histone 
deacetylase inhibitor i.e. sulforaphane on chromatin remodeling in human colorectal 
carcinoma. To understand the epigenetics-mediated changes in gene expression in 
response to sulforaphane and vitamin D, Caco-2 cells were exposed for 24 hours to 
vitamin D (100nM) either alone or in combination with L-sulforaphane and TSA 
(20μM and 1μM respectively) at 70% confluency (proliferating) and after 13 days post 
confluency (fully differentiated) and Changes to VDR, CYP24A1, CYP27B1 and 
TRPV6 gene expressions were quantified using real-time PCR-based assays. Histone 
deacetylase inhibitor activity was assessed using HDAC I/II assay that measured global 
changes in acetylation status. RESULTS: In proliferating Caco-2 cells, D+SFN 
(p<0.04) increased VDR expression and decreased CYP27B1 (p<0.01) more than D 
alone (p=0.38 and p=0.07 respectively). However, in differentiated Caco-2 cells, none 
of the genes had significant changes from D alone group. D+SFN (p=0.99) 
demonstrated an opposing effect from D alone and decreased VDR expression. 
Although statistically significant, D+SFN (p=0.01) effects on HDAC inhibitor activity 
was lower than TSA alone (p<0.0004) or SFN alone group (p<0.0014). 
CONCLUSION: These data suggest that colon cancer cells respond to dietary 
components differently under different culture conditions. The effect of vitamin D and 
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sulforaphane is selective and gene-specific in the complex multistep process of 
colorectal carcinogenesis in vitro. 
 
Key words: HAT, histone acetyltransferase; HDAC, histone deacetylase; SFN, 
sulforaphane; TSA, Trichostatin A; VDRE, vitamin-D response elements. 
6.2 Introduction 
Colorectal cancer is one of the most invasive and the third most common cancer in 
both men and women in the United States. Among men and women combined, colorectal 
malignancies are the second most common cause of cancer mortality in the United States, 
with approximately 50,000 deaths each year [1]. Although, a serum vitamin D level of 20 
ng/mL to 50 ng/mL is considered adequate for healthy people, it is more reasonable to say 
serum 25(OH)D3 levels of 30 ng/mL is physiologically beneficial in preventing chronic 
diseases like cancer. Per a study using data from NHANES 2000–2004, up to 78% of 
Americans have a serum levels less than 30ng/ml of 25(OH)D3 [2]. 
Vitamin D has been known to play an important role in bone and mineral 
homeostasis. However, it has been studied for its anti-neoplastic roles ever since it was 
discovered that colon cancer mortality rates were the highest in places with the least 
amount of sunlight in the US [3], suggesting a protective role of Vitamin D. The active, 
hormonal form of vitamin D, 1α,25-dihydroxyvitamin D [1α, 25(OH)2D] mediates its 
actions through activation of the Vitamin D Receptor (VDR), a ligand-dependent 
transcription factor.[4] The development of many cancers is often associated with a 
reduced expression of the vitamin D receptor protein resulting in decreased cellular 
sensitivity to 1α,25-dihydroxyvitamin D [1α, 25(OH)2D]  and a possible loss of the anti-
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proliferative action provided by vitamin D [5, 6]. Our understanding of epigenomic 
alterations in colorectal cancer, is less advanced than that of our understanding of gene 
mutations, but substantial progress has recently been made in this area [7]. However, the 
exact mechanisms are yet to be explored.  
Epigenetic effects, including changes in histone acetylation status, influence 
chromatin remodeling and gene expression in cancer cells. To date, no other study has 
looked at these specific vitamin D- dependent gene expressions in relation to histone 
modification in colorectal cancer cells. We have used Caco-2 cells as our model as opposed 
to HCT116 or other frequently used colon cancer cell lines. This is because Caco-2 cells 
are more commonly used as fully differentiated cells that mimic intestinal mucosal cells 
and therefore, are a preferred choice in studies involving intestinal uptake e.g. drug 
interventions. This study will also address the unique question as to how Caco-2 cells 
behave as colorectal cancer cells for the first time.  
Many bioactive compounds have been shown to alter genetic and epigenetic 
profiles in various cancers. Of these compounds, sulforaphane (SFN), found in cruciferous 
vegetables such as kale, cabbage, broccoli sprouts etc., has been present as one of the most 
potent, natural (histone deacetylase) HDAC inhibitors to date.[8] Trichostatin A (TSA) is 
a fungal metabolite with well-known histone deacetylase inhibitor activity as well and 
often used as positive controls in experiments with natural HDAC inhibitors such as 
sulforaphane. 
The objective of this study is to determine to what extent treatment with the histone 
deacetylation inhibitors (HDACs) sulforaphane or Trichostatin A (TSA), influences 
vitamin D-induced transcriptional activity. The rationale for this study is that treatment of 
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cells with these epigenetic modifiers will alter the acetylation status of histone proteins. 
This, in turn, will loosen the association of DNA with the histone protein complex of the 
allowing increased access of the vitamin D receptor - RXR heterodimer to the vitamin D 
response element (VDRE) found in the promoter of vitamin D-inducible genes.  
6.3 Methods  
6.3.1 Cell Culture 
Cells were treated on day 7 (proliferating) 14 from the date of seeding into 6-well 
plates (differentiated). The experiment included six different treatment groups namely- 
DMSO control (0.1%), 1,25 (OH)2D3 (100nM), SFN (20 µM), TSA (1µM), 1,25 (OH)2D3 
+ SFN and 1,25 (OH)2D3 + TSA (APPENDIX G).. After treatment, the cells were 
incubated for 24 hours before harvesting. Caco-2 cells were obtained from the American 
Type Culture Collection (HTB-37; American Type Culture Collection, Rockville, MD). 1, 
25 (OH)2D3 was purchased from Enzo Life Sciences, Plymouth Meeting, PA. Trichostatin 
A and SFN were purchased from Sigma-Aldrich, St. Louis, MO. Real-time PCR materials, 
including all primers and master mix were purchased from Applied Biosystems, Foster 
City, CA. Cell culture dishes were bought from Costar, Cambridge, MA. All other cell 
culture materials and materials for RNA isolation and cDNA synthesis were purchased 
from Life Technologies, Grand Island, NY.  
6.3.2 RNA Isolation and Reverse Transcription 
At the completion of the treatment period, cells were washed with saline, then 
treated with 1 mL Trizol per well of a 6-well plate, and cells were scraped to be harvested 
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for subsequent RNA extraction.  Cells were frozen at -80°C until RNA was ready to be 
isolated in collection tubes. To isolate the RNA, 200 µL chloroform was added to each 
homogenate for phase separation. Isopropanol (500 µL) was then used to precipitate the 
RNA. Washing three times with 1 mL of 75% ethanol was followed by the addition of 40 
µL of Diethyl pyrocarbonate (DEPC) water. The samples were then incubated for 10 
minutes at 56°C to ensure maximum RNA solubility. RNA samples were then quantified 
using a Nanodrop machine (λ260/280). cDNA was prepared using the SuperScript III First 
Strand Synthesis System for RT-PCR (Life Technologies, Grand Island, NY). Details of 
the protocol are listed in APPENDIX H. 
6.3.3 Real Time PCR 
For all experiments, mRNA expressions of GAPDH, VDR, CYP24A1, CYP27B1, 
and TRPV6, were measured by ViiA™ 7 Real-Time PCR System (Applied Biosystems, 
Foster City, CA). Reactions consisted of 10 µL of SYBR GREEN Gene Expression Master 
Mix (Applied Biosystems, Foster City, CA) with forward and reverse primers (10 nM each) 
and 10 µL of DNAse/RNAse Free Water with 100 ng of cDNA. Duplicates were set up for 
each sample. The levels of VDR, CYP24A1, CYP27B1, and TRPV6 were measured by 
the comparative ΔΔCT method (ThermoFisher Scientific, 2016). For each sample, the 
relative abundance of GAPDH and the target genes were obtained. The difference between 
those two abundances (target gene- GAPDH) is the ΔCT for that sample which were the 
values used for statistical analysis. The mean ΔCT values were then normalized against the 
mean ΔCT values of the control sample, Dimethyl Sulfoxide (DMSO), resulting in a ΔΔCT 
value. 2 was raised to the – ΔΔCT to produce a relative quotient (RQ) for each sample, 
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with the RQ of the control being one. RQ values were used to create the mRNA expression 
curves for each gene. Primer sequences are available on APPENDIX A. 
6.3.4 Histone Deacetylase (HDAC) Assay 
We used the HDAC-Glo™ I/II Assay (luminescent) (Promega, 2017). The assay 
uses an acetylated, live-cell-permeant, luminogenic peptide substrate that can be 
deacetylated by HDAC activities. Deacetylation of the peptide substrate is measured using 
a coupled enzymatic system in which a protease in the Developer Reagent cleaves the 
peptide from aminoluciferin, which is quantified in a reaction using Ultra-Glo™ 
Recombinant Luciferase. The HDAC-mediated luminescent signal is persistent and 
proportional to deacetylase activity.  
Cells were harvested 24 h after treatment with SFN (20 µM) and TSA exposure (1 
µM), and cell lysates were analyzed for HDAC activity, as reported [10].  
6.3.5 ATP Assay 
We used the CellTiter-Glo® 2.0 Assay (Promega, 2017). This assay provides a 
homogeneous method to determine the number of viable cells in culture by quantitating 
the amount of ATP present. Luminescence readout is directly proportional to the number 
of viable cells in culture. Cells were harvested 24 h after co-treatment with SFN (20 µM) 
and TSA (1 µM), and cell lysates were analyzed for ATP activity as per protocol. 
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6.3.6 MT Assay 
We used the RealTime-Glo™ MT Cell Viability Assay (Promega, 2017), and 
measured cell viability continually in the same sample well up to 48 hours. This gave us 
more information about the mode of action of our treatments about time dependence. The 
nonlytic nature and rapid response of the assay made it possible to monitor cell viability 
over time in the same well. The assay measures the reducing potential of viable cells, and 
is ATP-independent, providing an orthogonal method for viability or cytotoxicity 
determination. 
Luminescence readout is proportional to the number of viable cells in culture. Cells 
were harvested 24 h after co-treatment with SFN (20 µM) and TSA (1 µM), and cell lysates 
were analyzed for ATP activity. 
6.3.7 Caspase 3/7 Assay 
We used the Caspase-Glo® 3/7 Assay (Promega, 2017) to measure apoptosis in 
proliferating Caco-2 cells. The assay provides a pro luminescent caspase-3/7 DEVD-
aminoluciferin substrate and a proprietary thermostable luciferase in a reagent optimized 
for caspase-3/7 activity, luciferase activity and cell lysis. Adding the single Caspase-Glo® 
3/7 Reagent in an "add-mix-measure" format results in cell lysis, followed by caspase 
cleavage of the substrate. This liberates free aminoluciferin, which is consumed by the 
luciferase, generating a "glow-type" luminescent signal that is proportional to caspase-3/7 
activity. 
          Cells were harvested 24 h after co-treatment with SFN (20 µM) and TSA (1 µM), 
and cell lysates were analyzed for caspase 3/7 activity.  
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6.3.8 Migration Assay 
A simple scratch test is used to determine the rates of closure following treatments 
to assess their efficacy. Caco-2 cells were seeded in 6-well plates at a density of 300,000 
cells/well and allowed to attach overnight. Once the cells were 70% confluent, wounds 
were created using the etching at the bottom of the wells as guide, using a p-200 pipette 
tip. The wells were then washed with 1X sterile PBS and treated as designed. Photographs 
were taken on day 0 at four reference points (4 quadrants) and marked as the “0Hr”. Each 
wound was then followed over the course of 24 hours to determine the rate of closure in 
response to the treatments. Photographs were taken again and marked as “24Hr”. This 
entire experiment was repeated for an N=3. Percent closure was calculated as below: 
% closure= (0Hr avg. wound size- 24Hr avg. wound size)/ 0Hr avg. wound size 
6.3.9 Statistical Analysis 
Results from real-time PCR were analyzed using one-way ANOVA with a p-value 
of <0.05 used as the cut-off for statistical significance. The analysis was setup as a 
randomized block design with each experiment as a block. Dunnett’s Multiple Comparison 
Tests was also used to find which means of the treatment groups differed significantly from 
the control (DMSO) and used a P-value of <0.05 as a cut-off for statistical significance. 
All statistical analyses and figures were generated using GraphPad Prism (v 7.04). Tukey’s 
post-test was conducted to determine significant multiple comparison differences. For all 
assays ,the results are expressed as Mean±SEM. 
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6.4 Results 
6.4.1 Vitamin D-responsive gene expression 
We hypothesized that the expression of vitamin D-inducible genes would be 
increased by concomitant treatment of cells with SFN and TSA. We measured, with and 
without the HDAC inhibitors, the mRNA expression of genes known to be involved in 
vitamin D action and cell metabolism: namely, VDR (vitamin D receptor), CYP24A1 (24 
hydroxylase), CYP27B1 (1α hydroxylase) and TRPV6 (transient receptor potential, 
vanilloid family, member 6 calcium-specific channel protein) by real time quantitative 
polymerase chain reaction (RT-PCR); results are expressed as RQ values (2^-ΔΔCT)±SEM. 
(a) Undifferentiated Caco-2 Cells 
In proliferating Caco-2 cells, VDR expression was overall significant (p=0.03) 
from one-way ANOVA and Browne-Forsythe test (p<0.0001). From Dunnett’s multiple 
comparison test, VDR was significantly increased by D+SFN (3.44±0.39, p=0.01) and 
D+TSA (3.10±0.85,p=0.01) when compared to control. Tukey’s multiple comparison 
maintained the significance when compared to vitamin D , D+SFN (p=0.02) and D+TSA 
(p=0.03). 
CYP24A1 mRNA levels (N=4) were significantly affected by our experiment 
(p=0.01) from the one-way ANOVA and Browne-Forsythe test (p=0.02) analyses. There 
was about 372 fold increase by vitamin D alone (372.2±94.1, p=0.03). Vitamin D + SFN 
treatment did not increase CYP24A1 mRNA expression more than vitamin D alone; 
however, concomitant treatment of vitamin D + TSA resulted in a marked increase in 
CYP24A1 gene expression. ~3,500 fold  (3555±695, p=0.003) in proliferating Caco-2 
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cells. Tukey’s multiple comparison test did not show any additional significant association 
among vitamin D and the combination groups D+SFN or D+TSA. CYP27B1 mRNA 
expression (N=6) was not affected by vitamin D or the combination treatment with 
epigenetic modifiers SFN and TSA.     
TRPV6 mRNA expression (N=6) was increased by 44% by vitamin D alone 
(0.44±0.80, p=0.01). Combination treatment with vitamin D and TSA increased TRPV6 
gene expression by 93% (0.93±1.01, p=0.0006), and this increase was significantly 
different than vitamin D alone (p=0.04) from Tukey’s posttest. Although SFN had no 
significant effect on TRPV6 both alone and in combination with vitamin D, TSA alone 
was significantly different from control (0.13±0.39, p=0.003). Relative mRNA 
expression, compared to the DMSO control treatment, for proliferating Caco-2 cells are 
presented in Fig 6.1. 
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Fig 6.1: mRNA Expressions of Vitamin D Responsive Genes in Proliferating Caco-2 
Cells. (a) Vitamin D receptor (VDR) expression was increased more than D alone in 
D+TSA group; (b) TRPV6 showed the highest response in D+TSA group, (c) CYP24A1 
showed similar response as TRPV6 in D+TSA group; and (d) there was no effect on 
CYP27B1 expression across the treatment groups. Results are from N>3 experiments for 
all genes and *p<0.05, and **p<0.01 represent significance. 
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(b) Differentiated Caco-2 Cells 
In fully differentiated Caco-2 cells, CYP24A1 expression was increased ~650 fold 
by vitamin D treatment (643.2±122.2, p<0.0001) alone, but combination treatment with 
epigenetic modifiers and vitamin D blunted the increase. Albeit the decrease relative to D 
alone, D+SFN (142.2±29.53, p<0.0001) and D+TSA (191.3±29.38, p<0.0001) 
significantly increased CYP24A1 expression, ~140 fold and ~190 fold respectively, when 
compared to control. This association was intact when compared to D alone, i.e the 
combination treatments were significantly different from D alone, D+SFN (p=0.001) and 
D+TSA (p=0.009). The HDAC inhibitors SFN and TSA response on CYP24A1 were also 
significantly different from D alone, SFN (p<0.0001) and TSA (p<0.0001) from Tukey’s 
post test.  
TRPV6 expression in fully differentiated Caco-2 cells was significantly increased 
in D+TSA group (2.8±0.78, p=0.01) only.  SFN had no effect on TRPV6 expression both 
alone and in combination with vitamin D.  
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We found that neither vitamin D treatment nor vitamin D combination treatment 
with epigenetic modifiers influenced VDR and CYP27B1 mRNA expression (Figure 6.2).  
                         
Fig 6.2: mRNA expressions of vitamin D responsive genes in fully differentiated Caco-
2 cells. (a) CYP24A1 showed the highest response in D only group and was significantly 
different from D+SFN and D+TSA groups, (b) TRPV6 was significantly increased in 
D+TSA group, (c) VDR and (d) CYP27B1 expressions were not affected by the treatments. 
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Results are from N>3 experiments for all genes and *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001 represent significance. 
 
(c) Animal Tissue Sample Analyses 
We also analyzed small intestinal scrapings from APC 1638 mice (5 male+5 
female). The animals were fed on a diet containing 450 mg of SFN/kg. We then analyzed 
the cDNA samples (prepared as per protocol in APPENDIX H) for VDR, CYP24A1, 
CYP27B1 and TRPV6. We found that TRPV6 expression was significantly increased 
(30±8.8, p<0.0001) in sulforaphane group when compared to no sulforaphane (control) 
group (Fig. 6.3).  
 
 
 
 
 
 
 
 
Fig 6.3: TRPV6 Expression in Animal Tissue Samples. Sulforaphane increased TRPV6 
expression in small intestinal scrapings from TNF𝝰- K/O mice. GAPDH was used as 
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internal loading control. Results are expressed as Mean±SEM of 10 animal samples 
(N=10). 
6.4.2 Histone acetylation status  
To test the relative HDAC inhibitor activity of SFN and TSA, we measured nuclear 
global HDAC I/II activity. Caco-2 cells were seeded at 10,000 cells/well in a 96-well, 
opaque walled plate. Cells were treated at 70% confluency with the desired treatments and 
incubated for 24 hours before the assay was conducted. The cells were in their proliferating 
stage while we carried out the HDAC assay. Our expectation was that the selected dosages 
of SFN (20 μM) and TSA (1 μM), would cause significant changes in histone deacetylation 
activity in Caco-2 cells.  
  All treatments significantly increased HDAC inhibitor activity (n=6) when 
compared to control. Vitamin D had 30 fold decrease in HDAC activity (-30.17±7.07, 
p=0.03) which was similar to D+SFN alone (-32.75±9.63) and D+TSA group (-30.42±4.2). 
SFN alone had a bigger effect on HDAC inhibition (-42.92±9.5) with the highest effect 
seen in TSA alone group as expected (-47.5±8.9). 
 The results of HDAC assay (normalized to control- DMSO) are presented in Fig 
6.4.  
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Fig 6.4: HDAC Activity in Proliferating Caco-2 Cells. All treatments significantly 
decreased HDAC activity in the system. Each data point represents Mean± SEM (N=10). 
The data were analyzed by One-way ANOVA and *p <0.05, **p<0.01, and ***p<0.001 is 
significant. Tukey’s post test showed no significant difference among vitamin D and the 
combination treatments of D+SFN and D+TSA.  
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6.4.3 ATP-dependent Cell Viability Assay 
To determine cell viability, we measured cellular ATP activity. Caco-2 cells were 
seeded at 10,000 cells/well in a 96-well, opaque walled plate. Cells were treated at 70% 
confluency with the desired treatments and incubated for 24 hours before the assay was 
conducted. Our expectation was that the selected dosages of SFN (20 μM) and TSA (1 μM) 
with vitamin D (100 nM) would be sufficient to decrease ATP-dependent viability in 
proliferating Caco-2 cells. There was no effect of vitamin D and the HDAC inhibitors on 
cell viability in an ATP-dependent manner, although Bartlett’s test (p<0.0001) and 
Browne-Forsythe Test (p=0.03) results came back as significant. Tukey’s posttest also 
showed no effect on ATP-dependent cell viability in vitamin D and the combination 
treatments. The results are presented as percent (%) control in Fig 6.5. 
 
 
 
 
 
 
 
 
Fig 6.5: ATP-dependent Cell Viability in Proliferating Caco-2 Cells. There was no 
significant difference among the treatment groups on cell viability. Values are 
 125 
 
representative of three independent experiments (N=3). (Mean±SEM) represented as % 
control. No significant difference was observed across the treatments.  
6.4.4 ATP-independent Cell Viability Assay 
To determine cell viability in an ATP-independent manner, we measured cellular 
MT Cell Viability Substrate activity. Caco-2 cells were seeded at 10,000 cells/well in a 96-
well, opaque walled plate. Cells were treated at 70% confluency with the desired treatments 
and incubated for 24 hours before the assay was conducted. Our expectation was that the 
selected dosages of SFN (20 μM) and TSA (1 μM) with vitamin D (100 nM) would be 
sufficient to decrease viability in proliferating Caco-2 cells. Two- way ANOVA test was 
performed to test for time X treatment interaction. 
Compared to control, all treatments were significant different at all time points 
(p<0.0001) with an overall significant interaction(p<0.0001). Tukey’s post test showed 
significant difference in D+SFN (p<0.0001) and D+TSA (p<0.0001) at 12 hours, D+TSA 
only (p=0.02) at 24 hours, again D+SFN (p<0.0001) and D+TSA (p<0.0001) at 48 hours 
with observed increase in cytotoxicity by SFN and TSA. The results are presented as 
relative luminescence in Fig 6.6. 
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Fig 6.6: ATP-independent Cell Viability in Proliferating Caco-2 Cells.  All treatments 
significantly changed cell viability in a time-dependent manner. Maximum decrease in cell 
viability was observed at 24H. Each data point represents 4 replicates and results are 
expressed as (Mean±SEM).  
6.4.5 Apoptosis in Proliferating Caco-2 Cells 
 We used Caspase-Glo® 3/7 lytic assay and measured the degree of caspase 
cleavage of the substrate. The cleavage liberates free aminoluciferin, which is consumed 
by the luciferase enzyme, generating the luminescent signal that is proportional to caspase-
3/7 activity (used as a proxy measure of apoptosis). In other words, the higher the activity, 
the higher the luminescent signal. Caco-2 cells were seeded at 10,000 cells/well in a 96-
well, opaque walled plate. Cells were treated at 70% confluency with the desired treatments 
and incubated for 24 hours before the assay was conducted. Our expectation was that the 
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selected dosages of SFN (20 μM) and TSA (1 μM) with vitamin D (100 nM) would be 
sufficient to induce apoptosis in proliferating Caco-2 cells. The results are presented as 
relative luminescence in Fig 6.7. 
 
 
 
 
 
 
 
 
 
 
Fig 6.7: Apoptosis in Proliferating Caco-2 Cells.  All treatments had significant increase 
in caspase 3/7 activity. Values are representative of four independent experiments (N=4) 
and represented as Mean±SEM. Tukey’s post test showed no significant difference between 
D+SFN and D+TSA when compared to D alone.   
6.4.6 Migration Assay 
Caco-2 cells were plated and treated as per protocol described previously. The 
representative pictures per treatment (one of four wounds created) are shown in Fig 6.8. 
We then calculated the % closure (Fig. 6.9) for each treatment compared to the control per 
the formula shown in the methods section. Compared to control (N=3), D alone group 
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(1.18±0.15) showed protective effect in Caco-2 cell migration. The combination groups 
D+SFN (0.70±0.06) and D+TSA (0.87±0.02), as well as the individual HDAC inhibitors, 
SFN (0.79±0.08) and TSA (0.88±0.10) alone showed no significant difference in 
migration. 
  
Fig 6.8: Migration assay in Proliferating Caco-2 Cells. The combination treatments had 
no change in migration, D alone showed a tendency to prevent migration while the rest of 
the treatment groups were unable to reflect this change. 
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Fig 6.9: Percent (%) Closure in Proliferating Caco-2 Cells. No significant difference 
was observed when compared to control in migration but was overall significant (p=0.03). 
D+SFN reduced migration significantly when compared to D (p=0.02) from Tukey’s 
posttest.  
6.5 Discussion 
Colorectal cancer (CRC) is a major cause of cancer morbidity and mortality in the 
US. Factors involved in the pathogenesis of colorectal cancer appear to be complex and 
heterogeneous and include dietary and lifestyle factors as well as inherited and somatic 
mutations [9]. It is believed that although the underlying form of genomic or epigenomic 
instability determines the types of mutations that occur in colon cancer, the selective 
pressures that lead to the clonal evolution of the tumors are largely the same across all 
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colorectal cancers. This can explain why certain genes are more frequently mutated in 
colon cancers than in other cancers (e.g. breast cancer, prostate cancer) and vice versa.  
Epigenetic mechanisms that modify chromatin structure are divided into the 
following: DNA methylation, histone modifications, nucleosome remodeling and non-
coding RNAs. The complex interaction of these mechanisms regulate the way genes are 
expressed in different cell types, developmental stages and disease states, including cancer. 
[10] 
Histone modification is controlled by a balance in activity between histone 
acetyltransferase (HAT) and histone deacetylase (HDAC) activities. The former adds an 
acetyl group to histones resulting in uncoiling or “opening” of the chromatin structure, 
facilitating gene transcription. The HDACs remove acetyl groups from the histones, 
leading to increased binding of DNA to histone proteins, and the coiling or “closing” of 
chromatin, which inhibits transcription [11]. The HDACs are known to be critical in the 
regulation of expression of genes important for cell survival, proliferation, differentiation, 
and apoptosis [12]. HDACs also act as members of a protein complex responsible for 
recruitment of transcription factors to the promoter region of genes, including those of 
tumor suppressors, and regulation of acetylation status of specific cell cycle regulatory 
proteins [13]. High HDAC expression and histone hypoacetylation have been observed in 
cancer with associated transcriptional repression of genes, providing a rationale for the 
investigation of HDAC inhibitors in cancer therapeutics [14].  
Sulforaphane is an isothiocyanate derived from cruciferous vegetables and is 
particularly enriched in broccoli and broccoli sprouts. Sulforaphane has been received great 
attention due to its promising chemo preventive and therapeutic effects established in a 
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variety of human cancer cell lines and in preclinical cancer models, including colon 
cancer.[15] Although more cited for its antioxidative and anti-inflammatory defense 
mechanisms, the induction of proliferation arrest and apoptotic death primarily contribute 
to the anticancer mechanisms against post-initiated/transformed cells. [15, 16, 17] 
However, the precise molecular mechanisms of sulforaphane-elicited anticancer effect are 
not thoroughly elucidated.[18] 
Vitamin D receptor (VDR) is a transcription factor that binds to specific vitamin D 
response elements (VDREs) within the promoter regions of its primary target genes [19]. 
Most VDR target genes contain multiple VDREs. In the absence of a ligand, VDR acts via 
co-repressor proteins i.e.  histone deacetylases (HDACs) [20]. HDACs can also inactivate 
non-histone proteins, e.g. p53 by deacetylation. Therefore, HDACs have multiple 
influences in cellular processes. [21] Studies in animals (xenografted tumors, chemically-
induced carcinogenesis, genetic models for CRC) and cultured cells show that 
1,25(OH)2D3 exerts a variety of antitumor effects on colon carcinoma cells, including 
inhibition of proliferation, increase in differentiation, sensitization to apoptosis, and 
inhibition of angiogenesis and metastasis [22] Moreover, two studies have shown that 
APCmin mice lacking the VDR gene develop bigger intestinal tumors [23] Zheng et al., 
2012). In addition, 1,25(OH)2D3 inhibits the pro-tumoral properties of CRC-associated 
fibroblasts and, accordingly, high VDR expression in these fibroblasts is associated with a 
favorable clinical outcome for metastatic CRC patients [208]. Mechanistically, these 
effects are based on regulation by 1,25(OH)2D3 of crucial genes controlling the cell cycle 
CDKN1A/ p21CIP1, CDKN1B/p27KIP1,c-MYC, and others), apoptosis (BAX, and 
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others), invasion (metalloproteases, and others), the epithelial-to-mesenchymal transition 
(CDH1/E-cadherin, and others) and angiogenesis [24]. 
A series of studies have shown that the expression of VDR and CY27B1 in colon 
epithelial cells increases at early steps of tumorigenesis (adenomas and well differentiated 
carcinomas) as compared to that in normal cells but it strongly declines in advanced, poorly 
differentiated tumors [25,26]. Thus, although rarely mutated, VDR and Cyp27b1 are 
downregulated in a relatively high proportion of advanced colorectal tumors. [27].  
24-Hydroxylase, encoded by the CYP24A1 gene, is the key enzyme that catabolizes 
1,25(OH)2D3 to the less active calcitroic acid. It has been reported that CYP24A1 is 
overexpressed in several human tumor types and that changes in CYP24A1 expression are 
associated with cancer development and progression. A recent study showed that 
CYP24A1 expression is closely associated with CRC progression, and might be a novel 
prognostic biomarker for colorectal cancer. [28]  
TRPV6 mRNA was first shown to be regulated by 1,25(OH)2D3 [29] in Caco-2 
cells. The dependence of TRPV6 mRNA expression on the VDR-mediated genomic 
actions of 1,25(OH)2D3is supported by increased intestinal TRPV6 mRNA expression 
after injection of mice with 1,25(OH)2D3[30,31]. It regulates TRPV6 expression by a 
process that requires new mRNA and protein synthesis and the point of regulation lies most 
likely at the transcriptional level [32] 
It is clear from the results that TSA enhanced vitamin D activity in more than one 
genes related to Vitamin D. The responses differed within the same gene based on the 
condition of Caco-2 cells (differentiated vs. proliferating) as they were gene-specific. SFN, 
really had the opposite effect of TSA in fully differentiated cells. However, in proliferating 
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cells, it showed a greater impact in combination with vitamin D in two of the four genes. 
Overall, we saw a mixed association between vitamin D and SFN from what we 
hypothesized and therefore merits further exploration. 
It has been proposed that gene mutations and epigenetic alterations contribute to 
colon cancer formation through the activation of oncogenic pathways and the inactivation 
of tumor suppressor genes, which regulate hallmark behaviors of cancers (Fearon et al., 
2011). Insights into the biology of colorectal cancers have been gained from the 
identification of genes commonly mutated in these cells signaling pathways in colon cancer 
and have led to paradigms that have informed the study of epigenetic alterations in cancer. 
These insights are also currently being used to develop new diagnostic and prognostic 
assays and potential therapies for colorectal cancer. 
In summary, we state that the components of the vitamin D pathway can potentially 
be used both as treatment and preventive strategies for colorectal cancer. In colorectal 
cancers with low VDR expression, it may be possible that future treatments could target 
the genomic and epigenomic level alterations present to increase VDR expression by 
modulating expression of transcription factors or utilizing HDAC inhibitors, respectively.  
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CHAPTER 7 
 
DISCUSSION 
Epigenetics refers primarily to alterations in gene expression at the promoter 
regions of genes. Unlike genetic mutations, epigenetic alterations do not change the actual 
genetic sequence and, therefore, are part of a new avenue in cancer research [1]. 
7.1 Epigenetic Alterations in Cancer 
The epigenetic landscape is largely a reflection of factors that determine the state 
of the chromatin, which determines whether the DNA is accessible to proteins that control 
gene transcription or not. A relaxed or “open” chromatin state allows for gene transcription, 
whereas a condensed or “closed” chromatin state prevents gene transcription [2]. The 
epigenetic mechanisms currently believed to play a role in cancer include:  
1) DNA methylation of cytosine bases in CG rich sequences, called CpG Islands;  
2) Post-translational modifications of histones, which regulate the packaging 
structure of the DNA (called chromatin);  
3) microRNAs and noncoding RNAs; and  
4) nucleosome positioning   
7.1.1 DNA Methylation 
Gene silencing may occur due to methylation of DNA in the promoter region of 
genes [3]. DNA methyltransferase enzymes (DNMTs) add a methyl group (-CH3) to the 
DNA structure causing hypermethylation and possibly a reduced expression of tumor 
suppressor genes. DNA methylation refers to the enzymatic addition of a methyl group to 
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the 5-position of cytosine by DNA methyltransferases (DNMT) to produce 5-
methylcytosine, a normal base in DNA [4]. Most CpGs (a dinucleotide sequence) are 
methylated in normal mammalian cells with unmethylated CpGs being typically present 
only in regions of DNA called CpG Islands. CpG islands are regions in the genome where 
the percentage of the CpG dinucleotides is higher than expected- greater than 200–500 
bases in length with greater than 50% GC content [5]. CpG islands, although protected 
from methylation under normal circumstances, can become aberrantly methylated in 
cancer. Methylation of CpG islands within the promoter region is correlated with 
transcriptional silencing although it appears that decreased gene expression is only 
characteristic of a subset of methylated genes in CRC [6, 7]. 
Unmethylated CpG islands within the promoter region of genes are correlated with 
an open chromatin structure (euchromatin) whereas methylated CpG islands are correlated 
with a condensed, closed chromatin structure (heterochromatin) and transcriptional 
silencing [8]. For example, normal colonic epithelium generally has unmethylated CpG 
islands in the promoter regions of genes, whereas aberrant hypermethylation of promoter 
associated CpG islands is a hallmark of neoplasms. 
The concept of “CpG island shores” [9] (areas of less dense CpG dinucleotides) 
have been linked to hypermethylation in cancer [10].  The methylation of these CpG island 
shores are generally tissue specific and has recently been shown to be altered in colorectal 
cancer [10, 11].  This driving role of aberrant methylation of CpG island shores in the 
development of cancer is still controversial and remains to be supported with additional 
studies.  
 139 
 
It is important to recognize that DNA methylation is a normal mechanism in the 
mammalian genome by which cells regulate gene expression. Most of the CpG sites in the 
human genome, which are located outside of promoter regions, are heavily methylated. 
The methylation state of a gene is regulated by a family of DNA methyltransferases 
(DNMTs). When the DNMTs are not functioning properly, either due to structural 
abnormalities caused by epigenetic changes or functional inabilities, formation of 
malignant cells and/or progression leads to the development of a specific cancer e.g. 
colorectal, breast, prostate cancer etc.  
7.1.1.1 DNMT Inhibitors 
DNMT inhibitors, also referred to as demethylating agents, have been under 
preclinical and clinical investigation for over 30 years [12]. After formation of an 
irreversible complex with DNMT, the enzymes degrade [13] and prevent methylation of 
daughter DNA in CpG islands during DNA replication. At low concentrations (30-300nM), 
these inhibitors (e.g. 5-Aza-2'-deoxycytidine or AZA) exhibit potent DNA 
hypomethylation properties, whereas high concentrations (≈3–10 μM) are cytotoxic [14]. 
Other DNMT inhibitors in an earlier phase of development include 5-aza-2′-deoxycytidine 
(DAC) analogues such as SGI-110 and zebularine.  
Although DNA methylation is one of the two key epigenetic mechanisms in cancer, 
we focused on histone modification for our research, which will be discussed now.  
 140 
 
7.1.2 Histone Modification 
DNA is packaged into chromatin and coils around structural histone proteins in 
cells. The histones are responsible for maintaining the shape and structure of chromatin. 
Many post translational alterations can occur at specific amino acids (e.g. lysine) in the 
exposed tail of histone proteins, which result in a conformational change in the chromatin 
structure and in the transcription of important genes necessary to suppress carcinogenesis, 
such as tumor suppressor genes. These chromatin alterations include acetylation, 
methylation or phosphorylation [15]. 
Histone acetylation is controlled by a balance in activity between histone 
acetyltransferase (HAT)-adds the “acetyl” group (open state) and histone deacetylase 
(HDAC)- removes the “acetyl” group (closed state). The HDACs are known to be critical 
in the regulation of expression of genes important for cell survival, proliferation, 
differentiation, and apoptosis [3]. HDACs also act as members of a protein complex that 
recruit transcription factors to the promoter region of genes, e.g. tumor suppressor genes, 
and regulation of acetylation status of specific cell cycle regulatory proteins [16].  
7.1.2.1 HDAC Inhibitors 
High HDAC expression and histone hypoacetylation have been observed in cancer 
with associated transcriptional repression of genes, providing a rationale for the 
investigation of HDAC inhibitors in cancer therapeutics [17]. 
Aberrant HDAC activity has been documented in a variety of tumor types and led 
to the development of HDAC inhibitors as anticancer therapeutics [18]. Modest clinical 
benefits were previously reported with relatively weak HDAC inhibitors such as valproic 
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acid and phenylbutyrate in advanced solid tumors or hematologic malignancies [19]. More 
potent HDAC inhibitors include both class-specific (I and II) inhibitors (entinostat and 
romidepsin) and pan HDAC inhibitors (vorinostat, belinostat and panobinostat). Clinical 
studies in solid tumors are ongoing with HDAC inhibitors, alone or in combination with 
other agents.  
7.2 Epigenetics and CRC 
Epigenetic alterations, like gene mutations, contribute to the pathogenesis and 
molecular heterogeneity of various cancers. This is highlighted by the identification of a 
CpG island methylator subtype of colorectal cancer (CRC) that has a distinct epigenome 
with a high frequency of methylated genes [20].  Our understanding of epigenomic 
alterations in colorectal cancer, however, is less advanced than that of our understanding 
of gene mutations, but substantial progress has recently been made in this area [2]. In the 
following sub-sections, we will discuss the role of epigenetics in CRC, including the 
contribution of epigenetics to the molecular heterogeneity of colorectal cancer, and the 
clinical applications of these epigenetic alterations as biomarkers for early detection, 
diagnosis, and management of patients with CRC. 
7.2.1 Epigenetic pathophysiology of CRC 
The classic view of cancer is that it arises because of the accumulation of mutations 
in key tumor-suppressor genes or oncogenes, which deregulate homeostatic functions and 
cause the transformation of normal cells into cancer cells. Sequencing of colon cancer 
genomes has revealed that there is only a small number of functionally important gene 
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mutations out of the hundreds of mutations found in the average colon cancer genome. A 
recent analysis of approximately 13,000 genes revealed mutations in the coding sequence 
of approximately 67 genes in the average colon cancer genome, of which a subset of 12 
genes were proposed to be the genes most likely to be involved with cancer formation in 
individual cancers [21]. The current cancer genome sequencing efforts demonstrate that 
most cancer genomes carry hundreds of mutations, providing a major challenge to 
determine which of these mutations play a pathogenic role in the formation of the cancer 
(“driver mutations”) and which are merely a consequence of this process (“passenger 
mutations”).  
Furthermore, CRC can be sub-grouped based on the type of genomic instability that 
they display. Different patterns of mutant genes demonstrate the underlying genomic 
instability in cancer and influences the susceptibility to and selection for specific mutations. 
It is believed that although the underlying form of genomic or epigenomic 
instability determines the types of mutations that occur in CRC, the selective pressures that 
lead to the clonal evolution of the tumors are largely the same across all CRCs. This 
concept can explain why certain genes are more frequently mutated in colon cancers than 
in other cancer types (e.g. breast cancer, prostate cancer) and vice versa. 
It has been proposed that gene mutations and epigenetic alterations contribute to 
colon cancer formation through the activation of oncogenic pathways and the inactivation 
of tumor suppressor genes, which regulate hallmark behaviors of cancers [22].  
7.3 Epigenetics and BC 
Breast cancer is generally induced by the accumulation of altered gene regulations 
which cause abnormal cell growth and expansion. In addition to genetic mutations, 
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epigenetics also play an important role in breast cancer tumorigenesis. Studies have 
focused on initiating molecular mechanisms in cancer development; identification of new 
biomarkers to predict breast cancer aggressiveness and the potential of epigenetic therapy 
[23].  
7.3.1 Epigenetic pathophysiology of BC 
7.3.1.1 DNA Methylation 
Aberrant methylation plays an important role in BC development. DNA 
hypomethylation has been generally demonstrated on a genome-wide scale in cancer 
studies while hypermethylated DNA regions of certain genes, especially normally 
unmethylated CpG islands, were frequently reported. A growing number of studies have 
focused on hypermethylated genes in breast cancer which have crucial roles in cell-cycle 
regulation, apoptosis, tissue invasion and metastasis, angiogenesis and hormone signaling 
[24, 25]. Aberrant methylation profiles of these genes are associated with BC stage and 
prognosis, therefore methylation status of key cell cycle regulating genes have been 
proposed as reliable markers for BC [26].  
Global DNA hypomethylation is prevalent in breast tumors. Up to 50% of the cases 
represent reduced 5-methylcytosine content when compared with matched-control normal 
tissues [23]. Whole genome distribution of aberrant DNA methylation in eight breast 
cancer cell lines and normal human mammary epithelial cells was analyzed by [27].  It was 
shown that hypomethylation was distributed throughout the whole genome and 
simultaneous hypermethylation occurred at CpG-rich regions. In addition, 
hypomethylation was three- to five-times more frequent than hypermethylation. Studies 
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have shown that promoter hypermethylation of tumor suppressor genes has mostly resulted 
in downregulation of gene expression.  
7.3.1.2 Histone Modification 
In breast cancer, investigations carried out on histone modifications are relatively 
newer than DNA methylation studies. Post-translational histone modifications have a 
critical role in breast tumorigenesis and aggressiveness of prognosis. In addition, they are 
potential therapeutic targets. Since different breast cancer subtypes represent distinct gene 
expression profiles, it is important to clarify the effect of histone marks on gene expression 
levels in breast tumors. However, there are limited studies about histone modification 
patterns in breast cancer tumors, though the numbers of investigations are increasing in 
this field. 
In a study of global histone modifications in breast cancer tumors, histone 
modification levels were significantly higher in steroid receptor [27]. The study concluded 
that reduced detection levels of these histone marks would be correlated with poor 
prognostic characteristics. Another study investigated the arginine and lysine methylation 
of BRCA1 in breast cancer cell lines and breast tumor tissue samples [28] and found that 
BRCA1 is methylated at arginine and lysine residues both in cell lines and tumor samples. 
However, lysine methylation was only detected in triple negative MDA-MB-231 cells, 
while arginine methylation was detected in both MDA-MB-231 and MCF-7 cells. MCF-7 
cells are estrogen, progesterone receptor positive, HER2 receptor negative and show wild-
type p53. Per these results, they proposed that methylation may affect the ability of BRCA1 
binding to specific promoters or affects protein-protein interactions that alter the 
recruitment of BRCA1 to these promoters. 
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Another study demonstrated lysine histone modification patterns in breast cancer 
cell line MCF-7 and normal mammary epithelial cell line MCF-10A and found no 
significant difference [29].  In another study, histone modification profiles in MCF-7 cells 
demonstrated that the promoters were the most abundant regulatory elements [30]. 
Modified histones have gained importance as biomarkers of breast cancer prognosis. The 
investigations carried out on mechanisms of histone modifications are also promising for 
the development of efficient HDAC inhibitor therapies. 
7.4 Epigenetics of Vitamin D 
Insufficient intake or metabolism of vitamin D appears to play a key role in the 
development of a multitude of diseases affecting the central nervous system, the skeleton 
and various organs where metabolic disturbances may contribute to the generation of 
malignancies [31]. In the following section, we will discuss the effects of different 
epigenetic components of vitamin D metabolism.  
7.4.1 Regulation of Vitamin D Receptor (VDR) 
Although several rapid and non-genomic actions of active vitamin D have been 
described [32], most of the effects of vitamin D are mediated by the vitamin D receptor 
(VDR). VDR is the only protein that binds 1,25(OH)2D3 effectively at sub-nanomolar 
concentration [33]. This finding somewhat simplifies the understanding of vitamin D 
signaling, since the physiological effects of the hormone largely overlap with the actions 
of the transcription factor VDR, a ligand-activated transcription factor.  
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Unbound 1,25(OH)2D3 freely enter a cell and bind to a VDR present in the 
cytoplasm or the nucleus [34].  VDR is classified as a class II nuclear receptor, which forms 
a heterodimer with retinoid X receptor (RXR). This heterodimer binds to the vitamin D 
response elements (VDREs), which are in the promoter region of key genes [35]. Many 
vitamin D target genes, e.g. p21, p27 and e-cadherin, have been found to regulate cell cycle 
arrest and cell differentiation [36, 37]. Therefore, it has been proposed that 1,25(OH)2D3 
or its pharmaceutical analogs can possibly be used as a therapeutic for cancer by mediating 
VDR activity.  
VDR is one of approximately 1900 transcription factors, which are encoded by the 
human genome [38]. In addition, VDR is a member of the superfamily of nuclear receptors, 
most of which are specifically activated by lipophilic molecules [39]. The transcription 
factor VDR is the only high-affinity target for 1,25(OH)2D3 within the cell nucleus [33]. 
Its lipophilic properties allow 1,25(OH)2D3 to pass through all biological membranes, i.e., 
gene regulation by vitamin D does not involve additional plasma membrane-associated 
signal transduction steps. Moreover, VDR is rather ubiquitously expressed, i.e., most 
human tissues and cell types are responsive to 1,25(OH)2D3 [40].  
Proliferation of the non-malignant breast epithelial cell line, MCF-12A, was 
sensitively and completely inhibited by 1,25(OH)2D3 (70 nM) [41] while MDA-MB-231 
cells demonstrated a resistance towards 1,25(OH)2D3 (> 100 nM) which correlated 
significantly with reduced Vitamin D receptor (VDR).  
7.4.1.1 Mechanism of Action 
Vitamin D exerts its activity in association with its receptor (VDR) and another 
nuclear receptor, the retinoid X receptor (RXR), in combination with histone 
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acetyltransferase (HAT). The chromatin of a previously inactive gene can become relaxed 
upon binding of transcription factors to DNA recognition sequences. This process is 
counteracted by recruitment of factors having HDAC activity. Accessory transcription 
factors (ATFs) may be localized proximal or distal of VDR, with distances of up to several 
hundreds of base pairs, which can be overcome by loop domains of the transcriptional 
complex [31]. 
7.4.2 Regulation of CYP27B1 
CYP27B1 possesses 1α-hydroxylase activity, which is critical for the last step in 
vitamin D activation. This enzyme is found in the inner mitochondrial membrane and 
converts 25(OH)D3 to its active form 1,25(OH)2 D3. It is mainly expressed in the proximal 
tubule of the kidneys, but it is also expressed in many other vitamin D target tissues, albeit 
at lower activity levels [42]. The CYP27B1 gene has been reported to harbor a CpG island 
in its promoter [43]. However, recent DNA sequence updates have shifted the CpG island 
from the CYP27B1 promoter region into the gene coding sequence.  
7.4.2.1 Mechanism of Action 
The promoter region of CYP27B1 contains a negative vitamin D response element 
or nVDRE [44]. This region is responsible for 1,25(OH)2D3-dependent trans repression. 
This repression seems to be achieved through recruitment of both HDACs and DNMTs by 
VDR/RXR to the promoter region of CYP27B1 [45]. In cancer, expression of CYP27B1 
is often downregulated. This may be explained by increased methylation of the CpG island 
located within CYP27B1. Methylation of CYP27B1 in various diseases cause reduced 
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local activation of 1,25(OH)2D3 thus reducing local levels of active vitamin D and 
restricting its functions [46]. 
In the breast cancer cells MDA-MB231, CYP27B1 hypermethylation led to gene 
silencing, while in prostate cancer cell lines, combination of the DNMT1 inhibitor and the 
HDAC inhibitor TSA resulted in increased activity of CYP27B1 [47].  
7.4.3 Regulation of CYP24A1 
The 1,25(OH)2D3 24-hydroxylase is an inner mitochondrial membrane enzyme, 
which catalyzes and inactivates both 25(OH)D3 and 1,25(OH)2D3 [48-50]. Its primary site 
of expression are the kidneys, playing a crucial role in regulating systemic vitamin D 
metabolite levels. However, CYP24A1 is also found in many other vitamin D target tissues 
i.e. skin, gut etc. The promoter of CYP24A1 is spanned by a CpG island which can be 
regulated by DNA methylation [46] and has several response elements including two 
VDREs. 
7.4.3.1 Mechanism of Action 
In healthy kidney, skeletal muscle, whole blood, brain, skin fibroblasts, and sperm 
the CYP24A1 promoter is not methylated [51], although the expression levels are highly 
variable. Although, methylation of CYP24A1 was low (5%) peripheral blood lymphocytes 
[52], it was highly methylated in full term human placenta (56%). In colon cancer cell lines, 
administration of anti-tumor drug, 5-aza-2-deoxycytidine (DAC), induced CYP24A1 
expression in a cell line-specific manner, independent of the methylation level of the 
promoter. In these cells, induction of CYP24A1 expression by DAC seemed to be 
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independent of CYP24A1 promoter methylation [53]. Moreover, the methylation level of 
the CYP24A1 promoter was comparably low both in colon adenocarcinomas and the 
adjacent mucosa, although the expression of CYP24A1 was significantly higher in the 
tumors [54]. Taken together, the regulation of CYP24A1 by DNA methylation appears to 
be tissue-dependent, both in health and disease.  
One study investigated the mRNA expression levels of the CYP24A1 gene in 
malignant and normal breast tissues [55] and found that the mRNA expression of 
CYP24A1 was significantly upregulated in the tumor tissues (P<0.01). This major 
difference revealed that the normal breast tissues transcriptionally expressed CYP24A1 
slightly. These results are suggestive of dysregulation of the vitamin D signaling and 
metabolic pathways during tumorigenesis in breast cancer.  
7.4.4 Regulation of TRPV6 
TRPV6 is a member of the vanilloid subfamily of transient receptor potential (TRP) 
proteins and functions as an epithelial calcium channel in organs, such as the intestine, 
kidney, and placenta [56]. TRPV6 mRNA expression is strongly regulated by 
1,25(OH)2D3 in the intestine and in Caco-2 (human colon) cells. 1,25(OH)2D3 regulates 
TRPV6 expression by a process that requires new mRNA and protein synthesis and the 
point of regulation lies likely at the transcriptional level. In Caco-2 cells, 1,25(OH)2D3  is 
the primary hormonal regulator of intestinal calcium absorption by a process involving an 
increase in transcellular calcium transport [57]. However, the molecular mechanism has 
not been fully described. TRPV6 mRNA was first shown to be regulated by 1,25(OH)2D3 
[58] in Caco-2 cells. The dependence of TRPV6 mRNA expression on the VDR-mediated 
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genomic actions of 1,25(OH)2D3 is supported by increased intestinal TRPV6 mRNA 
expression after injection of mice with 1,25(OH)2D3 and that TRPV6 expression was 
lower in vitamin D receptor knockout mice as compared to wild type mice [56]. Few studies 
have investigated TRP genes in human breast cancer and have demonstrated that TRPC6 
and TRPV6 expression increased in both breast cancer tissues and cell lines, with both 
TRPC6 and TRPV6 regulating cell proliferation [59]. In a study examining the effect of 
tamoxifen on TRPV6 function and intracellular calcium homeostasis in MCF-7 breast 
cancer cells, tamoxifen decreased the transport rates of calcium [60].  
7.4.4.1 Mechanism of Action 
The TRPV6 gene codes for an epithelial calcium channel protein known to play an 
important role in intestinal calcium absorption. Upregulation of TRPV6 mRNA expression 
in the colon may be an important mechanism of vitamin D-mediated calcium absorption. 
TRPV6 gene expression in Caco-2 cells was enhanced in presence of Vitamin D Receptor 
Elements (VDREs) in the promoter region [56].   
Migration and invasion are important features of malignant cells and their 
therapeutic inhibition might be critical to avoid metastasis of solid tumors. One study 
attempted to characterize the abilities of TRPV6 expressing cells, by studying their 
migration potential and the effect of channel [61]. They found that, TRPV6 was strongly 
expressed in breast adenocarcinoma tissue and TRPV6 mRNA expression was up-
regulated between 2fold and 15-fold compared with the average in normal breast tissue. 
Whereas TRPV6 is expressed in the cancer tissue, its role as a calcium channel in breast 
carcinogenesis is poorly understood. An in vitro model showed that TRPV6 can be 
regulated by estrogen, progesterone, tamoxifen, and 1,25(OH)2D3 and has a large 
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influence on breast cancer cell proliferation [59]. TRPV6 may be a novel target for the 
development of calcium channel inhibitors to treat breast adenocarcinoma expressing 
TRPV6. 
7.5 Epigenetics of Sulforaphane  
Cruciferous vegetables (crucifers), include species predominantly from 
Brassicaceae family and the more common members are cultivars of Brassica oleracea 
genus including broccoli, cabbage, cauliflower, Brussel sprouts, and kale; as well as 
Raphanus genus, i.e. various types of radish. The health benefits of these vegetables are 
partly due to the nature of the phytochemicals they contain and the glucosinolates [62], the 
enzymatic hydrolysis products that can modify genes [63]. Nutraceuticals can target 
survival, proliferation, invasion, angiogenesis, and metastasis, thereby influencing various 
steps of tumor cell development [64]. 
Sulforaphane is a bioactive food component or nutraceutical, with potential health 
benefits that are mainly exerted through epigenetic modification of genes. The principal 
role of sulforaphane in these epigenetic modifications is believed to be primarily due to its 
histone deacetylase (HDAC) inhibitor activity.  
7.5.1 Phase II Detoxification and SFN 
Potentially harmful, foreign compounds (e.g. carcinogens) [65, 66] often involve 
Phase I and II components, which eventually permits their excretion from the cells. A 
compound which activates Phase I and Phase II enzymes is called a bifunctional inducer; 
and, if it activates only Phase II enzymes, it is a monofunctional inducer [67]. Upon 
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treatment in the cells with oxidants including H2O2, oxidative stress and conformational 
changes occur. Therefore, for an optimal cellular detoxification environment, Phase II 
reactions should be at a rate that prevents intermediate products of Phase I from 
accumulating. Aliphatic sulforaphane acts as a monofunctional inducer, whereas the indole 
isothiocyanates (ITCs) from mature broccoli are bifunctional inducers derived from 
another glucosinolate, glucobrassicin [68].  
7.5.2 Histone Deacetylase Inhibition  
In a recent study to test whether SFN inhibits HDAC activity in vivo, an average 
daily dose of 7.5 μmol per animal for 21 days, suppressed the growth of human PC-3 
prostate cancer cells by 40% in male nude mice [69]. There was a significant decrease in 
HDAC activity in the xenografts, as well as in the prostates and mononuclear blood cells 
(MBC), of mice treated with SFN, compared to controls. In human subjects, a single dose 
of 68 g BroccoSprouts inhibited HDAC activity significantly in peripheral blood 
mononuclear cells (PBMC) 3 and 6 hrs. following consumption from the same study.  
In human embryonic kidney 293 cells, SFN dose-dependently increased the activity 
of TOPflash reporter and inhibited HDAC activity, resulting in an increase in acetylated 
histones [70]. Bioactive dietary supplements such as green tea polyphenols (GTPs) and 
sulforaphane (SFN) inhibit DNA methyltransferases (DNMTs) and histone deacetylases 
(HDACs), respectively, which are of central importance to cancer prevention. In a recent 
study of estrogen receptor ER-negative MDA-MB-231 cells, GTPs and SFN alone or in 
combination lead to the reactivation of ER expression which was consistently correlated 
with promoter hypomethylation and hyperacetylation [71]. General hypothesis regarding 
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SFN action was that the ability of SFN to target aberrant acetylation patterns, in addition 
to effects on phase II enzymes, might make it an effective chemoprevention agent.  
7.6 Epigenetics of vitamin D in CRC 
The components of the vitamin D pathway can potentially be used both as treatment 
and preventive strategies for CRC. The active metabolite 1,25 (OH)2 D3 targets the Wnt/β-
catenin signaling pathway by up regulating key tumor suppressor genes, which promotes 
an epithelial phenotype, but is only useful when the VDR is present [72]. In colorectal 
cancers with low VDR expression, it may be possible that future treatments could target 
the genomic and epigenomic level alterations present to increase VDR expression by 
modulating expression of transcription factors or utilizing HDAC inhibitors, respectively.  
Colorectal cancer can be treated by targeting transcription factors that down-
regulate the vitamin D receptor, which is essential for vitamin D to mediate its effects in 
promoting an epithelial phenotype. Furthermore, potential preventative measures to protect 
individuals from colon cancer include- increasing serum levels of 25(OH)D3 by either sun 
exposure, diet or supplements. 
7.6.1 Mechanistic links between vitamin D and CRC 
High levels of serum 25(OH)D3 are related to lower incidence rates in many 
cancers, particularly colon cancer [73-75]. 25(OH)D3 is a hepatic metabolite in the vitamin 
D pathway that is converted by the 1α-hydroxylase enzyme in the kidneys to form 
1,25(OH)2D3. The vitamin D pathway includes both endogenous (cutaneous synthesis) 
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and exogenous sources (diet, supplements) of vitamin D, so both can cause a significant 
increase in serum 25(OH)D3.  
Unbound 1,25(OH)2D3 enters a cell and bind to a VDR present in the cytoplasm 
or the nucleus [34]. VDRs are expressed in normal colonic cells, but it has been shown that 
VDR expression levels decrease in the later stages of colon cancer; the mechanism behind 
this phenomenon is not fully understood [76]. Therefore, treatment with 1,25(OH)2D3 may 
not be as effective in the later stages of colon carcinogenesis due to the development of 
cellular resistance to 1,25(OH)2D3. It has been suggested that both genomic and epigenetic 
modifications might be involved in the reduction of VDR expression [77-82].  For instance, 
Malinen and colleagues demonstrated that the down regulation of 25(OH)D3 due to 
reduced expression of CYP27A1 via HDACs can be overcome with the use of HDAC 
inhibitors [83]. Furthermore, it is proposed that an individual could reduce their risk of 
colorectal cancer approximately 30–50% by either increasing vitamin D intake to 2000 
IU/day or increasing their sun exposure to raise blood levels of 25 (OH)D3 to greater than 
30 ng/ml [84]. 
7.7 Epigenetics of vitamin D in BC 
A large proportion of breast cancer cells contain the VDR protein, however the 
level of expression is variable within individual cells [85] and, therefore, the biological 
response to vitamin D also varies between patients. The primary effect of exposure of 
breast cancer cells to 1,25 (OH)2D3 is cell cycle arrest due to changes in the functional 
status of the proteins that regulate cell cycle [86]. An effect of 1,25(OH)2D3 on cell 
proliferation can also be mediated in an indirect way, via interference to the function of 
estrogen receptors (ER)[87]. 1,25 (OH)2D3 and its analogues decrease the expression of 
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ERα, which in turn reduces the level of mitogenic signals to breast cancer cells from 
estrogens [88]. Another mechanism of the anticancer action of 1,25 (OH)2D3 against 
breast cancer cells is that it down-regulates the expression of aromatase, which catalyzes a 
step-in estrogen synthesis [89].  
One of the key factors regarding the activity of 1,25 (OH)2D3 is its availability in 
the BC environment. This is maintained by the balance between synthesis and catabolism. 
CYP27B1 is present in some breast cancer cells, to control the autocrine synthesis of 1,25 
(OH)2D3, but this enzyme is also active in breast cancer microenvironment. It has been 
shown that breast adipocytes produce CYP27B1, bio-activate 25(OH)D3 to 1,25 (OH)2D3 
and in a paracrine fashion deliver 1,25 (OH)2D3 to the breast epithelium [90]. On the other 
hand, the availability of 1,25 (OH)2D3 is maintained by its degradation, maintained by the 
24-hydroxylase enzyme (CYP24A1). In normal tissues, this enzyme is expressed in 
response to 1,25 (OH)2D3 exposure, providing a negative feedback mechanism that 
maintains a steady concentration of 1,25 (OH)2D3 in the plasma [91]. Genome 
hybridization studies have revealed that in certain human breast cancers the CYP24A1 
gene is amplified and this may cause a reduction in the level of 1,25 (OH)2D3 and cause 
cells to proliferate unduly [87]. 
7.7.1 Mechanistic links between vitamin D and BC 
The mechanism behind reduction in BC risk related to vitamin D intake is mainly 
due to cell cycle arrest and apoptosis by 1,25(OH)2D3 [86, 92]. 1,25(OH)2D3 can also 
induce morphological changes associated with apoptosis in breast cancer cells [93]. 
1,25(OH)2D3 can also inhibit metastasis of cancer cells and has potential anti-angiogenic 
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properties that can inhibit tumor cell invasion [94]. Vitamin D can act as an anti-
inflammatory agent such that 1,25(OH)2D3 can down-regulate the expression of 
cyclooxygenase-2, which plays a role in prostaglandin synthesis in human breast cancer 
[89]. Many epidemiological studies have reported positive associations between gene 
polymorphisms and risk of BC; these include vitamin D related genes such as VDR, 
vitamin D-binding protein (VDBP), as well as the CYP24A1 gene [95]. 
Several studies have examined the effects of 1,25(OH)2D3 on mammary 
carcinogenesis in cells and animal models and found a protective role of 1,25(OH)2D3 in 
BC development. The relationship of vitamin D with risk of breast cancer may be subtype-
specific, with evidence of stronger effects of vitamin D for more aggressive breast cancer, 
especially in African women.  
7.8 Epigenetic effects of SFN in CRC 
Colorectal cancer (CRC) has high morbidity and mortality rates worldwide and is 
a global health problem. The conventional radiotherapy and chemotherapy regimen for 
CRC not only has a low cure rate but also causes side effects [96]. Many studies have 
shown that adequate intake of fruits and vegetables in the diet may have a protective effect 
on CRC occurrence, possibly due to the special biological protective effect of the 
phytochemicals in these foods. SFN is one such compound present in cruciferous 
vegetables. In colon cancer cells, sulforaphane is associated with decreased cell 
proliferation, cell cycle arrest and apoptosis [97].  
A few mechanisms that are known to be affected by SFN in CRC are as below: 
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7.8.1 Inhibiting phase I metabolic enzymes  
Cytochrome P450 is a major component of phase I metabolic enzymes and can 
convert xenobiotics into more electrophilic, reactive, mutagenic or even carcinogenic 
bioactive compounds. 1,25(OH)2D3 in Caco2 cells, can induce some cytochrome enzymes 
which can mediate the metabolism of carcinogens, making them less carcinogenic. 
Previous studies have shown that SFN competitively inhibited or covalently modified some 
cytochrome enzyme isoforms and reduced their expression, thereby inhibiting DNA-
adduct and chemical carcinogenesis [98, 99]. In another study, SFN was found to 
significantly reduce the expression of the enzyme mRNA in Caco-2 cells [100]. 
7.8.2 Inducing phase II metabolic enzymes  
Phase II metabolism is composed mainly of binding reactions, wherein carcinogens 
and their metabolite reactive oxygen species (ROS) bind to endogenous ligands such as 
glutathione and glucuronic acid. Currently, many studies have confirmed that SFN induces 
the expression of several phase II metabolic enzymes in CRC cells, including glutathione 
reductase (GR), glutathione S-transferase (GST), aldehyde reductase (AR), NAD[P]H: 
quinone oxidoreductase (NQO) and uridine 5’-diphospho (UDP)-glucuronosyltransferase 
(UGT) [96]. Glutathione reductase converts the active and oxidized glutathione to stable 
and reduced glutathione (GSH). Glutathione transferase catalyzes the binding of 
electrophilic substrate with GSH to induce its excretion. AR and NQO catalyze the 
conversion of metabolically active aldehydes and quinones to relatively stable alcohols and 
hydroquinones respectively, reducing their activities and damaging effects. UGT catalyzes 
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the transferring of β-glucuronic acid from UDP-glucuronic acid to active substrates, 
thereby increasing their solubility and facilitating their excretion.   
Treatment of Caco-2 cells with 25 μM SFN for 24 h significantly increased mRNA 
and protein expression levels of UGT1A1, 1A8 and 1A10 as well as their enzymatic 
activity [100]. It has also been shown that SFN and SFN-GSH significantly improved 
mRNA and protein expression levels of UGT1A1, mRNA expression level of GSTA1 and 
activity of bilirubin in HepG2 and HT-29 cells [101]. 
7.8.3 Inhibiting HDAC activity 
Nrf2 pathway is likely to play a role in the inhibition of HDAC by SFN. A study 
has found that carcinogen 1,2-dimethylhydrazine more likely induced CRC in wild-type 
Nrf2+/+ mice than in mutant Nrf2-/+ mice and that HDAC level in wild-type mice was 
significantly increased as compared to that in Nrf2-/+ mice upon treatment with 400 ppm 
SFN in diet (Rajendran et al., 2015). SFN treatment had a more profound effect on reducing 
tumors in wild-type mice than in Nrf2-/+ mice. Other studies have shown that SFN 
inhibited the activity of HDAC by promoting its degradation in the cytoplasm (Yin et al., 
2016).  
7.8.4 Cell cycle arrest 
Previous studies have shown that SFN arrested cell cycle in many types of CRC 
cells. For example, SFN arrested Caco-2 cells in the G1/G2 [100] and G2/M phases [102], 
and arrested HCT116 cells in the G2/M phase [103]. SFN also augmented the expression 
of p21, which exerted inhibitory activity on cyclin-dependent kinase (CDK) and regulated 
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the levels of many cell cycle proteins. While arresting HT-29 cells in the G0/G1 phase, 
SFN significantly induced the expression of p21 and reduced the expression level of some 
regulatory proteins, which is vital for G1phase, such as cyclin A, cyclin D1 and c-Myc, at 
high doses (>25 μM) [104].  
7.8.5 Inhibiting tumor angiogenesis 
Kim et al., 2015, have found that SFN significantly reduced the expression level of 
vascular endothelial growth factor (VEGF) and hypoxia inducible factor-1α (HIF-1α), both 
of which are associated with angiogenesis and tumor metastasis, and inhibited tumor 
metastasis in a dose-dependent manner in hypoxia-treated HCT116 cells [105]. SFN might 
inhibit CRC progression and tumor angiogenesis in a similar manner.  
7.8.6 Enhancing the efficacy of chemotherapy drugs 
Studies have shown that both SFN and antineoplastic agent oxaliplatin could inhibit 
the proliferation of Caco-2 cells in a dose-dependent manner. Pretreatment of HT-29 cells 
with 2.5 μM SFN activated the cancer drug PR-104A and reduced its EC50 by 3.6-fold. 
Similar results were observed with SW620 cells. However, SFN had little effect on normal 
colon cells [106]. Therefore, SFN combined with traditional chemotherapy drugs might 
reduce drug resistance and enhance drug efficacy. The potential chemopreventive effect of 
SFN on CRC has also been confirmed by in vivo animal studies. Animal experiments have 
shown that 2-6 h after oral gavage of 5-20 μmol/L SFN, the highest level of SFN was 
detected in small intestine, prostate, kidney and lung (in a descending order) [107]. 
Therefore, SFN might provide a targeted chemopreventive effect in the prevention of CRC.  
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7.9 Epigenetics of SFN in BC 
Phytochemicals have been studied extensively for the treatment of various diseases 
and disorders [96]. They exhibit a wide range of safety and target multiple pathways and 
targets in breast cancer cells [108]. Current evidence suggests that naturally occurring 
phytochemicals can effectively target breast cancer stem cells, [109, 110] and are proposed 
to be useful in the treatment of BC.  
Consumption of cruciferous vegetables such as broccoli, bok choy, Brussel sprouts 
etc. correlates with decreased risk of cancer induction and this protective effect has been 
shown to be in part due to the presence of an isothiocyanate (ITC) glucoraphanin [62, 111]. 
The four important ITCs formed from glucosinolates by the activity of myrosinase are 
benzyl-ITC, allyl-ITC, phenylethyl-ITC (PEITC) and methylsulphinylbutyl-ITC 
(sulforaphane). PEITC [112] and sulforaphane [113].  
Sulforaphane was found to inhibit proliferation, angiogenesis, and metastasis as 
well as induce cell cycle arrest and apoptosis in breast cancer cells. Sulforaphane 
reactivated expression and reduced proliferation in MDA-MB-231 cells, probably via 
histone modifications and DNA demethylation-facilitated activation of ER-α [71]. 
Sulforaphane treatment caused cell cycle arrest at S- and G2/M-phase with enhanced levels 
of p21WAF1 and p27KIP1 and decreased cyclin A, cyclin B1 and CDC2 expression in 
breast cancer cells [114]. It also decreased the production of IL-1β, IL-6, TNF-α, 
interferon-γ, IL-4, platelet-derived growth factor and VEGF in breast cancer cells [115]. 
In addition, sulforaphane has a marked effect on cell cycle checkpoint controls and 
cell survival and/or apoptosis in various other cancer cell lines, though the molecular 
mechanisms that remain poorly understood [116-120]. 
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The effect of SFN on various human cell lines, animal models as well as human 
subjects have been listed below: 
Table 7.1:  Summary of SFN effects in cancer  
Subjects SFN Dosage Duratio
n 
Outcome 
Measure 
Effect References 
Human  200 μmol 1 hour SFN 
metabolites 
in breast 
tissue 
(left)1.45±1.1
2 and (right) 
2.00±1.95 
pmol/mg 
tissue 
[121] 
Human 102 μmol 1 hour NQO1 mRNA 
expression 
Increase 
mRNA 
expression by 
200% 
[122] 
Cell Type SFN Dosage Duratio
n 
Outcome 
Measure 
Effect References 
HEK293 
(human 
embryonic 
Kidney cells) 
5µM SFN + 
100ng/L TSA 
48 hours HDAC 
activity 
Reduced 
HDAC activity 
SFN+TSA 
<60% 
SFN<30% 
TSA <25%  
[69] 
SW620 (human 
colon cancer 
cell) 
100 µM 72 hours Cell 
Proliferation 
<20% than 
control 
[123] 
Caco2, HT-29 
and SW480 
(human 
colorectal 
cancer cells) 
1, 5, 10 and 
20 
μmol  
24 and 
48 hours 
β-defensin-2 
(HBD-2) 
gene 
expression 
At 24 hours: 
1.6X increase 
(by 20 μmol) 
in HBD-2 
At 48 hours: 
2X increase 
(by 20 μmol)  
in HBD-2 
[124]  
HepG2 cells 
(human hepatic 
cancer cells) 
1.0, 2.5, 5.0 
and 10.0 
μmol 
6 hours CYP1A1 
mRNA 
expression 
Increased 
mRNA 
expression: 
1.0 μmol= 
2.2X 
   2.5 μmol= 
2.8X 
   5.0 μmol= 
3.8X 
 10.0 μmol= 
3.6X 
[125] 
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LNCap 
C4-2 (human 
prostate cancer 
cells) 
10 μmol 
20 μmol 
40 μmol 
24 hours Androgen 
Receptor 
(AR) 
And Prostate 
Specific 
Antigen 
(PSA) 
protein 
levels 
Decrease in AR 
and PSA 
protein 
expression by 
25% 
compared to 
control when 
treated with 
40 μmol SFN 
 
[126] 
Mice triple 
negative breast 
cancer (TNBC) 
cells  
Various 
Concentratio
ns of SFN 
72 h Effects of 
SFN 
treatments 
on Cell 
proliferation
, cell cycle 
arrest and 
apoptosis 
SFE exhibited 
antiproliferati
ve effects 
against 
multiple kinds 
of TNBC cells 
ex and in vivo 
[127] 
Animals SFN dosage Exposur
e time 
Outcome 
measure 
Effect  References 
F344 rats 5 µM 2 weeks colonic 
aberrant 
crypt foci 
(ACF) and 
multicrypt 
foci 
Reduction in 
the total ACF 
from 153 to 
109–115 (P < 
0.01) and 
multicrypt foci 
from 52 to 35 
(more than 
four 
crypts/focus; 
P < 0.05). 
[128] 
Sprague-
Dawley Rats 
(female) 
glucosinolate
s (25 and 100 
μmol) and 
isothiocyanat
es (25, 50, 
and 100 
μmol) 
5 days mammary 
tumor 
formation 
Reduced 
incidence at all 
doses of 
glucosinolate 
and 
isothiocyanate 
treatment (P = 
0.0197 and 
0.0190, 
respectively) 
[68]  
Sprague-
Dawley Rats 
(female) 
SFN 75 and 
150 μmol 
5 days Multiplicity 
of tumors 
Reduction in 
tumor 
multiplicity by 
75 and 150 
μmol, 0.45 and 
0.26 times 
respectively 
((P = 0.01) 
[99] 
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7.10 SFN in carcinogenesis: Overall 
It is important to understand the metabolism of drugs or pharmaceutical substances 
(also known as xenobiotic metabolism) or bioactive food components like SFN, to fully 
elucidate its mechanism of action.  The goal of xenobiotic metabolism is to transform 
various non-polar metabolites generated by multiple chemical reactions, to a more polar 
form that can then be more easily eliminated from the body. There are three phases of 
xenobiotic metabolism: (i) Phase I reactions introduce or expose functional groups on the 
drug to increase the polarity of the compound and activate them. The primary and first pass 
site of this metabolism occurs during hepatic circulation. Additional Phase I metabolism 
occurs in gastrointestinal epithelial, renal, skin, and lung tissues. Phase I reactions are 
broadly grouped into three categories, oxidation, reduction, and hydrolysis (ii) In Phase II 
reactions, these activated xenobiotic metabolites are conjugated with charged species such 
as glutathione (GSH), sulfate, glycine, or glucuronic acid. The addition of large anionic 
groups (such as GSH) detoxifies reactive electrophiles and produces more polar 
metabolites that cannot diffuse across membranes, and may, therefore, be actively 
transported. (iii) Conjugates and their metabolites are excreted from cells in Phase III of 
their metabolism. 
Sulforaphane (SFN) has shown to be an effective cancer chemopreventive agent in 
several animal carcinogenic models as presented in the summary table above (Table 7.1) 
and is thought to induce Phase II detoxification enzymes with promoter antioxidant 
response elements [129-131]. Recent work has implicated multiple mechanisms of 
sulforaphane action, with the majority of studies focusing on SFN as a potent Phase II 
enzyme inducer and additional evidence for cell cycle arrest and apoptosis. Early research 
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focused on Phase II enzyme induction by sulforaphane as well as on the inhibition of 
enzymes involved in carcinogen activation, but there has been growing interest in other 
mechanisms of chemoprotection by sulforaphane. Upregulation of Phase II metabolism is 
likely a critical mechanism leading to cancer prevention by sulforaphane in the “initiation” 
phase, helping to more rapidly eliminate genotoxins from the body.  
To date, very few human clinical trials have evaluated the effects of sulforaphane 
on cancer outcome; however, several pilots and Phase I human sulforaphane trials have 
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CHAPTER 8 
 
SUMMARY AND CONCLUSIONS 
How the complex interactions of human exposures, metabolism, and genetics are 
related to the development of colorectal and breast cancers being influenced by vitamin D 
and sulforaphane is not yet known. 
A more complete understanding of vitamin D and sulforaphane in human 
carcinogenesis from organ site–specific biologic mechanisms, prospective serologic 
analyses, genetic variation, and short-term clinical trials including metabolomic profiling 
holds the key to elucidating the effect of vitamin D in colorectal and breast cancers in the 
future.  
Insights into the biology of these cancers have been gained from the identification 
of genes commonly mutated in the cell signaling pathways and have led to paradigms that 
enriched the study of epigenetic alterations in cancer. These insights are also currently 
being used to develop new diagnostic and prognostic assays and potential therapies for 
colorectal cancer. Possible mechanisms include, effects of vitamin D on cell proliferation 
and differentiation, and apoptosis.  
It is evident from the existing literature that clinical trials of vitamin D 
supplementation at both the blood and tissue levels are needed to pinpoint the specific 
mechanisms in both colorectal and breast cancer. Finally, examination of vitamin D in 
relation to cancer survival is a relatively uncharted area that deserves much greater 
attention.  
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Large-scale clinical cohort studies are critical and required to confirm the 
chemopreventive effects of SFN on CRC and BC. 
Future studies should determine whether sulforaphane in food might play a 
chemopreventive role through the molecular mechanisms discussed previously, as well as 
determine its effective concentration, bioavailability and interactions with other dietary 
components. Understanding the distribution, metabolism and excretion of SFN in 
vivo could become a significant avenue of research.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 179 
 
 
 
 
APPENDIX A 
 
 
TABLE: GENE PRIMER SEQUENCES 
 
Genes Forward Seq. Reverse Seq. 
VDR 5'-GAG GGA ACA GAC AGG 
AGA AAT G-3' 
5'-TAT CGT GAG TAG GCA 
GGA GAG-3' 
TRPV6 5'-GAC CTG CGT GGG ATA 
ATC AA-3' 
5'-CAG GAA GCG AAG TGA 
GAA CA-3' 
Cyp24a1 5'-TGT GTG TGT GTC CGT 
GTA TG-3' 
5'-CCT GCA CCA CAG ATC 
CTA AAT-3' 
Cyp27b1 5'-CCA TGT GGC AGA AGG 
GAT AA-3' 
5'-AAA CCG TAA ACC AGG 
CTA GG-3' 
GAPDH 5'-CAT GGG TGT GAA CCA 
TGA GA-3' 
5'-GGG TGC TAA GCA GTT 
GGT-3' 
  
1
8
0
 
APPENDIX B 
 
 
TABLE: SUMMARY OF STUDIES SELECTED IN OUR META-ANALYSIS OF VITAMIN D AND BC, PUBMED 2000-
2017 
 
STUD
Y # 
Author
/year 
Endnot
e Link 
Cou
ntry 
Study 
name; 
Study 
Design; 
Sample 
Size 
Menop
ausal 
status; 
Baseli
ne age; 
Follow
-up 
time 
Exposur
e; 
Outcom
e 
assessme
nt 
25(OH) 
D 
Mean 
±SD 
% 
deficien
t 
Dietar
y 
vitami
n D 
 
Mean±
SD 
Supp. 
use, 
% 
Adjustme
nt 
Findings Conclus
ion 
QS=0+1+1+2=4 (Range:0-8) _ 
1 
[129] 
USA Nurses’ 
Health 
Study; 
 
Nested 
case-
control; 
 
Cases 
(N=701) 
and 
controls 
(N=724) 
Total 
30-55y 
Mean: 
~57.1 
y* 
25(OH)D
: 
IA; 
 
Self-
reported 
diagnosis 
of BC 
during 
follow-
up. 
 
 
Mean: 
32.3 
ng/mL*
* 
n/a n/a BMI, 
menopausa
l status, 
menopausa
l hormone 
use, height, 
age at 
menarche, 
parity and 
age at first 
birth, 
weight at 
age 18, age 
Women 
in the 
highest 
quintile 
of 
25(OH)D 
had 
RR=0.73
; (95% 
CI: 0.49-
1.07; P-
trend = 
0.06) 
High 
levels of 
25(OH)
D 
may be 
modestl
y 
associat
ed with 
reduced 
risk of 
BC. 
  
1
8
1
 
at 
menopause
, family 
history of 
BC, history 
of benign 
breast 
disease, 
alcohol 
intake, and 
smoking 
status. 
compare
d with 
those in 
the 
lowest 
quintile 
QS=2+2+2+2=8 (Range:0-8)_ 
2 
 
[185] 
 
USA Cancer 
Preventio
n Study II 
Nutrition 
Cohort; 
 
Prospecti
ve cohort; 
 
N=68,567 
Post 
50-74y 
Mean: 
~62 y* 
 
Up to 
9y of 
follow-
up 
Dietary/s
uppleme
ntal 
calcium 
and 
vitamin 
D, 68-
item food 
frequenc
y 
question
naire 
(FFQ); 
 
 
BC 
incidence 
ascertain
n/a Dietary 
vitamin 
D:  
Mean: 
167 
IU/d** 
 
 
 
 
 
 
Total 
vitamin 
D: 
Mean: 
320 
IU/d 
n/a Age, 
energy, 
history of 
breast cyst, 
family 
history BC, 
height, 
weight 
gain since 
age 18, 
alcohol 
use, race, 
age at 
menopause
, age at 
first birth 
and 
number of 
Using 
suppleme
ntal 
vitamin 
D intake 
was not 
associate
d with 
BC risk, 
overall. 
The 
associati
on 
suggeste
d a 
protectiv
e effect 
among 
Our 
results 
support 
the 
hypothe
sis that 
dietary 
calcium 
and/or 
some 
other 
compon
ents in 
dairy 
products 
may 
modestl
y reduce 
  
1
8
2
 
ed with 
NDI.  
 
 
 live births, 
education, 
mammogra
phy. 
history, 
and HRT 
use.  
women 
with 
estrogen 
receptor-
positive 
tumors 
comparin
g highest 
to lowest 
intake of 
dietary 
vitamin 
D (RR= 
0.74; 
95% CI, 
0.59-
0.93; P-
trend = 
0.006) 
risk of 
postmen
opausal 
BC. The 
stronger 
inverse 
associati
ons 
among 
estrogen 
receptor
-positive 
tumors 
deserve 
further 
study. 
 
QS=0+2+2+2=6 (Range:0-8) 
3 
 
[177] 
Cana
da 
Populatio
n-based 
case-
control 
study 
 
Cases 
(N=972) 
and 
Controls 
Total 
20-69 
y 
Mean: 
~51.7 
y* 
Dietary 
suppleme
ntation 
question
naire; 
 
Ontario 
cancer 
registry: 
women 
with a 
n/a n/a Supple
ment 
use:  
Vitami
n D/ 
multiv
itamin
: 
Cases:
15% 
Age, 
education, 
and 
ethnicity, 
the 
variables in 
the fully 
adjusted 
models 
included 
age at 
Reduced 
BC risk 
was 
associate
d with 
use of 
vitamin 
D or 
multivita
min 
Vitamin 
D could 
help 
prevent 
BC 
  
1
8
3
 
(N=1,135
) 
patholog
y report 
indicatin
g 
invasive 
BC, age-
matched 
populatio
n-based 
controls.  
Contro
ls:22% 
 
  
menarche 
(<12, 12, 
13, 14+), 
first degree 
family 
history of 
BC 
(yes/no), 
ever 
breast-fed 
(yes/no), 
and age at 
first birth 
(<20, 20-
24, 25-29, 
30+, 
nulliparous
). 
suppleme
nts: 
OR=0.62
; 95% 
CI:0.49-
0.79.  
QS=2+2+2+2=8(Range:0-8) 
4 
 
[184] 
USA Iowa 
Women’s 
Health 
Study 
(IWHS) 
 
Prospecti
ve cohort 
N=34,321 
 
 
Post 
55-69 
y 
~61.5 
y* 
 
Follow
-up up 
to 18y 
127-item 
FFQ 
 
Dietary 
suppleme
nt 
question
naire; 
 
Incident 
cases of 
BC were 
n/a Mean 
total 
vitamin 
D 
intake: 
~520 
IU/d* 
n/a Baseline 
age (y), 
smoking 
status, age 
at 
menarche, 
age at 
reported 
menopause
, first 
degree 
relative 
The 
adjusted 
RR of 
BC for 
women 
consumi
ng >800 
IU/day 
versus 
<400 
IU/day 
total 
Vitamin 
D intake 
of >800 
IU/day 
appears 
to be 
associat
ed with 
a small 
decrease 
in risk 
of BC 
  
1
8
4
 
identified 
between 
1986 and 
2004 
through 
linkage 
to the 
State 
Health 
Registry 
of Iowa, 
part of 
the 
National 
Cancer 
Institute’
s 
Surveilla
nce, 
Epidemi
ology 
and End 
Results 
program 
(SEER). 
with BC, 
estrogen 
use, age at 
first live 
birth, 
number of 
live births, 
education 
category, 
BMI 
category, 
activity 
level, live 
on a farm, 
mammogra
m history, 
daily 
energy, fat 
and alcohol 
intakes. 
vitamin 
D was 
0.89 
(95% CI: 
0.77-
1.03). 
RRs 
were 
stronger 
among 
women 
who 
were 
ER+ or 
PR+ 
status. 
The 
associati
on of 
high 
vitamin 
D intake 
with BC 
was 
strongest 
in the 
first 5 
years 
after 
baseline 
dietary 
among 
postmen
opausal 
women. 
  
1
8
5
 
assessme
nt (RR = 
0.66; 
95% CI: 
0.46-0.94 
compare
d with 
lowest-
intake 
group), 
and 
diminish
ed over 
time. 
QS=0+2+1+2=5(Range:0-8) 
5 
 
[127] 
USA Women’s 
Health 
Initiative 
 
Nested 
case- 
control 
study 
within 
randomiz
ed trial 
 
Cases 
(N=1,067
) and 
controls 
Post 
50-79 
y 
Mean: 
~63 y* 
 
 
25(OH)D
: 
IA; 
 
 
Modified 
block 
food 
frequenc
y 
question
naire 
and 
suppleme
nt use 
~50.0 ± 
20.0 
nmol/L
**  
 
 
Mean 
total 
vitamin 
D 
intake: 
350 
IU/d* 
Supple
ment 
use:  
Vitami
n D/ 
multiv
itamin
: 
Cases:
47% 
Contro
ls:48% 
 
 
Baseline 
age (y), 
weight, 
and 
baseline 
percentage 
of energy 
from total 
fat. 
Baseline 
25(OH)D 
levels 
were not 
associate
d with 
BC risk 
in 
analyses 
that were 
adjusted 
for BMI 
and 
physical 
activity 
(P trend 
25(OH)
D levels 
were not 
associat
ed with 
subsequ
ent BC 
risk 
  
1
8
6
 
(N=1,067
) 
question
naire; 
 
 
BCs 
were 
confirme
d by both 
local and 
central 
medical 
record 
and 
patholog
y report 
review 
by 
trained 
adjudicat
ors who 
were 
blinded 
to 
randomiz
ed 
allocatio
n, with 
such 
records 
available 
= .20) 
  
1
8
7
 
in 98.2% 
of cases. 
QS=0+2+2+2=6(Range:0-8) 
6 
 
[128] 
USA Prostate, 
Lung, 
Colorecta
l, and 
Ovarian 
(PLCO) 
Cancer 
Screening 
Trial 
 
Nested 
case-
control 
study 
within a 
screening 
trial 
 
Cases 
(N=1,005
) 
And 
controls 
(N=1,005
) 
 
 
Post 
55-74 
y 
Mean:  
~62 
y** 
 
Mean 
follow-
up 
time:3.
9 y 
25(OH)D
: 
IA; 
 
Incident 
BC cases 
were 
ascertain
ed 
through 
self-
report in 
an annual 
health 
survey, 
linkage 
to state 
cancer 
registries
, death 
certificat
es, 
physician 
reports, 
and next-
of-kin 
reports 
(for 
26.7 
ng/mL 
n/a n/a BMI at age 
18 to 20, 
age at 
menarche, 
age at 
menopause
, HRT use, 
history of 
benign 
breast 
disease, 
family 
history of 
BC, 
combined 
parity, age 
at first 
birth, 
smoking 
status, 
alcohol 
intake, and 
total 
calcium 
intake. 
The RR 
of BC for 
the 
highest 
quintile 
of 
25(OH)D 
concentr
ation 
versus 
the 
lowest 
was 1.04 
(95% CI, 
0.75-
1.45; P-
trend = 
0.81) 
No 
inverse 
associati
on 
between 
circulati
ng 
25(OH)
D and 
BC risk 
  
1
8
8
 
deceased 
participa
nts). A 
total of 
92% of 
the 
ascertain
ed BC 
cases 
were 
confirme
d through 
review of 
medical 
records. 
QS=0+1+1+2=4(Range:0-8) 
7 
 
[178] 
Germ
any 
Populatio
n-based 
case-
control 
study 
from  
 southern 
Germany 
(Freiburg 
and 
Rhein-
Neckar-
Odenwald
) 
 
Pre 
30-50 
y 
Mean: 
~42.6 
y* 
25(OH)D
: 
IA; 
 
Cases 
were 
identified 
through 
frequent 
monitori
ng of 
hospital 
admissio
ns, 
surgery 
51.3 
nmol/L 
n/a n/a Stratified 
by age 
and 
adjusted 
for time of 
blood 
collection, 
number of 
births, 
first-degree 
family 
history, 
age at 
menarche, 
duration of 
Compare
d with 
the 
lowest 
category 
(<30 
nmol/L), 
the ORs 
(95% CI) 
for the 
upper 
categorie
s (30–45, 
45–60, 
≥60 
There is 
a 
protectiv
e effect 
of 
vitamin 
D for 
premeno
pausal 
BC 
  
1
8
9
 
 
Cases 
(N=289) 
and 
controls 
(N=595) 
schedule
s and 
patholog
y reports 
in 38 
hospitals. 
breast-
feeding, 
BMI, 
alcohol 
consumpti
on. 
nmol/L) 
were 
0.68 
(0.43–
1.07), 
0.59 
(0.37–
0.94) and 
0.45 
(0.29–
0.70), 
respectiv
ely (P-
trend= 
0.0006) 
QS=0+1+1+2=4(Range:0-8) 
8 
 
[125] 
USA Cancer 
Preventio
n Study-II 
(CPS-II) 
Nutrition 
Cohort 
 
 
Nested 
case-
control 
within  
Prospecti
ve cohort 
study 
Post 
47-85 
y 
Mean:  
~69.5 
y** 
25(OH)D
: 
IA; 
 
Eligible 
cases 
included 
women 
who 
reported 
a new 
diagnosis 
of BC on 
a 
biennial 
Mean: 
49.1-
59.5 
nmol/L 
dependi
ng on 
season. 
n/a n/a Reproducti
ve risk 
factors, 
history of 
benign 
breast 
disease, 
family 
history, 
education, 
alcohol 
use, 
postmenop
ausal 
hormone 
No 
associati
on 
between 
25(OH)D 
and BC 
(OR = 
1.09, 
95% CI 
0.70-
1.68, P = 
0.60) for 
the top 
vs 
Results 
do not 
support 
an 
associati
on 
between 
adulthoo
d serum 
25(OH)
D and 
postmen
opausal 
BC. 
  
1
9
0
 
 
 
Cases 
(N=516) 
and 
controls 
(N=516) 
CPS-II 
Nutrition 
Cohort 
Survey 
between 
the date 
of their 
blood 
draw and 
30 June, 
2005 (n 
= 514) or 
who did 
not 
report an 
incident 
BC but 
for 
whom 
fatal BC 
was 
identified 
through 
linkage 
with the 
National 
Death 
Index (n 
= 2). 
use, diet, 
recreationa
l physical 
activity 
and zip 
code (for 
latitude). 
bottom 
quintile. 
QS=0+0+2+1=3(Range:0-8) 
  
1
9
1
 
9 
 
[124] 
Den
mark 
Case-
control 
study 
 
 
Cases 
(N=142) 
and 
controls 
(N=420) 
Total 
29-87 
y 
Mean: 
~58 
y** 
25(OH)D
: 
LC; 
 
Mammo
graphy, 
followed 
by 
pathologi
c 
examinat
ion.  
Informati
on on 
studied 
subjects 
from The 
Danish 
National 
Hospital 
Discharg
e 
Register 
and the 
Danish 
Cancer 
Register 
were also 
retrieved. 
Cases:  
69 ± 23 
nmol/L  
Control
s: 
76 ± 28 
nmol/L 
 
 
 
n/a n/a Controls 
matched 
with cases 
on 
menopausa
l 
state, and 
time of 
year of 
blood 
sampling 
(± 2 mo). 
Compare
d with 
the 
lowest 
tertile of 
25(OH)D 
levels, 
risk of 
BC was 
significa
ntly 
reduced 
among 
women 
in the 
highest 
tertile 
(RR= 
0.52; 
95% CI: 
0.32-
0.85) 
Risk of 
BC was 
inversel
y 
associat
ed with 
25(OH)
D levels 
QS=0+1+0+1=2(Ramge:0-8) 
  
1
9
2
 
10 
 
[180] 
Finla
nd 
Finnish 
Maternity 
Cohort 
 
Nested 
case-
control 
study 
within 
cohort 
 
Cases 
(N=311) 
and 
controls 
(N=311) 
Pre 
30-34 
y 
Mean: 
~33 
y** 
25(OH)D
: 
IA; 
 
 
 
Missing 
informati
on on 
diagnosis 
of BC.  
Mean: 
43 
nmol/L
* 
 
n/a n/a Controls 
matched to 
cases by 
parity, age, 
year, and 
season.  
Serum 
25(OH)D 
level was 
not 
associate
d with an 
increased 
risk 
neither at 
the 1st 
nor at the 
2nd 
pregnanc
y 
samples 
(OR = 
1.4, 
95%CI 
0.6–3.4; 
OR 1.4, 
95%CI 
0.7–2.8, 
respectiv
ely), but 
was 
associate
d with an 
increased 
risk of 
PABC 
(OR = 
Vitamin 
D may 
not be 
related 
to BC 
risk 
  
1
9
3
 
2.7; 
95%CI 
1.04–6.7) 
QS=0+1+1+2=4(Range:0-8) 
11 
 
[121] 
Franc
e 
French 
E3N 
Cohort 
 
Nested 
case-
control 
within 
cohort 
 
 
Cases  
(N = 636) 
Controls  
(N= 
1,272) 
Total 
 
Cases 
(56.9±
6.4) 
and 
control
s 
(56.9±
6.4) 
25(OH)D
: 
IA; 
 
 
 
Every 2-
3 y, 
question
naire was 
sent out. 
In each 
question
naire, 
participa
nts were 
asked 
whether 
a cancer 
had been 
diagnose
d, and if 
so, 
patholog
y 
reports 
were 
Cases: 
24.4±10
.9 
ng/mL 
 
Control
s: 
25.1 ± 
11.0 
ng/mL 
n/a n/a BMI 
, HRT use, 
history of 
mammogra
phy history 
and of 
breast 
benign 
disease, 
family 
history of 
BC, parity, 
smoking 
status, use 
of oral 
contracepti
ves, age at 
menarche, 
and 
physical 
activity, 
alcohol 
consumpti
on, total 
energy, 
calcium/vit
amin D 
Found a 
decrease
d risk of 
BC with 
increasin
g 
25(OH)D
3 serum 
concentr
ations 
(odds 
ratio, 
0.73; 
95% 
confiden
ce 
interval, 
0.55-
0.96; P-
trend = 
0.02) 
among 
women 
in the 
highest 
tertile) 
There is 
a 
decrease
d risk of 
BC 
associat
ed with 
high 
25(OH) 
vitamin 
D3 
serum 
concentr
ations, 
especiall
y in 
younger 
women 
  
1
9
4
 
requested 
from the 
attending 
physician
s. 
 
 
dietary 
intakes, 
vitamin 
D/calcium 
supplement 
use, serum 
calcium, 
PTH, 
estradiol, 
progestero
ne, 
estradiol 
(pmol/L, 
continuous
) and 
progestero
ne 
(nmol/L, 
continuous
).  
QS=0+1+1+2=4(Range:0-8) 
12 
 
[181] 
USA Nurses’ 
Health 
Study II 
 
Nested 
case-
control 
study 
within 
cohort.  
Both 
All 
women 
(50.9±
12.6), 
pre-
menop
ausal 
(39.73
±7.83), 
25(OH)D
: 
IA; 
 
BC cases 
were 
identified 
on 
biennial 
question
Cases: 
25.4±9.
5 
ng/mL 
 
Control
s: 
25.0± 
9.6 
ng/mL 
n/a n/a BMI at age 
18 y and at 
the time of 
blood 
collection, 
ages at 
menarche 
and first 
birth, 
parity, 
No 
significa
nt 
associati
on was 
observed 
between 
plasma 
25(OH)D 
levels 
Circulati
ng 
25(OH)
D levels 
were not 
significa
ntly 
associat
ed with 
BC risk 
  
1
9
5
 
 
Cases (N 
= 613) 
Controls 
(N= 
1,218) 
post-
menop
ausal 
(58.68
±7.46) 
naires; 
the 
National 
Death 
Index 
was 
searched 
for non-
responde
rs. All 
BC cases 
occurred 
after 
blood 
collectio
n but 
before 1 
June 
2007. 
 family 
history of 
BC, and 
history of 
benign 
breast 
disease. 
and BC 
risk (top 
vs. 
bottom 
quartile 
multivari
ate RR = 
1.20, 
95% CI 
(0.88 to 
1.63), P-
value, 
test for 
trend = 
0.32) 
in this 
mostly 
pre-
menopa
usal 
populati
on 
QS=0+0+1+2=3(Range:0-8) 
13 
 
[175] 
USA Case-
control 
study 
 
Cases  
(N = 194) 
Controls 
(N= 194) 
Total 
40-70y 
Mean:  
~58.3 
y* 
 
 
25(OH)D
: 
IA; 
 
Histologi
cally 
confirme
d 
primary, 
incident, 
BC, with 
Cases: 
32.7±14
.4 
ng/mL 
 
Control
s 
37.4±15
.9 
ng/mL 
n/a n/a Age, race, 
date of 
blood 
collection, 
and 
laboratory 
used for 
vitamin D 
testing. 
BC cases 
had 
significa
ntly 
lower 
25(OH)D 
levels 
than CF 
controls 
(BC: 
32.7 
BC 
patients 
with a 
more 
aggressi
ve 
molecul
ar 
phenoty
pe 
(basal-
  
1
9
6
 
no prior 
cancer 
history 
except 
nonmela
noma 
skin 
cancer. 
ng/mL 
vs. CF: 
37.4 
ng/mL; P 
= .02) 
like) and 
worse 
prognost
ic 
indicator
s had 
lower 
mean 
25(OH)
D levels 
QS=0+2+2+2=6(Range:0-8) 
14 
 
[182] 
USA, 
Swed
en 
Nested 
Case- 
control 
From two 
cohorts: 
 
New 
York 
Universit
y 
Women’s 
Health 
Study and 
the 
Northern 
Sweden 
Mammar
y 
Screening 
Cohort 
Total 
34-65 
y 
Mean: 
~52.6 
y* 
25(OH)D
: 
IA; 
 
For the 
NYUWH
S, 
incident 
cases of 
invasive 
BC 
were 
identified 
by 
mailed 
question
naires or 
follow-
up 
Cases: 
53.0±14
.9 
nmol/L 
 
 
Control
s: 
54.2±18
.6 
nmol/m
L 
n/a n/a Age at 
menarche, 
age at first 
birth/parity
, family 
history of 
BC, BMI, 
past HRT 
use, and 
alcohol 
consumpti
on. 
No 
associati
on was 
observed 
between 
circulatin
g levels 
of 
25(OH)D 
and 
overall 
BC risk 
(multivar
iate-
adjusted 
model 
OR = 
0.94; 
95% CI: 
0.76-1.16 
Circulati
ng 
25(OH)
D levels 
were not 
associat
ed with 
BC risk 
overall 
  
1
9
7
 
 
Cases (N 
= 1,585) 
Controls 
(N= 
2,940) 
 
telephon
e 
interview
s every 2 
to 4 
years 
after 
1991, 
suppleme
nted 
by 
linkages 
to state 
cancer 
registries 
in New 
York, 
New 
Jersey, 
and 
Florida 
and the 
US 
National 
Death 
Index. 
Medical 
records 
were 
reviewed 
to 
for the 
highest 
vs. 
lowest 
quintile, 
P-trend = 
0.30) 
  
1
9
8
 
confirm 
self-
reported 
cases. 
Using a 
capture-
recapture 
analysis, 
we 
estimated 
that 
combinin
g active 
and 
cancer 
registry-
based 
follow-
up 
resulted 
in a BC 
ascertain
ment rate 
of 95%.  
For the 
NSMSC, 
annual 
linkages 
to the 
Swedish 
National 
  
1
9
9
 
Cancer 
Registry 
were 
used to 
identify 
incident 
cases of 
BC in the 
cohort. 
QS=0+0+1+2=3(Range:0-8) 
15 
 
[176] 
Saudi 
Arabi
a 
Case-
control 
study 
 
 
Cases (N 
= 120) 
Controls 
(N= 120) 
 
Total 
 
47.8±1
2.4 y 
25(OH)D
: LC 
 
All 
women 
presented 
with 
invasive 
BC at the 
clinic 
or were 
receiving 
standard 
medical 
check-
ups at the 
same 
women’s 
clinic 
and were 
shown on 
15.4±12
.3 
ng/mL 
 
 
 
n/a n/a Age, BMI, 
history of 
cancer, 
parity, 
family 
history of 
cancer, 
exercise, 
location of 
exercise 
(indoors or 
outdoors), 
multivitam
in use, 
presence 
BC in 
daughters, 
benign 
breast 
disease, 
menopause
In 
comparis
on with 
those in 
the 
highest 
category 
of 
vitamin 
D status 
for this 
populatio
n (>20 
ng/mL), 
the 
adjusted 
ORs 
(95% 
CIs) for 
invasive 
BC were 
An 
inverse 
associati
on exists 
between 
serum 
25(OH)
D 
concentr
ations 
and BC 
risk in 
Saudi 
Arabian 
women 
  
2
0
0
 
medical 
record 
review to 
be 
free of 
cancer. 
 
 
 
, and 
breastfeedi
ng 
6.1 (2.4, 
15.1) for 
women 
with a 
serum 
25(OH)D 
concentr
ation ,10 
ng/mL 
and 4.0 
(1.6, 
10.4) for 
women 
with a 
serum 
concentr
ation of 
10 -20 
ng/mL 
(P-trend 
= 
0.0001) 
QS=0+0+1+2=3(Range:0-8) 
16 
 
[179] 
 
Iran Populatio
n based 
case- 
control 
study 
 
Cases 
Pre 
34-36 
y 
Mean: 
~35y** 
25(OH)D
: IA 
 
 
Daily 
intake of 
calcium 
and 
Cases: 
15.2±8.
2 
ng/mL 
 
 
Control
s: 
n/a Vitami
n D 
supple
ment, 
% yes: 
 
Cases: 
0.0% 
Daily 
sunlight 
exposure, 
covering 
body 
against 
sunlight, 
calcium 
The lack 
of 
vitamin 
D and 
calcium 
suppleme
ntation 
increased 
Vitamin 
D may 
have a 
role in 
BC 
incidenc
e but it 
needs 
  
2
0
1
 
(N=60) 
and 
controls 
(N=116) 
vitamin 
D and all 
dietary 
resources 
of 
mentione
d factors 
were 
collected. 
 
 
We 
selected 
cases 
from 
patients 
who 
underwe
nt 
surgery 
from 
2010 to 
2012 in 
Emdad 
Shahid 
Beheshti 
Universit
y 
hospital. 
Cases 
were 
15.5±7.
5 
ng/mL 
 
Overall: 
15.4 
ng/mL* 
 
 
 
Contro
ls: 
9.7% 
 
supplement
s, vitamin 
D 
supplement
s, fish and 
egg intakes 
and weekly 
profile of 
egg 
consumpti
on. 
slightly 
the risk 
of 
premeno
pausal 
BC 
(p=0.009
, 
OR=1.11
5, CI 
95%=1.0
49-
1.187) 
further 
proof 
  
2
0
2
 
identified 
from 
both self-
reports 
registrati
on and 
confirme
d by 
pathologi
cal 
reports. 
The 
pathologi
cal 
feature of 
cases 
was 
collected 
from 
pathologi
cal 
reports in 
the 
patholog
y archive 
of the 
mentione
d 
hospital. 
QS=0+1+2+2=5(Ramge:0-8) 
  
2
0
3
 
17 
 
[118] 
USA Nested 
case-
control 
study 
within the 
Multiethn
ic Cohort 
Study 
 
Cases: 
N=707 
 
Controls: 
N=707 
Post 
Mean: 
~67.8 
y** 
25(OH)D
: 
LC 
 
Incident 
invasive 
BC cases 
were 
identified 
by 
linkage 
to the 
Surveilla
nce, 
Epidemi
ology, 
and End 
Results 
Program 
registries 
in the 
states of 
Hawaii 
and 
Californi
a 
through 
October, 
2010, 
including 
729 
Overall: 
 
Mean 
25(OH)
D: 
31.4 
ng/mL*
* 
 
Vitamin 
D 
deficien
cy (<16 
ng/mL): 
7.2%* 
 
 
 
 
 
 
 
n/a n/a Body mass 
index, 
parity, 
family 
history of 
BC, use of 
multivitam
in and 
calcium 
supplement
s, season, 
sunburn 
history and 
engagemen
t in 
strenuous 
sports.  
20 
ng/mL 
increases 
of 
plasma 
25(OH)D
3 [OR= 
0.28; 
95% CI: 
0.14-
0.56] and 
25(OH)D 
[OR=0.4
3; 95% 
CI: 0.23-
0.80] 
were 
inversely 
associate
d with 
BC risk 
among 
white 
women, 
but not 
among 
women 
in other 
race/ethn
ic 
groups. 
Circulati
ng 
25(OH)
D3 and 
25(OH)
D were 
associat
ed with 
a 
reduced 
risk of 
postmen
opausal 
BC 
among 
whites, 
but not 
in other 
ethnic 
groups, 
who 
reside in 
low 
latitude 
regions. 
  
2
0
4
 
eligible 
postmen
opausal 
women 
with a 
diagnosis 
of 
invasive 
BC. 
QS=0+1+1+2=4(Ramge:0-8) 
18 
 
[183] 
USA Nurses’ 
Health 
Study II 
 
Nested 
case-
control 
within a 
cohort.  
 
Cases (N 
= 584) 
Controls 
(N= 584) 
 
Pre 
45-46 
y 
 
Mean: 
~45.1±
4.4 y** 
25(OH)D
: 
IA 
 
BC cases 
were 
identified 
through 
the 
biennial 
question
naires: 
Cases 
had no 
previousl
y 
reported 
cancer 
diagnosis 
before 
blood 
Median 
25(OH)
D 
 
Cases:6
2.6 
nmol/L 
 
 
 
Control
s: 
61.4 
nmol/L 
n/a n/a Body mass 
index 
(BMI) at 
age 18 and 
at blood 
collection, 
age at 
menarche, 
parity and 
age at first 
birth, 
history of 
benign 
breast 
disease, 
family 
history of 
BC, and 
alcohol 
consumpti
on. 
No 
associati
on 
between 
plasma 
calculate
d free 
25(OH)D 
and risk 
of BC 
overall 
(highest 
vs. 
lowest 
quartile 
RR=1.21
; 95 % 
CI: 0.83–
1.77), P-
trend = 
0.50) 
There is 
no 
associati
on 
between 
circulati
ng free 
25(OH)
D or 
circulati
ng 
VDBP 
levels 
with BC 
risk 
among 
mostly 
pre-
menopa
usal 
women. 
  
2
0
5
 
collectio
n and 
were 
diagnose
d after 
blood 
collectio
n but 
before 
June 1, 
2007. 
 
Abbreviations: 95%CI=95% confidence interval; 25(OH)D=25-hydroxyvitamin D; BC=BC; BMI=Body Mass Index; HR=Hazard 
Ratio; HRT=Hormone Replacement Therapy; IA= Immunoassay; LC= Liquid Chromatography; n/a=Not applicable; NDI=National 
Death Index; OR=Odds Ratio; P-trend=P-value for the trend test; QS=Quality Score; RR=Risk Ratio;  
 
*Estimated based on available categorical data and ranges within each category, with sample sizes for each category.  
**Estimated based on available data on mean and SD for cases and controls and sample sizes of cases and controls. 
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APPENDIX C 
SEARCH TERMS 
 
((((("vitamin d"[MeSH Terms] OR "vitamin d"[All Fields] OR "ergocalciferols"[MeSH 
Terms] OR "ergocalciferols"[All Fields]) AND incident[All Fields]) AND ("breast 
neoplasms"[MeSH Terms] OR ("breast"[All Fields] AND "neoplasms"[All Fields]) OR 
"breast neoplasms"[All Fields] OR ("breast"[All Fields] AND "cancer"[All Fields]) OR 
"BC"[All Fields])) AND ("25-hydroxyvitamin D"[Supplementary Concept] OR "25-
hydroxyvitamin D"[All Fields] OR "25 hydroxyvitamin d"[All Fields] OR 
"calcifediol"[MeSH Terms] OR "calcifediol"[All Fields])) OR 25[All Fields] AND 
("hydroxide ion"[Supplementary Concept] OR "hydroxide ion"[All Fields] OR "oh"[All 
Fields]) AND D[All Fields]) AND ("epidemiology"[Subheading] OR "epidemiology"[All 
Fields] OR "incidence"[All Fields] OR "incidence"[MeSH Terms]) AND ("free full 
text"[sb] AND ("2007/01/01"[PDAT] : "2017/01/01"[PDAT]) AND "humans"[MeSH 
Terms] AND English[lang] AND "female"[MeSH Terms] AND "adult"[MeSH Terms]). 
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APPENDIX D 
SUPPLEMENTAL METHODS 
 
Quality score 
 
The quality score is composed of 5 items, and each item was allocated 0, 1 or 2 points. This 
allowed a total score between 0 and 8 points, 8 representing the highest quality. The 
following items are included in the score: 
 
1. Study design 
0 for case-control studies 
1 for cross-sectional studies 
2 for longitudinal studies (retrospective or prospective) or non-randomized intervention 
studies 
 
2. Population 
Observational studies 
0 if n <500  
1 if n 500 to 2000 
2 if n >2000 
 
 
3. Outcome (see table below) 
 0 1 2 
BC If not reported or if 
diagnosis was 
based on a proxy 
for disease 
(i.e. use of 
medication that is 
not specific to the 
disease or 
symptoms) 
If diagnosis was 
self-reported or 
retrieved from 
reports (e.g. 
medical records) 
not collected 
specifically for 
study or was based 
on the use of 
disease-specific 
medication (e.g. 
antidiabetic 
medication) 
If diagnosis was 
made during study 
using adequate test 
or official 
registries were 
checked by a 
researcher 
 
 
4. Adjustments 
0 if findings are not controlled** for at least age and gender 
1 if findings are controlled for age and gender  
2 if an intervention study is adequately randomized or if findings are additionally 
controlled for other key covariates (e.g. age at menarche, parity, family history of BC 
etc.)  
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** ‘Controlled for’ here refers to: adjusted for in the statistical analyses (e.g. with multiple 
regression); stratified for in the analyses (e.g. pre- and post-menopausal separately); or 
narrow selection criteria of study participants on this covariate (e.g. Pre-menopausal 
women only). 
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Meta-
analyzed 
study 
Author/year Assessment Study 
design 
Population Outcome Adjustments QS 
[129] Bertone-
Johnson/2005 
A      
B      
C      
[185] McCullough/2005 A      
B      
C      
[177] Knight/2007 A      
B      
C      
[184] Robien/2007 A      
B      
C      
[127] Chlebowski/2008 A      
B      
C      
[128] Freedman/2008 A      
B      
C      
[178] Abbas/2009 A      
B      
C      
[125] McCullough/2009 A      
B      
C      
[124] Rejnmark/2009 A      
B      
C      
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[180] Agborsangaya/2010 A      
B      
C      
[121] Engel/2010 A      
B      
C      
[181] Eliassen/2011 A      
B      
C      
[175] Peppone/2012 A      
B      
C      
[182] Scarmo/2013 A      
B      
C      
[176] Yousef/2013 A      
  B      
  C      
[179] Bidgoli/2014 A      
  B      
  C      
[118] Kim/2014 A      
  B      
  C      
[183] Wang/2014 A      
  B      
  C      
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APPENDIX E 
BEGG’S FUNNEL PLOT 
 
 
Begg's Test 
adj. Kendall's Score (P-Q) =      35 
Std. Dev. of Score =   35.46  
Number of Studies =      22 
z  =    0.99 
Pr > z =   0.324 
z  =    0.96 (continuity corrected) 
Pr > z =   0.338 (continuity corrected) 
Egger's test 
   
Std_Eff                Coef.     Std. Err.      t        P>t        [95% Conf. Interval] 
    
           slope      -.0223186   .0158607   -1.41   0.175    -.0554034 .0107662 
           bias        .6823854    .8081164     0.84   0.408    -1.003316 2.368087 
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APPENDIX F 
QUALITATIVE FINDINGS 
 
 
 
 
 
FIGURE: GRAPHS BY EXPOSURE AND FINDINGS 
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APPENDIX G 
CALCULATION OF TREATMENTS 
 
 
Vitamin D (Enzo: BML-DM200-0050) 
Stock Solution 50 µg in 50 µL EtOH 
=2.4 mM (2.4X10-3M) 
Working Solution Dilute to 1:1000 
2µL stock solution in 2000 µL (2mL) 
EtOH 
= 2.4 µM (2.4X10-6M) 
Treatment Solution Dilute to 42 µL working solution in 13mL 
media 
=100 nM 
 
Trichostatin A (TSA) (Sigma: T1952) 
Stock Solution 10 mM Concentration 
Working Solution Dilute to 1:1000 
2 µL Stock Solution in 2mL DMSO 
=10 µM 
Treatment Solution 1 µM =200 µL working solution in 2mL 
media 
 
L- Sulforaphane (SFN) (Sigma: S6317) 
Stock Solution 20 mM in DMSO 
Working Solution 17.5 µL Stock Solution in 3.5 mL DMSO 
=100 µM concentration 
Treatment Solution 20µM= 400µL working solution in 2mL 
media 
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APPENDIX H 
LABORATORY PROTOCOL 
RNA Isolation 
1. Cell Harvest 
a. Remove the media 
b. Use 1mL Tri-reagent (Trizol) per well (6-well plates) 
c. Scratch the cells from the well with a cell scraper 
d. Pipet suspension till thick and stringy, transfer to 1.5 mL Eppendorf tubes 
e. Samples can be stored at -80˚c if necessary 
f. If frozen, samples need to be kept at room temperature for 5 minutes before 
starting the phase separation 
 
2. Phase Separation (samples need to be kept on ice) 
a. Add 150 µL chloroform reagent to the homogenate 
b. Invert vigorously for 15 seconds 
c. Allow the mixture to sit at room temperature for 5 minutes 
d. Centrifuge at 12,000g for 15 minutes at 4˚c 
 
3. RNA Precipitation 
a. Transfer the aqueous phase into a fresh 1.5 mL Eppendorf tubes 
b. Add 0.5 mL of 100% isopropanol and mix gently by inversion 
c. Keep on ice for 15 minutes 
d. Centrifuge at 12,000g for 20 min at 4˚c 
 
4. RNA Washing and Solubilization 
a. Remove the supernatant (be careful not to disturb the pellet) 
b. Add 1 mL of 75% Ethanol (EtOH) 
c. Kick samples at the bottom to dislodge the pellet 
d. Centrifuge at 7,500g for 5 minutes at 
e. Remove EtOH (careful not to lose the pellet at the bottom) 
f. Briefly spin samples down, remove the remaining liquid 
g. Air dry (keep samples open for several minutes) 
h. Add 40 µL DEPC water to the samples, invert and spin down 
i. Incubate 10 minutes at 56˚c to homogenize the RNA and then keep on ice 
for several minutes 
 
B. RNA Quantification 
a. Turn on the NanoDrop machine 
b. Blank the machine with 1 µL of DEPC water 
c. Take 1 µL of sample 
d. Press OK to get readings at 260/280 nm 
e. Dilute samples as necessary (we need at least 2µg RNA for PCR) 
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C. cDNA Synthesis 
a. The following protocol is designed to convert 5µg of total RNA into cDNA) 
b. Mix and briefly centrifuge each component before use 
f. Combine the following in 0.5 mL DNA/RNAse free tubes(final volume 10 
µL) 
• 1 µL Primer: 50 mM oligo (DT) 
• 1 µL 10 mM dNTP mix 
• 8 µL of 5 µg RNA and DEPC water 
• Incubate for 5 minutes at 65˚c then place on ice for at least 1 
minute (Protocol Library: Wood Lab) 
g. Prepare the following mix (for one reaction) 
• 2 µL 10X RT buffer 
• 4 µL 25 mM MgCl2 
• 2 µL 0.1 M DTT 
• 1 µL RNaseOUT (40 U/µL) 
• 1 µL SuperScript III- RT (200 U/µL) 
h. Add 10 µL of cDNA Synthesis mix to each RNA/primer mixture (mix gently 
and collect by brief centrifugation) 
i. Incubate as follows: 
• 10 minutes at 25˚c followed by  
• 50 minutes at 50 ˚c 
• Terminate the reaction at 85 ˚c for 5 minutes, then chill on 
ice 
j. cDNA synthesis reactions can be stored at -30 ˚c to -10 ˚c or used for PCR 
immediately 
 
D. Real Time qPCR 
 
1. cDNA Quantification 
a. Take 1 µL of each sample and measure the concentrations by using the 
NanoDrop machine 
b. Total Volume= 1 µL cDNA and DEPC water to make each sample 
have 50 µg/mL cDNA 
2. Preparation of MasterMix (each tube will have 20 µL of final volume) 
a. 10 µL TaqMan Gene Expression Master Mix (Applied Biosystems 
#4369016) 
b. 1 µL TaqMan Gene Expression Assay 
• Housekeeping gene (GAPDH) with VIC dye- Applied 
Biosystems Hs 99999905_m1 
c. 1 µL TaqMan Gene Expression Assay 
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• Target gene (VDR) with FAM dye- Applied Biosystems Hs 
99999905_m1 
• Target gene (TRPV6) with FAM dye - Applied Biosystems Hs 
01114089_g1 
• Target gene (DKK1) with FAM dye - Applied Biosystems Hs 
_m1 
• Target gene (CYP24a1) with FAM dye - Applied Biosystems 
Hs 00167999_m1 
• Target gene (CYP27b1) with FAM dye - Applied Biosystems 
Hs 00168017_m1 
d. 4 µL of DEPC water 
e. 4 µL cDNA (200ng/ mL total cDNA 
 Formula for the amount pipetted into each tube: 
(# of reactions) X (Volume of reagent per reaction) + (# of reactions) X (Volume of 
reagent per reaction) X (.10) = Amount in the MasterMix 
[Note: 10% more is added because the mixture is sticky and pipetting can be difficult] 
3. Preparation of qPCR plate 
a. Pipette 16 µL of prepared MasterMix into each micro centrifuge tube 
(Applied Biosystems # 4346906) 
b. Pipette 4 µL of cDNA samples into each reaction tube (run in duplicates) 
c. Homogenize samples by spinning the tubes down 
 
4. ViiA-7 Real-Time PCR System 
a. Turn on the machine 
b. Place the plate holding all reaction tubes into the plate reader 
c. Click on ViiA-7 software on Desktop 
• Give the new experiment a name  
• Set up the reaction plate: 96 well 
• Method of comparison: standard curve 
• Protocol: TaqMan Standard MasterMix 
d. Setting up the experiment 
• Define target genes (choose different colors for each gene) 
• Select VIC dye for GAPDH and FAM for all the target genes 
• Mark concentrations for each treatment 
• Assign Target and samples: mark the boxes with appropriate 
labels and concentrations  
• Select ROX dye for passive reference 
e. Select Start and then click on the experiment number to start the 
experiment (Note: clicking on Start alone will not initiate the 
experiment) 
f. The experiment will be completed in 1.45 hours for the data to be 
exported to an excel file for analysis.
 217 
 
BIBLIOGRAPHY 
 
1. Woolcott CG, Wilkens LR, Nomura AM, Horst RL, Goodman MT, Murphy SP, 
Henderson BE, Kolonel LN, Le Marchand L: Plasma 25-hydroxyvitamin D levels and the 
risk of colorectal cancer: the multiethnic cohort study. Cancer epidemiology, biomarkers 
& prevention : a publication of the American Association for Cancer Research, 
cosponsored by the American Society of Preventive Oncology 2010, 19:130-134. 
2. Holt PR, Arber N, Halmos B, Forde K, Kissileff H, McGlynn KA, Moss SF, 
Kurihara N, Fan K, Yang K, Lipkin M: Colonic epithelial cell proliferation decreases 
with increasing levels of serum 25-hydroxy vitamin D. Cancer epidemiology, biomarkers 
& prevention : a publication of the American Association for Cancer Research, 
cosponsored by the American Society of Preventive Oncology 2002, 11:113-119. 
3. Albanes D: Vitamin D and Cancer: Diversity, Complexity, and Still a Ways to 
Go. Cancer Prev Res (Phila) 2015, 8:657-661. 
4. Navarro SL, Li F, Lampe JW: Mechanisms of action of isothiocyanates in cancer 
chemoprevention: an update. Food Funct 2011, 2:579-587. 
5. Byun S, Shin SH, Park J, Lim S, Lee E, Lee C, Sung D, Farrand L, Lee SR, Kim 
KH, et al: Sulforaphene suppresses growth of colon cancer-derived tumors via induction 
of glutathione depletion and microtubule depolymerization. Mol Nutr Food Res 2016, 
60:1068-1078. 
6. Jacobs ET, Kohler LN, Kunihiro AG, Jurutka PW: Vitamin D and Colorectal, 
Breast, and Prostate Cancers: A Review of the Epidemiological Evidence. J Cancer 2016, 
7:232-240. 
7. Bouillon R, Eelen G, Verlinden L, Mathieu C, Carmeliet G, Verstuyf A: Vitamin 
D and cancer. J Steroid Biochem Mol Biol 2006, 102:156-162. 
8. Colston KW, Hansen CM: Mechanisms implicated in the growth regulatory 
effects of vitamin D in breast cancer. Endocr Relat Cancer 2002, 9:45-59. 
9. Saez S, Falette N, Guillot C, Meggouh F, Lefebvre MF, Crepin M: William L. 
McGuire Memorial Symposium. 1,25(OH)2D3 modulation of mammary tumor cell 
growth in vitro and in vivo. Breast Cancer Res Treat 1993, 27:69-81. 
10. Trump DL, Hershberger PA, Bernardi RJ, Ahmed S, Muindi J, Fakih M, Yu WD, 
Johnson CS: Anti-tumor activity of calcitriol: pre-clinical and clinical studies. J Steroid 
Biochem Mol Biol 2004, 89-90:519-526. 
11. John EM, Schwartz GG, Dreon DM, Koo J: Vitamin D and breast cancer risk: the 
NHANES I Epidemiologic follow-up study, 1971-1975 to 1992. National Health and 
Nutrition Examination Survey. Cancer Epidemiol Biomarkers Prev 1999, 8:399-406. 
12. John EM, Schwartz GG, Koo J, Wang W, Ingles SA: Sun exposure, vitamin D 
receptor gene polymorphisms, and breast cancer risk in a multiethnic population. Am J 
Epidemiol 2007, 166:1409-1419. 
13. Hayes JD, Kelleher MO, Eggleston IM: The cancer chemopreventive actions of 
phytochemicals derived from glucosinolates. Eur J Nutr 2008, 47 Suppl 2:73-88. 
14. Fahey JW, Zhang Y, Talalay P: Broccoli sprouts: an exceptionally rich source of 
inducers of enzymes that protect against chemical carcinogens. Proceedings of the 
National Academy of Sciences of the United States of America 1997, 94:10367-10372. 
 218 
 
15. Juge N, Mithen RF, Traka M: Molecular basis for chemoprevention by 
sulforaphane: a comprehensive review. Cellular and molecular life sciences : CMLS 
2007, 64:1105-1127. 
16. Myzak MC, Karplus PA, Chung FL, Dashwood RH: A novel mechanism of 
chemoprotection by sulforaphane: inhibition of histone deacetylase. Cancer Res 2004, 
64:5767-5774. 
17. Dashwood RH, Ho E: Dietary agents as histone deacetylase inhibitors: 
sulforaphane and structurally related isothiocyanates. Nutr Rev 2008, 66 Suppl 1:S36-38. 
18. Myzak MC, Tong P, Dashwood WM, Dashwood RH, Ho E: Sulforaphane retards 
the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects. Exp 
Biol Med (Maywood) 2007, 232:227-234. 
19. Fahey JW, Talalay P: Antioxidant functions of sulforaphane: a potent inducer of 
Phase II detoxication enzymes. Food and chemical toxicology : an international journal 
published for the British Industrial Biological Research Association 1999, 37:973-979. 
20. Kensler TW, Egner PA, Agyeman AS, Visvanathan K, Groopman JD, Chen JG, 
Chen TY, Fahey JW, Talalay P: Keap1-nrf2 signaling: a target for cancer prevention by 
sulforaphane. Topics in current chemistry 2013, 329:163-177. 
21. Fahey JW, Wehage SL, Holtzclaw WD, Kensler TW, Egner PA, Shapiro TA, 
Talalay P: Protection of humans by plant glucosinolates: efficiency of conversion of 
glucosinolates to isothiocyanates by the gastrointestinal microflora. Cancer prevention 
research (Philadelphia, Pa) 2012, 5:603-611. 
22. Xu WS, Parmigiani RB, Marks PA: Histone deacetylase inhibitors: molecular 
mechanisms of action. Oncogene 2007, 26:5541-5552. 
23. Vieth R: Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and 
safety. The American Journal of Clinical Nutrition 1999, 69:842-856. 
24. Atkinson SA: [The new dietary reference intakes from the Institute of Medicine 
for calcium and vitamin D]. Perspect Infirm 2011, 8:5. 
25. Yetley EA: Assessing the vitamin D status of the US population. Am J Clin Nutr 
2008, 88:558S-564S. 
26. Holick MF, Frommer JE, McNeill SC, Richtand NM, Henley JW, Potts JT, Jr.: 
Photometabolism of 7-dehydrocholesterol to previtamin D3 in skin. Biochemical and 
biophysical research communications 1977, 76:107-114. 
27. Holick MF, Schnoes HK, DeLuca HF, Gray RW, Boyle IT, Suda T: Isolation and 
identification of 24,25-dihydroxycholecalciferol, a metabolite of vitamin D made in the 
kidney. Biochemistry 1972, 11:4251-4255. 
28. Hewison M, Zehnder D, Chakraverty R, Adams JS: Vitamin D and barrier 
function: a novel role for extra-renal 1 alpha-hydroxylase. Molecular and cellular 
endocrinology 2004, 215:31-38. 
29. Tieu EW, Tang EK, Tuckey RC: Kinetic analysis of human CYP24A1 
metabolism of vitamin D via the C24-oxidation pathway. The FEBS journal 2014, 
281:3280-3296. 
30. Haussler MR, Whitfield GK, Haussler CA, Hsieh JC, Thompson PD, Selznick 
SH, Dominguez CE, Jurutka PW: The nuclear vitamin D receptor: biological and 
molecular regulatory properties revealed. Journal of bone and mineral research : the 
official journal of the American Society for Bone and Mineral Research 1998, 13:325-
349. 
 219 
 
31. Storey ML, Forshee RA, Anderson PA: Beverage consumption in the US 
population. Journal of the American Dietetic Association 2006, 106:1992-2000. 
32. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-
Arvizu RA, Gallagher JC, Gallo RL, Jones G, et al: The 2011 report on dietary reference 
intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to 
know. J Clin Endocrinol Metab 2011, 96:53-58. 
33. Holick MF: Vitamin D and sunlight: strategies for cancer prevention and other 
health benefits. Clin J Am Soc Nephrol 2008, 3:1548-1554. 
34. Gamet-Payrastre L, Li P, Lumeau S, Cassar G, Dupont MA, Chevolleau S, Gasc 
N, Tulliez J, Terce F: Sulforaphane, a naturally occurring isothiocyanate, induces cell 
cycle arrest and apoptosis in HT29 human colon cancer cells. Cancer Res 2000, 60:1426-
1433. 
35. Talalay P: Chemoprotection against cancer by induction of phase 2 enzymes. 
BioFactors (Oxford, England) 2000, 12:5-11. 
36. Abdull Razis AF, Noor NM: Sulforaphane is superior to glucoraphanin in 
modulating carcinogen-metabolising enzymes in Hep G2 cells. Asian Pacific journal of 
cancer prevention : APJCP 2013, 14:4235-4238. 
37. Andelova H, Rudolf E, Cervinka M: In vitro antiproliferative effects of 
sulforaphane on human colon cancer cell line SW620. Acta Medica (Hradec Kralove) 
2007, 50:171-176. 
38. Barrera LN, Johnson IT, Bao Y, Cassidy A, Belshaw NJ: Colorectal cancer cells 
Caco-2 and HCT116 resist epigenetic effects of isothiocyanates and selenium in vitro. 
Eur J Nutr 2013, 52:1327-1341. 
39. Clarke JD, Dashwood RH, Ho E: Multi-targeted prevention of cancer by 
sulforaphane. Cancer Lett 2008, 269:291-304. 
40. Chen MJ, Tang WY, Hsu CW, Tsai YT, Wu JF, Lin CW, Cheng YM, Hsu YC: 
Apoptosis Induction in Primary Human Colorectal Cancer Cell Lines and Retarded 
Tumor Growth in SCID Mice by Sulforaphane. Evid Based Complement Alternat Med 
2012, 2012:415231. 
41. Rudolf E, Cervinka M: Sulforaphane induces cytotoxicity and lysosome- and 
mitochondria-dependent cell death in colon cancer cells with deleted p53. Toxicol In 
Vitro 2011, 25:1302-1309. 
42. Brooks JD, Paton VG, Vidanes G: Potent induction of phase 2 enzymes in human 
prostate cells by sulforaphane. Cancer epidemiology, biomarkers & prevention : a 
publication of the American Association for Cancer Research, cosponsored by the 
American Society of Preventive Oncology 2001, 10:949-954. 
43. Pappa G, Lichtenberg M, Iori R, Barillari J, Bartsch H, Gerhauser C: Comparison 
of growth inhibition profiles and mechanisms of apoptosis induction in human colon 
cancer cell lines by isothiocyanates and indoles from Brassicaceae. Mutat Res 2006, 
599:76-87. 
44. Petri N, Tannergren C, Holst B, Mellon FA, Bao Y, Plumb GW, Bacon J, O'Leary 
KA, Kroon PA, Knutson L, et al: Absorption/metabolism of sulforaphane and quercetin, 
and regulation of phase II enzymes, in human jejunum in vivo. Drug metabolism and 
disposition: the biological fate of chemicals 2003, 31:805-813. 
45. Hu R, Hebbar V, Kim BR, Chen C, Winnik B, Buckley B, Soteropoulos P, Tolias 
P, Hart RP, Kong AN: In vivo pharmacokinetics and regulation of gene expression 
 220 
 
profiles by isothiocyanate sulforaphane in the rat. The Journal of pharmacology and 
experimental therapeutics 2004, 310:263-271. 
46. Ye L, Dinkova-Kostova AT, Wade KL, Zhang Y, Shapiro TA, Talalay P: 
Quantitative determination of dithiocarbamates in human plasma, serum, erythrocytes 
and urine: pharmacokinetics of broccoli sprout isothiocyanates in humans. Clinica 
chimica acta; international journal of clinical chemistry 2002, 316:43-53. 
47. Bandera Merchan B, Morcillo S, Martin-Nunez G, Tinahones FJ, Macias-
Gonzalez M: The role of vitamin D and VDR in carcinogenesis: Through epidemiology 
and basic sciences. J Steroid Biochem Mol Biol 2017, 167:203-218. 
48. Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H: Meta-analysis: Serum 
vitamin D and colorectal adenoma risk. Preventive medicine 2011, 53:10-16. 
49. Wei MY, Garland CF, Gorham ED, Mohr SB, Giovannucci E: Vitamin D and 
prevention of colorectal adenoma: a meta-analysis. Cancer epidemiology, biomarkers & 
prevention : a publication of the American Association for Cancer Research, cosponsored 
by the American Society of Preventive Oncology 2008, 17:2958-2969. 
50. Jacobs ET, Kohler LN, Kunihiro AG, Jurutka PW: Vitamin D and Colorectal, 
Breast, and Prostate Cancers: A Review of the Epidemiological Evidence. Journal of 
Cancer 2015, 7:232-240. 
51. Zhalehjoo N, Shakiba Y, Panjehpour M: Gene expression profiles of CYP24A1 
and CYP27B1 in malignant and normal breast tissues. Mol Med Rep 2017, 15:467-473. 
52. Matusiak D, Benya RV: CYP27A1 and CYP24 expression as a function of 
malignant transformation in the colon. The journal of histochemistry and cytochemistry : 
official journal of the Histochemistry Society 2007, 55:1257-1264. 
53. Horvath HC, Lakatos P, Kosa JP, Bacsi K, Borka K, Bises G, Nittke T, 
Hershberger PA, Speer G, Kallay E: The candidate oncogene CYP24A1: A potential 
biomarker for colorectal tumorigenesis. The journal of histochemistry and cytochemistry 
: official journal of the Histochemistry Society 2010, 58:277-285. 
54. Ekmekcioglu C, Haluza D, Kundi M: 25-Hydroxyvitamin D Status and Risk for 
Colorectal Cancer and Type 2 Diabetes Mellitus: A Systematic Review and Meta-
Analysis of Epidemiological Studies. Int J Environ Res Public Health 2017, 14. 
55. Garland CF, Gorham ED: Dose-response of serum 25-hydroxyvitamin D in 
association with risk of colorectal cancer: A meta-analysis. J Steroid Biochem Mol Biol 
2017, 168:1-8. 
56. Dimitrakopoulou VI, Tsilidis KK, Haycock PC, Dimou NL, Al-Dabhani K, 
Martin RM, Lewis SJ, Gunter MJ, Mondul A, Shui IM, et al: Circulating vitamin D 
concentration and risk of seven cancers: Mendelian randomisation study. BMJ 2017, 
359:j4761. 
57. Choi YJ, Kim YH, Cho CH, Kim SH, Lee JE: Circulating levels of vitamin D and 
colorectal adenoma: A case-control study and a meta-analysis. World journal of 
gastroenterology 2015, 21:8868-8877. 
58. Lee JE, Li H, Chan AT, Hollis BW, Lee IM, Stampfer MJ, Wu K, Giovannucci E, 
Ma J: Circulating levels of vitamin D and colon and rectal cancer: the Physicians' Health 
Study and a meta-analysis of prospective studies. Cancer prevention research 
(Philadelphia, Pa) 2011, 4:735-743. 
59. Touvier M, Chan DS, Lau R, Aune D, Vieira R, Greenwood DC, Kampman E, 
Riboli E, Hercberg S, Norat T: Meta-analyses of vitamin D intake, 25-hydroxyvitamin D 
 221 
 
status, vitamin D receptor polymorphisms, and colorectal cancer risk. Cancer 
epidemiology, biomarkers & prevention : a publication of the American Association for 
Cancer Research, cosponsored by the American Society of Preventive Oncology 2011, 
20:1003-1016. 
60. Ma Y, Zhang P, Wang F, Yang J, Liu Z, Qin H: Association between vitamin D 
and risk of colorectal cancer: a systematic review of prospective studies. J Clin Oncol 
2011, 29:3775-3782. 
61. Gandini S, Boniol M, Haukka J, Byrnes G, Cox B, Sneyd MJ, Mullie P, Autier P: 
Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and 
colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer 2011, 
128:1414-1424. 
62. Gorham ED, Garland CF, Garland FC, Grant WB, Mohr SB, Lipkin M, Newmark 
HL, Giovannucci E, Wei M, Holick MF: Optimal vitamin D status for colorectal cancer 
prevention: a quantitative meta analysis. American Journal of Preventive Medicine 2007, 
32:210-216. 
63. Baron JA, Barry EL, Mott LA, Rees JR, Sandler RS, Snover DC, Bostick RM, 
Ivanova A, Cole BF, Ahnen DJ, et al: A Trial of Calcium and Vitamin D for the 
Prevention of Colorectal Adenomas. The New England journal of medicine 2015, 
373:1519-1530. 
64. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP: Vitamin D 
and calcium supplementation reduces cancer risk: results of a randomized trial. The 
American Journal of Clinical Nutrition 2007, 85:1586-1591. 
65. Wactawski-Wende J, Kotchen JM, Anderson GL, Assaf AR, Brunner RL, 
O'Sullivan MJ, Margolis KL, Ockene JK, Phillips L, Pottern L, et al: Calcium plus 
vitamin D supplementation and the risk of colorectal cancer. The New England journal of 
medicine 2006, 354:684-696. 
66. Trivedi DP, Doll R, Khaw KT: Effect of four monthly oral vitamin D3 
(cholecalciferol) supplementation on fractures and mortality in men and women living in 
the community: randomised double blind controlled trial. BMJ (Clinical research ed) 
2003, 326:469. 
67. Pradhan AD, Manson JE: Update on the vitamin D and omega-3 trial (VITAL)(). 
The Journal of steroid biochemistry and molecular biology 2016, 155:252-256. 
68. Song M, Konijeti GG, Yuan C, Ananthakrishnan AN, Ogino S, Fuchs CS, 
Giovannucci EL, Ng K, Chan AT: Plasma 25-Hydroxyvitamin D, Vitamin D Binding 
Protein, and Risk of Colorectal Cancer in the Nurses' Health Study. Cancer Prev Res 
(Phila) 2016, 9:664-672. 
69. Chandler PD, Buring JE, Manson JE, Giovannucci EL, Moorthy MV, Zhang S, 
Lee IM, Lin JH: Circulating Vitamin D Levels and Risk of Colorectal Cancer in Women. 
Cancer Prev Res (Phila) 2015, 8:675-682. 
70. Weinstein SJ, Purdue MP, Smith-Warner SA, Mondul AM, Black A, Ahn J, 
Huang WY, Horst RL, Kopp W, Rager H, et al: Serum 25-hydroxyvitamin D, vitamin D 
binding protein and risk of colorectal cancer in the Prostate, Lung, Colorectal and 
Ovarian Cancer Screening Trial. Int J Cancer 2015, 136:E654-664. 
71. Grant WB: 25-hydroxyvitamin D and breast cancer, colorectal cancer, and 
colorectal adenomas: case-control versus nested case-control studies. Anticancer Res 
2015, 35:1153-1160. 
 222 
 
72. Sun Z, Wang PP, Roebothan B, Cotterchio M, Green R, Buehler S, Zhao J, 
Squires J, Zhao J, Zhu Y, et al: Calcium and vitamin D and risk of colorectal cancer: 
results from a large population-based case-control study in Newfoundland and Labrador 
and Ontario. Can J Public Health 2011, 102:382-389. 
73. Adams SV, Newcomb PA, Burnett-Hartman AN, White E, Mandelson MT, Potter 
JD: Circulating 25-hydroxyvitamin-D and risk of colorectal adenomas and hyperplastic 
polyps. Nutr Cancer 2011, 63:319-326. 
74. Fedirko V, Bostick RM, Goodman M, Flanders WD, Gross MD: Blood 25-
hydroxyvitamin D3 concentrations and incident sporadic colorectal adenoma risk: a 
pooled case-control study. Am J Epidemiol 2010, 172:489-500. 
75. Jenab M, Bueno-de-Mesquita HB, Ferrari P, van Duijnhoven FJ, Norat T, Pischon 
T, Jansen EH, Slimani N, Byrnes G, Rinaldi S, et al: Association between pre-diagnostic 
circulating vitamin D concentration and risk of colorectal cancer in European 
populations:a nested case-control study. Bmj 2010, 340:b5500. 
76. Lipworth L, Bender TJ, Rossi M, Bosetti C, Negri E, Talamini R, Giacosa A, 
Franceschi S, McLaughlin JK, La Vecchia C: Dietary vitamin D intake and cancers of the 
colon and rectum: a case-control study in Italy. Nutr Cancer 2009, 61:70-75. 
77. Mizoue T, Kimura Y, Toyomura K, Nagano J, Kono S, Mibu R, Tanaka M, 
Kakeji Y, Maehara Y, Okamura T, et al: Calcium, dairy foods, vitamin D, and colorectal 
cancer risk: the Fukuoka Colorectal Cancer Study. Cancer Epidemiol Biomarkers Prev 
2008, 17:2800-2807. 
78. Wu K, Feskanich D, Fuchs CS, Willett WC, Hollis BW, Giovannucci EL: A 
nested case control study of plasma 25-hydroxyvitamin D concentrations and risk of 
colorectal cancer. J Natl Cancer Inst 2007, 99:1120-1129. 
79. Kesse E, Boutron-Ruault MC, Norat T, Riboli E, Clavel-Chapelon F: Dietary 
calcium, phosphorus, vitamin D, dairy products and the risk of colorectal adenoma and 
cancer among French women of the E3N-EPIC prospective study. Int J Cancer 2005, 
117:137-144. 
80. Feskanich D, Ma J, Fuchs CS, Kirkner GJ, Hankinson SE, Hollis BW, 
Giovannucci EL: Plasma vitamin D metabolites and risk of colorectal cancer in women. 
Cancer epidemiology, biomarkers & prevention : a publication of the American 
Association for Cancer Research, cosponsored by the American Society of Preventive 
Oncology 2004, 13:1502-1508. 
81. Levine AJ, Harper JM, Ervin CM, Chen YH, Harmon E, Xue S, Lee ER, Frankel 
HD, Haile RW: Serum 25-hydroxyvitamin D, dietary calcium intake, and distal colorectal 
adenoma risk. Nutr Cancer 2001, 39:35-41. 
82. Braun MM, Helzlsouer KJ, Hollis BW, Comstock GW: Colon cancer and serum 
vitamin D metabolite levels 10-17 years prior to diagnosis. Am J Epidemiol 1995, 
142:608-611. 
83. Pritchard RS, Baron JA, Gerhardsson de Verdier M: Dietary calcium, vitamin D, 
and the risk of colorectal cancer in Stockholm, Sweden. Cancer Epidemiol Biomarkers 
Prev 1996, 5:897-900. 
84. Wesa KM, Segal NH, Cronin AM, Sjoberg DD, Jacobs GN, Coleton MI, Fleisher 
M, Dnistrian AM, Saltz LB, Cassileth BR: Serum 25-hydroxy vitamin D and survival in 
advanced colorectal cancer: a retrospective analysis. Nutrition and cancer 2015, 67:424-
430. 
 223 
 
85. Mezawa H, Sugiura T, Watanabe M, Norizoe C, Takahashi D, Shimojima A, 
Tamez S, Tsutsumi Y, Yanaga K, Urashima M: Serum vitamin D levels and survival of 
patients with colorectal cancer: post-hoc analysis of a prospective cohort study. BMC 
cancer 2010, 10:347. 
86. Ng K, Sargent DJ, Goldberg RM, Meyerhardt JA, Green EM, Pitot HC, Hollis 
BW, Pollak MN, Fuchs CS: Vitamin D status in patients with stage IV colorectal cancer: 
findings from Intergroup trial N9741. Journal of clinical oncology : official journal of the 
American Society of Clinical Oncology 2011, 29:1599-1606. 
87. Otani T, Iwasaki M, Sasazuki S, Inoue M, Tsugane S: Plasma vitamin D and risk 
of colorectal cancer: the Japan Public Health Center-Based Prospective Study. Br J 
Cancer 2007, 97:446-451. 
88. Freedman DM, Looker AC, Chang SC, Graubard BI: Prospective study of serum 
vitamin D and cancer mortality in the United States. Journal of the National Cancer 
Institute 2007, 99:1594-1602. 
89. Skaaby T, Husemoen LL, Thuesen BH, Pisinger C, Jorgensen T, Roswall N, 
Larsen SC, Linneberg A: Prospective population-based study of the association between 
serum 25-hydroxyvitamin-D levels and the incidence of specific types of cancer. Cancer 
Epidemiol Biomarkers Prev 2014, 23:1220-1229. 
90. Ordonez-Mena JM, Schottker B, Haug U, Muller H, Kohrle J, Schomburg L, 
Holleczek B, Brenner H: Serum 25-hydroxyvitamin d and cancer risk in older adults: 
results from a large German prospective cohort study. Cancer Epidemiol Biomarkers 
Prev 2013, 22:905-916. 
91. Giovannucci E, Liu Y, Rimm EB, Hollis BW, Fuchs CS, Stampfer MJ, Willett 
WC: Prospective study of predictors of vitamin D status and cancer incidence and 
mortality in men. J Natl Cancer Inst 2006, 98:451-459. 
92. Abbas S, Chang-Claude J, Linseisen J: Plasma 25-hydroxyvitamin D and 
premenopausal breast cancer risk in a German case-control study. International journal of 
cancer 2009, 124:250-255. 
93. Garland CF, Gorham ED, Mohr SB, Grant WB, Giovannucci EL, Lipkin M, 
Newmark H, Holick MF, Garland FC: Vitamin D and prevention of breast cancer: pooled 
analysis. The Journal of steroid biochemistry and molecular biology 2007, 103:708-711. 
94. Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H: Meta-analysis: serum 
vitamin D and breast cancer risk. European journal of cancer (Oxford, England : 1990) 
2010, 46:2196-2205. 
95. Gandini S, Boniol M, Haukka J, Byrnes G, Cox B, Sneyd MJ, Mullie P, Autier P: 
Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and 
colorectal, breast and prostate cancer and colorectal adenoma. International Journal of 
Cancer 2011, 128:1414-1424. 
96. Chen P, Li M, Gu X, Liu Y, Li X, Li C, Wang Y, Xie D, Wang F, Yu C, et al: 
Higher blood 25(OH)D level may reduce the breast cancer risk: evidence from a Chinese 
population based case-control study and meta-analysis of the observational studies. PloS 
one 2013, 8:e49312. 
97. Kim Y, Je Y: Vitamin D intake, blood 25(OH)D levels, and breast cancer risk or 
mortality: a meta-analysis. British journal of cancer 2014, 110:2772-2784. 
98. Vrieling A, Seibold P, Johnson TS, Heinz J, Obi N, Kaaks R, Flesch-Janys D, 
Chang-Claude J: Circulating 25-hydroxyvitamin D and postmenopausal breast cancer 
 224 
 
survival: Influence of tumor characteristics and lifestyle factors? International journal of 
cancer 2014, 134:2972-2983. 
99. Rose AA, Elser C, Ennis M, Goodwin PJ: Blood levels of vitamin D and early 
stage breast cancer prognosis: a systematic review and meta-analysis. Breast Cancer Res 
Treat 2013, 141:331-339. 
100. Sperati F, Vici P, Maugeri-Sacca M, Stranges S, Santesso N, Mariani L, Giordano 
A, Sergi D, Pizzuti L, Di Lauro L, et al: Vitamin D supplementation and breast cancer 
prevention: a systematic review and meta-analysis of randomized clinical trials. PLoS 
One 2013, 8:e69269. 
101. Li M, Chen P, Li J, Chu R, Xie D, Wang H: Review: the impacts of circulating 
25-hydroxyvitamin D levels on cancer patient outcomes: a systematic review and meta-
analysis. J Clin Endocrinol Metab 2014, 99:2327-2336. 
102. Maalmi H, Ordonez-Mena JM, Schottker B, Brenner H: Serum 25-
hydroxyvitamin D levels and survival in colorectal and breast cancer patients: systematic 
review and meta-analysis of prospective cohort studies. Eur J Cancer 2014, 50:1510-
1521. 
103. Wang D, Velez de-la-Paz OI, Zhai JX, Liu DW: Serum 25-hydroxyvitamin D and 
breast cancer risk: a meta-analysis of prospective studies. Tumour Biol 2013, 34:3509-
3517. 
104. Bauer SR, Hankinson SE, Bertone-Johnson ER, Ding EL: Plasma vitamin D 
levels, menopause, and risk of breast cancer: dose-response meta-analysis of prospective 
studies. Medicine (Baltimore) 2013, 92:123-131. 
105. Hong Z, Tian C, Zhang X: Dietary calcium intake, vitamin D levels, and breast 
cancer risk: a dose-response analysis of observational studies. Breast Cancer Res Treat 
2012, 136:309-312. 
106. Mohr SB, Gorham ED, Alcaraz JE, Kane CJ, Macera CA, Parsons JK, Wingard 
DL, Garland CF: Serum 25-hydroxyvitamin D and prevention of breast cancer: pooled 
analysis. Anticancer Res 2011, 31:2939-2948. 
107. Chen P, Hu P, Xie D, Qin Y, Wang F, Wang H: Meta-analysis of vitamin D, 
calcium and the prevention of breast cancer. Breast Cancer Res Treat 2010, 121:469-477. 
108. Chung M, Lee J, Terasawa T, Lau J, Trikalinos TA: Vitamin D with or without 
calcium supplementation for prevention of cancer and fractures: an updated meta-analysis 
for the U.S. Preventive Services Task Force. Ann Intern Med 2011, 155:827-838. 
109. Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H: Meta-analysis: serum 
vitamin D and breast cancer risk. Eur J Cancer 2010, 46:2196-2205. 
110. Grant WB: Relation between prediagnostic serum 25-hydroxyvitamin D level and 
incidence of breast, colorectal, and other cancers. J Photochem Photobiol B 2010, 
101:130-136. 
111. Prentice RL, Pettinger MB, Jackson RD, Wactawski-Wende J, Lacroix AZ, 
Anderson GL, Chlebowski RT, Manson JE, Van Horn L, Vitolins MZ, et al: Health risks 
and benefits from calcium and vitamin D supplementation: Women's Health Initiative 
clinical trial and cohort study. Osteoporos Int 2013, 24:567-580. 
112. Peppone LJ, Huston AJ, Reid ME, Rosier RN, Zakharia Y, Trump DL, Mustian 
KM, Janelsins MC, Purnell JQ, Morrow GR: The effect of various vitamin D 
supplementation regimens in breast cancer patients. Breast Cancer Res Treat 2011, 
127:171-177. 
 225 
 
113. Jacot W, Firmin N, Roca L, Topart D, Gallet S, Durigova A, Mirr S, Abach L, 
Pouderoux S, D'Hondt V, et al: Impact of a tailored oral vitamin D supplementation 
regimen on serum 25-hydroxyvitamin D levels in early breast cancer patients: a 
randomized phase III study. Annals of Oncology : Official Journal of the European 
Society for Medical Oncology / ESMO 2016, 27:1235-1241. 
114. Shirazi L, Almquist M, Borgquist S, Malm J, Manjer J: Serum vitamin D 
(25OHD3) levels and the risk of different subtypes of breast cancer: A nested case–
control study. The Breast 2016, 28:184-190. 
115. Jamshidinaeini Y, Akbari ME, Abdollahi M, Ajami M, Davoodi SH: Vitamin D 
Status and Risk of Breast Cancer in Iranian Women: A Case-Control Study. J Am Coll 
Nutr 2016, 35:639-646. 
116. Sofi NY, Jain M, Kapil U, Seenu V, Kamal VK, Pandey RM: Nutritional risk 
factors and status of serum 25(OH)D levels in patients with breast cancer: A case control 
study in India. J Steroid Biochem Mol Biol 2018, 175:55-59. 
117. Eliassen AH, Warner ET, Rosner B, Collins LC, Beck AH, Quintana LM, Tamimi 
RM, Hankinson SE: Plasma 25-Hydroxyvitamin D and Risk of Breast Cancer in Women 
Followed over 20 Years. Cancer Res 2016, 76:5423-5430. 
118. Kim Y, Franke AA, Shvetsov YB, Wilkens LR, Cooney RV, Lurie G, Maskarinec 
G, Hernandez BY, Le Marchand L, Henderson BE, et al: Plasma 25-hydroxyvitamin D3 
is associated with decreased risk of postmenopausal breast cancer in whites: a nested 
case-control study in the multiethnic cohort study. BMC Cancer 2014, 14:29. 
119. Eliassen AH, Warner ET, Rosner B, Collins LC, Beck AH, Quintana LM, Tamimi 
RM, Hankinson SE: Plasma 25-Hydroxyvitamin D and Risk of Breast Cancer in Women 
Followed over 20 Years. Cancer research 2016, 76:5423-5430. 
120. Park S, Lee DH, Jeon JY, Ryu J, Kim S, Kim JY, Park HS, Kim SI, Park BW: 
Serum 25-hydroxyvitamin D deficiency and increased risk of breast cancer among 
Korean women: a case-control study. Breast Cancer Res Treat 2015, 152:147-154. 
121. Engel P, Fagherazzi G, Boutten A, Dupre T, Mesrine S, Boutron-Ruault MC, 
Clavel-Chapelon F: Serum 25(OH) vitamin D and risk of breast cancer: a nested case-
control study from the French E3N cohort. Cancer Epidemiol Biomarkers Prev 2010, 
19:2341-2350. 
122. Almquist M, Bondeson AG, Bondeson L, Malm J, Manjer J: Serum levels of 
vitamin D, PTH and calcium and breast cancer risk-a prospective nested case-control 
study. Int J Cancer 2010, 127:2159-2168. 
123. Crew KD, Gammon MD, Steck SE, Hershman DL, Cremers S, Dworakowski E, 
Shane E, Terry MB, Desai M, Teitelbaum SL, et al: Association between plasma 25-
hydroxyvitamin D and breast cancer risk. Cancer Prev Res (Phila) 2009, 2:598-604. 
124. Rejnmark L, Tietze A, Vestergaard P, Buhl L, Lehbrink M, Heickendorff L, 
Mosekilde L: Reduced prediagnostic 25-hydroxyvitamin D levels in women with breast 
cancer: a nested case-control study. Cancer Epidemiol Biomarkers Prev 2009, 18:2655-
2660. 
125. McCullough ML, Stevens VL, Patel R, Jacobs EJ, Bain EB, Horst RL, Gapstur 
SM, Thun MJ, Calle EE: Serum 25-hydroxyvitamin D concentrations and 
postmenopausal breast cancer risk: a nested case control study in the Cancer Prevention 
Study-II Nutrition Cohort. Breast Cancer Res 2009, 11:R64. 
 226 
 
126. Abbas S, Linseisen J, Slanger T, Kropp S, Mutschelknauss EJ, Flesch-Janys D, 
Chang-Claude J: Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer-
-results of a large case-control study. Carcinogenesis 2008, 29:93-99. 
127. Chlebowski RT, Johnson KC, Kooperberg C, Pettinger M, Wactawski-Wende J, 
Rohan T, Rossouw J, Lane D, O'Sullivan MJ, Yasmeen S, et al: Calcium plus vitamin D 
supplementation and the risk of breast cancer. J Natl Cancer Inst 2008, 100:1581-1591. 
128. Freedman DM, Chang SC, Falk RT, Purdue MP, Huang WY, McCarty CA, Hollis 
BW, Graubard BI, Berg CD, Ziegler RG: Serum levels of vitamin D metabolites and 
breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. 
Cancer Epidemiol Biomarkers Prev 2008, 17:889-894. 
129. Bertone-Johnson ER, Chen WY, Holick MF, Hollis BW, Colditz GA, Willett 
WC, Hankinson SE: Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk 
of breast cancer. Cancer Epidemiol Biomarkers Prev 2005, 14:1991-1997. 
130. Lowe LC, Guy M, Mansi JL, Peckitt C, Bliss J, Wilson RG, Colston KW: Plasma 
25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk 
in a UK Caucasian population. Eur J Cancer 2005, 41:1164-1169. 
131. Palmer JR, Gerlovin H, Bethea TN, Bertrand KA, Holick MF, Ruiz-Narvaez EN, 
Wise LA, Haddad SA, Adams-Campbell LL, Kaufman HW, et al: Predicted 25-
hydroxyvitamin D in relation to incidence of breast cancer in a large cohort of African 
American women. Breast Cancer Res 2016, 18:86. 
132. Yao S, Kwan ML, Ergas IJ, Roh JM, Cheng TD, Hong CC, McCann SE, Tang L, 
Davis W, Liu S, et al: Association of Serum Level of Vitamin D at Diagnosis With Breast 
Cancer Survival: A Case-Cohort Analysis in the Pathways Study. JAMA Oncol 2017, 
3:351-357. 
133. Acevedo F, Perez V, Perez-Sepulveda A, Florenzano P, Artigas R, Medina L, 
Sanchez C: High prevalence of vitamin D deficiency in women with breast cancer: The 
first Chilean study. Breast 2016, 29:39-43. 
134. Ordonez-Mena JM, Schottker B, Fedirko V, Jenab M, Olsen A, Halkjaer J, 
Kampman E, de Groot L, Jansen E, Bueno-de-Mesquita HB, et al: Pre-diagnostic vitamin 
D concentrations and cancer risks in older individuals: an analysis of cohorts 
participating in the CHANCES consortium. Eur J Epidemiol 2016, 31:311-323. 
135. Delage B, Dashwood RH: Dietary manipulation of histone structure and function. 
Annu Rev Nutr 2008, 28:347-366. 
136. Bonnesen C, Eggleston IM, Hayes JD: Dietary indoles and isothiocyanates that 
are generated from cruciferous vegetables can both stimulate apoptosis and confer 
protection against DNA damage in human colon cell lines. Cancer Res 2001, 61:6120-
6130. 
137. Hashem FA, Motawea H, El-Shabrawy AE, Shaker K, El-Sherbini S: Myrosinase 
hydrolysates of Brassica oleraceae L. var. italica reduce the risk of colon cancer. 
Phytother Res 2012, 26:743-747. 
138. Chung YK, Chi-Hung Or R, Lu CH, Ouyang WT, Yang SY, Chang CC: 
Sulforaphane down-regulates SKP2 to stabilize p27(KIP1) for inducing antiproliferation 
in human colon adenocarcinoma cells. J Biosci Bioeng 2015, 119:35-42. 
139. Frydoonfar HR, McGrath DR, Spigelman AD: Sulforaphane inhibits growth of a 
colon cancer cell line. Colorectal Dis 2004, 6:28-31. 
 227 
 
140. Shapiro TA, Fahey JW, Dinkova-Kostova AT, Holtzclaw WD, Stephenson KK, 
Wade KL, Ye L, Talalay P: Safety, tolerance, and metabolism of broccoli sprout 
glucosinolates and isothiocyanates: a clinical phase I study. Nutr Cancer 2006, 55:53-62. 
141. Clarke JD, Riedl K, Bella D, Schwartz SJ, Stevens JF, Ho E: Comparison of 
isothiocyanate metabolite levels and histone deacetylase activity in human subjects 
consuming broccoli sprouts or broccoli supplement. Journal of Agricultural and Food 
Chemistry 2011, 59:10955-10963. 
142. Connolly R, Stearns V: Epigenetics as a therapeutic target in breast cancer. 
Journal of mammary gland biology and neoplasia 2012, 17:191-204. 
143. Elsheikh SE, Green AR, Rakha EA, Powe DG, Ahmed RA, Collins HM, Soria D, 
Garibaldi JM, Paish CE, Ammar AA, et al: Global histone modifications in breast cancer 
correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer 
research 2009, 69:3802-3809. 
144. Ju YH, Carlson KE, Sun J, Pathak D, Katzenellenbogen BS, Katzenellenbogen 
JA, Helferich WG: Estrogenic effects of extracts from cabbage, fermented cabbage, and 
acidified brussels sprouts on growth and gene expression of estrogen-dependent human 
breast cancer (MCF-7) cells. Journal of Agricultural and Food Chemistry 2000, 48:4628-
4634. 
145. Kanematsu S, Uehara N, Miki H, Yoshizawa K, Kawanaka A, Yuri T, Tsubura A: 
Autophagy inhibition enhances sulforaphane-induced apoptosis in human breast cancer 
cells. Anticancer Research 2010, 30:3381-3390. 
146. Li Y, Zhang T, Korkaya H, Liu S, Lee H-F, Newman B, Yu Y, Clouthier SG, 
Schwartz SJ, Wicha MS, Sun D: Sulforaphane, a Dietary Component of 
Broccoli/Broccoli Sprouts, Inhibits Breast Cancer Stem Cells. Clin Cancer Res 2010, 
16:2580. 
147. Meeran SM, Patel SN, Li Y, Shukla S, Tollefsbol TO: Bioactive dietary 
supplements reactivate ER expression in ER-negative breast cancer cells by active 
chromatin modifications. PloS one 2012, 7:e37748. 
148. Yang M, Teng W, Qu Y, Wang H, Yuan Q: Sulforaphene inhibits triple negative 
breast cancer through activating tumor suppressor Egr1. Breast cancer research and 
treatment 2016, 158:277-286. 
149. Cornblatt BS, Ye L, Dinkova-Kostova AT, Erb M, Fahey JW, Singh NK, Chen 
MS, Stierer T, Garrett-Mayer E, Argani P, et al: Preclinical and clinical evaluation of 
sulforaphane for chemoprevention in the breast. Carcinogenesis 2007, 28:1485-1490. 
150. Society AC: Breast Cancer Facts and Figures 2017-18. 2017. 
151. Shi L, Nechuta S, Gao YT, Zheng Y, Dorjgochoo T, Wu J, Cai Q, Zheng W, Lu 
W, Shu XO: Correlates of 25-hydroxyvitamin D among Chinese breast cancer patients. 
PLoS One 2014, 9:e86467. 
152. Bjork A, Andersson A, Johansson G, Bjorkegren K, Bardel A, Kristiansson P: 
Evaluation of sun holiday, diet habits, origin and other factors as determinants of vitamin 
D status in Swedish primary health care patients: a cross-sectional study with regression 
analysis of ethnic Swedish and immigrant women. BMC Fam Pract 2013, 14:129. 
153. Bertrand KA, Rosner B, Eliassen AH, Hankinson SE, Rexrode KM, Willett W, 
Tamimi RM: Premenopausal plasma 25-hydroxyvitamin D, mammographic density, and 
risk of breast cancer. Breast Cancer Res Treat 2015, 149:479-487. 
 228 
 
154. Bodnar LM, Catov JM, Wisner KL, Klebanoff MA: Racial and seasonal 
differences in 25-hydroxyvitamin D detected in maternal sera frozen for over 40 years. Br 
J Nutr 2009, 101:278-284. 
155. Dudenkov DV, Yawn BP, Oberhelman SS, Fischer PR, Singh RJ, Cha SS, 
Maxson JA, Quigg SM, Thacher TD: Changing Incidence of Serum 25-Hydroxyvitamin 
D Values Above 50 ng/mL: A 10-Year Population-Based Study. Mayo Clin Proc 2015, 
90:577-586. 
156. Dimitrakopoulou VI, Tsilidis KK, Haycock PC, Dimou NL, Al-Dabhani K, 
Martin RM, Lewis SJ, Gunter MJ, Mondul A, Shui IM, et al: Circulating vitamin D 
concentration and risk of seven cancers: Mendelian randomisation study. Bmj 2017, 
359:j4761. 
157. de Sousa Almeida-Filho B, De Luca Vespoli H, Pessoa EC, Machado M, Nahas-
Neto J, Nahas EAP: Vitamin D deficiency is associated with poor breast cancer 
prognostic features in postmenopausal women. J Steroid Biochem Mol Biol 2017. 
158. Ma H, Lin H, Hu Y, Li X, He W, Jin X, Gao J, Zhao N, Liu Z, Gao X: Serum 25-
hydroxyvitamin D levels are associated with carotid atherosclerosis in normotensive and 
euglycemic Chinese postmenopausal women: the Shanghai Changfeng study. BMC 
Cardiovasc Disord 2014, 14:197. 
159. Lee JE, Li H, Chan AT, Hollis BW, Lee I-M, Stampfer MJ, Wu K, Giovannucci 
E, Ma J: Circulating Levels of Vitamin D and Colon and Rectal Cancer: The Physicians' 
Health Study and a Meta-analysis of Prospective Studies. Cancer Prevention Research 
2011, 4:735-743. 
160. Touvier M, Chan DSM, Lau R, Aune D, Vieira R, Greenwood DC, Kampman E, 
Riboli E, Hercberg S, Norat T: Meta-Analyses of Vitamin D Intake, 25-Hydroxyvitamin 
D Status, Vitamin D Receptor Polymorphisms, and Colorectal Cancer Risk. Cancer 
Epidemiology Biomarkers &amp; Prevention 2011, 20:1003-1016. 
161. Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H: Meta-analysis: 
longitudinal studies of serum vitamin D and colorectal cancer risk. Alimentary 
Pharmacology & Therapeutics 2009, 30:113-125. 
162. Yin L, Raum E, Haug U, Arndt V, Brenner H: Meta-analysis of longitudinal 
studies: Serum vitamin D and prostate cancer risk. Cancer Epidemiol 2009, 33:435-445. 
163. Bolland MJ, Grey A, Gamble GD, Reid IR: Calcium and vitamin D supplements 
and health outcomes: a reanalysis of the Women's Health Initiative (WHI) limited-access 
data set. The American Journal of Clinical Nutrition 2011, 94:1144-1149. 
164. Trivedi DP, Doll R, Khaw KT: Effect of four monthly oral vitamin 
D<sub>3</sub> (cholecalciferol) supplementation on fractures and mortality in men and 
women living in the community: randomised double blind controlled trial. BMJ 2003, 
326:469. 
165. Wactawski-Wende J, Kotchen JM, Anderson GL, Assaf AR, Brunner RL, 
O'Sullivan MJ, Margolis KL, Ockene JK, Phillips L, Pottern L, et al: Calcium plus 
vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006, 
354:684-696. 
166. Leermakers ET, Darweesh SK, Baena CP, Moreira EM, Melo van Lent D, 
Tielemans MJ, Muka T, Vitezova A, Chowdhury R, Bramer WM, et al: The effects of 
lutein on cardiometabolic health across the life course: a systematic review and meta-
analysis. Am J Clin Nutr 2016, 103:481-494. 
 229 
 
167. Borenstein MH, L. V.;  Higgins, J. P. T.;  Rothstein, H. R.: Introduction to Meta-
Analysis.2009. 
168. Petitti DB: Statistical methods in meat-analysis. In: Petitti DB. Ed. Meta-analysis. 
Decision Analysis, and cost-effectiveness analysis. 2nd ed. New York, NY: Oxford 
University Press; 2000. 
169. Carter P, Gray LJ, Troughton J, Khunti K, Davies MJ: Fruit and vegetable intake 
and incidence of type 2 diabetes mellitus: systematic review and meta-analysis. BMJ 
2010, 341:c4229. 
170. Egger M, Smith GD, Altman DG: Systematic Reviews in heatlh care: Meta-
analysis in context. 2nd ed. London. UK: the BMJ Publishing Group; 2001. 
171. Egger M, Smith GD, Schneider M, Minder C: Bias in meta-analysis detected by a 
simple, graphical test. BMJ 1997, 315:629-634. 
172. Begg CB, Mazumdar M: Operating characteristics of a rank correlation test for 
publication bias. Biometrics 1994, 50:1088-1101. 
173. Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected 
by a simple, graphical test. Bmj 1997, 315:629-634. 
174. STATA: Statistics/Data Analysis: Release 15.0. Texas: Stata Corporation; 2017. 
175. Peppone LJ, Rickles AS, Janelsins MC, Insalaco MR, Skinner KA: The 
association between breast cancer prognostic indicators and serum 25-OH vitamin D 
levels. Ann Surg Oncol 2012, 19:2590-2599. 
176. Yousef FM, Jacobs ET, Kang PT, Hakim IA, Going S, Yousef JM, Al-Raddadi 
RM, Kumosani TA, Thomson CA: Vitamin D status and breast cancer in Saudi Arabian 
women: case-control study. Am J Clin Nutr 2013, 98:105-110. 
177. Knight JA, Lesosky M, Barnett H, Raboud JM, Vieth R: Vitamin D and reduced 
risk of breast cancer: a population-based case-control study. Cancer Epidemiol 
Biomarkers Prev 2007, 16:422-429. 
178. Abbas S, Chang-Claude J, Linseisen J: Plasma 25-hydroxyvitamin D and 
premenopausal breast cancer risk in a German case-control study. Int J Cancer 2009, 
124:250-255. 
179. Bidgoli SA, Azarshab H: Role of vitamin D deficiency and lack of sun exposure 
in the incidence of premenopausal breast cancer: a case control study in Sabzevar, Iran. 
Asian Pac J Cancer Prev 2014, 15:3391-3396. 
180. Agborsangaya CB, Surcel HM, Toriola AT, Pukkala E, Parkkila S, Tuohimaa P, 
Lukanova A, Lehtinen M: Serum 25-hydroxyvitamin D at pregnancy and risk of breast 
cancer in a prospective study. Eur J Cancer 2010, 46:467-470. 
181. Eliassen AH, Spiegelman D, Hollis BW, Horst RL, Willett WC, Hankinson SE: 
Plasma 25-hydroxyvitamin D and risk of breast cancer in the Nurses' Health Study II. 
Breast Cancer Res 2011, 13:R50. 
182. Scarmo S, Afanasyeva Y, Lenner P, Koenig KL, Horst RL, Clendenen TV, Arslan 
AA, Chen Y, Hallmans G, Lundin E, et al: Circulating levels of 25-hydroxyvitamin D 
and risk of breast cancer: a nested case-control study. Breast Cancer Res 2013, 15:R15. 
183. Wang J, Eliassen AH, Spiegelman D, Willett WC, Hankinson SE: Plasma free 25-
hydroxyvitamin D, vitamin D binding protein, and risk of breast cancer in the Nurses' 
Health Study II. Cancer Causes Control 2014, 25:819-827. 
 230 
 
184. Robien K, Cutler GJ, Lazovich D: Vitamin D intake and breast cancer risk in 
postmenopausal women: the Iowa Women's Health Study. Cancer Causes Control 2007, 
18:775-782. 
185. McCullough ML, Rodriguez C, Diver WR, Feigelson HS, Stevens VL, Thun MJ, 
Calle EE: Dairy, calcium, and vitamin D intake and postmenopausal breast cancer risk in 
the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 
2005, 14:2898-2904. 
186. Crowther M, Avenell A, MacLennan G, Mowatt G: A further use for the Harvest 
plot: a novel method for the presentation of data synthesis. Res Synth Methods 2011, 
2:79-83. 
187. Ogilvie D, Fayter D, Petticrew M, Sowden A, Thomas S, Whitehead M, Worthy 
G: The harvest plot: a method for synthesising evidence about the differential effects of 
interventions. BMC Med Res Methodol 2008, 8:8. 
188. Segersten U, Holm PK, Bjorklund P, Hessman O, Nordgren H, Binderup L, 
Akerstrom G, Hellman P, Westin G: 25-Hydroxyvitamin D3 1alpha-hydroxylase 
expression in breast cancer and use of non-1alpha-hydroxylated vitamin D analogue. 
Breast Cancer Res 2005, 7:R980-986. 
189. Friedrich M, Rafi L, Mitschele T, Tilgen W, Schmidt W, Reichrath J: Analysis of 
the vitamin D system in cervical carcinomas, breast cancer and ovarian cancer. Recent 
Results Cancer Res 2003, 164:239-246. 
190. Neuhouser ML, Sorensen B, Hollis BW, Ambs A, Ulrich CM, McTiernan A, 
Bernstein L, Wayne S, Gilliland F, Baumgartner K, et al: Vitamin D insufficiency in a 
multiethnic cohort of breast cancer survivors. Am J Clin Nutr 2008, 88:133-139. 
191. Siegel R, Ma J, Zou Z, Jemal A: Cancer statistics, 2014. CA: a cancer journal for 
clinicians 2014, 64:9-29. 
192. Gulbake A, Jain A, Jain A, Jain A, Jain SK: Insight to drug delivery aspects for 
colorectal cancer. World J Gastroenterol 2016, 22:582-599. 
193. Dou R, Ng K, Giovannucci EL, Manson JE, Qian ZR, Ogino S: Vitamin D and 
colorectal cancer: molecular, epidemiological and clinical evidence. Br J Nutr 2016, 
115:1643-1660. 
194. Zhou S, Geng S, Glowacki J: Histone deacetylation mediates the rejuvenation of 
osteoblastogenesis by the combination of 25(OH)D3 and parathyroid hormone in MSCs 
from elders. J Steroid Biochem Mol Biol 2013, 136:156-159. 
195. Sharma S, Kelly TK, Jones PA: Epigenetics in cancer. Carcinogenesis 2010, 
31:27-36. 
196. Martin SL, Kala R, Tollefsbol TO: Mechanisms for inhibition of colon cancer 
cells by sulforaphane through epigenetic modulation of microRNA-21 and human 
telomerase reverse transcriptase (hTERT) down-regulation. Curr Cancer Drug Targets 
2017. 
197. Fearon ER: Molecular genetics of colorectal cancer. Annu Rev Pathol 2011, 
6:479-507. 
198. Jenuwein T, Allis CD: Translating the histone code. Science 2001, 293:1074-
1080. 
199. Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat 
Rev Genet 2002, 3:415-428. 
 231 
 
200. Arts J, de Schepper S, Van Emelen K: Histone deacetylase inhibitors: from 
chromatin remodeling to experimental cancer therapeutics. Curr Med Chem 2003, 
10:2343-2350. 
201. Prince HM, Bishton MJ, Harrison SJ: Clinical studies of histone deacetylase 
inhibitors. Clin Cancer Res 2009, 15:3958-3969. 
202. Minarini A, Milelli A, Fimognari C, Simoni E, Turrini E, Tumiatti V: Exploring 
the effects of isothiocyanates on chemotherapeutic drugs. Expert Opin Drug Metab 
Toxicol 2014, 10:25-38. 
203. Suppipat K, Park CS, Shen Y, Zhu X, Lacorazza HD: Sulforaphane induces cell 
cycle arrest and apoptosis in acute lymphoblastic leukemia cells. PLoS One 2012, 
7:e51251. 
204. Carlberg C, Polly P: Gene regulation by vitamin D3. Crit Rev Eukaryot Gene 
Expr 1998, 8:19-42. 
205. Polly P, Herdick M, Moehren U, Baniahmad A, Heinzel T, Carlberg C: VDR-
Alien: a novel, DNA-selective vitamin D(3) receptor-corepressor partnership. FASEB J 
2000, 14:1455-1463. 
206. Pereira LP, Silva P, Duarte M, Rodrigues L, Duarte CM, Albuquerque C, Serra 
AT: Targeting Colorectal Cancer Proliferation, Stemness and Metastatic Potential Using 
Brassicaceae Extracts Enriched in Isothiocyanates: A 3D Cell Model-Based Study. 
Nutrients 2017, 9. 
207. Larriba MJ, Ordonez-Moran P, Chicote I, Martin-Fernandez G, Puig I, Munoz A, 
Palmer HG: Vitamin D receptor deficiency enhances Wnt/beta-catenin signaling and 
tumor burden in colon cancer. PLoS One 2011, 6:e23524. 
208. Ferrer-Mayorga G, Gomez-Lopez G, Barbachano A, Fernandez-Barral A, Pena C, 
Pisano DG, Cantero R, Rojo F, Munoz A, Larriba MJ: Vitamin D receptor expression and 
associated gene signature in tumour stromal fibroblasts predict clinical outcome in 
colorectal cancer. Gut 2016. 
209. Bises G, Kallay E, Weiland T, Wrba F, Wenzl E, Bonner E, Kriwanek S, Obrist 
P, Cross HS: 25-hydroxyvitamin D3-1alpha-hydroxylase expression in normal and 
malignant human colon. J Histochem Cytochem 2004, 52:985-989. 
210. Barbachano A, Fernandez-Barral A, Ferrer-Mayorga G, Costales-Carrera A, 
Larriba MJ, Munoz A: The endocrine vitamin D system in the gut. Mol Cell Endocrinol 
2017, 453:79-87. 
211. Sun H, Wang C, Hao M, Sun R, Wang Y, Liu T, Cong X, Liu Y: CYP24A1 is a 
potential biomarker for the progression and prognosis of human colorectal cancer. Hum 
Pathol 2016, 50:101-108. 
212. Wood RJ, Tchack L, Taparia S: 1,25-Dihydroxyvitamin D3 increases the 
expression of the CaT1 epithelial calcium channel in the Caco-2 human intestinal cell 
line. BMC Physiol 2001, 1:11. 
213. Song Y, Peng X, Porta A, Takanaga H, Peng JB, Hediger MA, Fleet JC, 
Christakos S: Calcium transporter 1 and epithelial calcium channel messenger ribonucleic 
acid are differentially regulated by 1,25 dihydroxyvitamin D3 in the intestine and kidney 
of mice. Endocrinology 2003, 144:3885-3894. 
214. Van Cromphaut SJ, Dewerchin M, Hoenderop JG, Stockmans I, Van Herck E, 
Kato S, Bindels RJ, Collen D, Carmeliet P, Bouillon R, Carmeliet G: Duodenal calcium 
 232 
 
absorption in vitamin D receptor-knockout mice: functional and molecular aspects. Proc 
Natl Acad Sci U S A 2001, 98:13324-13329. 
215. Taparia S, Fleet JC, Peng JB, Wang XD, Wood RJ: 1,25-Dihydroxyvitamin D and 
25-hydroxyvitamin D--mediated regulation of TRPV6 (a putative epithelial calcium 
channel) mRNA expression in Caco-2 cells. Eur J Nutr 2006, 45:196-204. 
216. Bojang P, Jr., Ramos KS: The promise and failures of epigenetic therapies for 
cancer treatment. Cancer treatment reviews 2014, 40:153-169. 
217. Bestor TH: The DNA methyltransferases of mammals. Human molecular genetics 
2000, 9:2395-2402. 
218. Gardiner-Garden M, Frommer M: CpG islands in vertebrate genomes. Journal of 
Molecular Biology 1987, 196:261-282. 
219. Hinoue T, Weisenberger DJ, Lange CP, Shen H, Byun HM, Van Den Berg D, 
Malik S, Pan F, Noushmehr H, van Dijk CM, et al: Genome-scale analysis of aberrant 
DNA methylation in colorectal cancer. Genome research 2012, 22:271-282. 
220. Bird A: DNA methylation patterns and epigenetic memory. Genes & development 
2002, 16:6-21. 
221. Lao VV, Grady WM: Epigenetics and colorectal cancer. Nature 
reviewsGastroenterology & hepatology 2011, 8:686-700. 
222. Feinberg AP, Ohlsson R, Henikoff S: The epigenetic progenitor origin of human 
cancer. Nature reviewsGenetics 2006, 7:21-33. 
223. Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P, Cui H, Gabo 
K, Rongione M, Webster M, et al: The human colon cancer methylome shows similar 
hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nature 
genetics 2009, 41:178-186. 
224. Doi A, Park IH, Wen B, Murakami P, Aryee MJ, Irizarry R, Herb B, Ladd-Acosta 
C, Rho J, Loewer S, et al: Differential methylation of tissue- and cancer-specific CpG 
island shores distinguishes human induced pluripotent stem cells, embryonic stem cells 
and fibroblasts. Nature genetics 2009, 41:1350-1353. 
225. Jones PA, Taylor SM: Cellular differentiation, cytidine analogs and DNA 
methylation. Cell 1980, 20:85-93. 
226. Ghoshal K, Datta J, Majumder S, Bai S, Kutay H, Motiwala T, Jacob ST: 5-Aza-
deoxycytidine induces selective degradation of DNA methyltransferase 1 by a 
proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and 
nuclear localization signal. Molecular and cellular biology 2005, 25:4727-4741. 
227. Qin T, Youssef EM, Jelinek J, Chen R, Yang AS, Garcia-Manero G, Issa JP: 
Effect of cytarabine and decitabine in combination in human leukemic cell lines. Clinical 
cancer research : an official journal of the American Association for Cancer Research 
2007, 13:4225-4232. 
228. Munshi A, Shafi G, Aliya N, Jyothy A: Histone modifications dictate specific 
biological readouts. Journal of genetics and genomics = Yi chuan xue bao 2009, 36:75-
88. 
229. Gore SD, Weng LJ, Figg WD, Zhai S, Donehower RC, Dover G, Grever MR, 
Griffin C, Grochow LB, Hawkins A, et al: Impact of prolonged infusions of the putative 
differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute 
myeloid leukemia. Clinical cancer research : an official journal of the American 
Association for Cancer Research 2002, 8:963-970. 
 233 
 
230. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP: CpG island 
methylator phenotype in colorectal cancer. Proceedings of the National Academy of 
Sciences of the United States of America 1999, 96:8681-8686. 
231. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, 
Leary RJ, Ptak J, Silliman N, et al: The consensus coding sequences of human breast and 
colorectal cancers. Science 2006, 314:268-274. 
232. Karsli-Ceppioglu S, Dagdemir A, Judes G, Ngollo M, Penault-Llorca F, Pajon A, 
Bignon Y-J, Bernard-Gallon D: Epigenetic mechanisms of breast cancer: an update of the 
current knowledge. Epigenomics 2014, 6:651+. 
233. Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, 
Bussaglia E, Prat J, Harkes IC, Repasky EA, et al: Promoter hypermethylation and 
BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000, 
92:564-569. 
234. Costa FF, Verbisck NV, Salim AC, Ierardi DF, Pires LC, Sasahara RM, Sogayar 
MC, Zanata SM, Mackay A, O'Hare M, et al: Epigenetic silencing of the adhesion 
molecule ADAM23 is highly frequent in breast tumors. Oncogene 2004, 23:1481-1488. 
235. Sturgeon SR, Balasubramanian R, Schairer C, Muss HB, Ziegler RG, Arcaro KF: 
Detection of promoter methylation of tumor suppressor genes in serum DNA of breast 
cancer cases and benign breast disease controls. Epigenetics 2012, 7:1258-1267. 
236. Ruike Y, Imanaka Y, Sato F, Shimizu K, Tsujimoto G: Genome-wide analysis of 
aberrant methylation in human breast cancer cells using methyl-DNA 
immunoprecipitation combined with high-throughput sequencing. BMC Genomics 2010, 
11:137. 
237. Guendel I, Carpio L, Pedati C, Schwartz A, Teal C, Kashanchi F, Kehn-Hall K: 
Methylation of the tumor suppressor protein, BRCA1, influences its transcriptional 
cofactor function. PloS one 2010, 5:e11379. 
238. Choe MK, Hong CP, Park J, Seo SH, Roh TY: Functional elements demarcated 
by histone modifications in breast cancer cells. Biochemical and biophysical research 
communications 2012, 418:475-482. 
239. Hong CP, Choe MK, Roh TY: Characterization of Chromatin Structure-
associated Histone Modifications in Breast Cancer Cells. Genomics & informatics 2012, 
10:145-152. 
240. Karlic H, Varga F: Impact of vitamin D metabolism on clinical epigenetics. 
Clinical Epigenetics 2011, 2:55-61. 
241. Haussler MR, Jurutka PW, Mizwicki M, Norman AW: Vitamin D receptor 
(VDR)-mediated actions of 1alpha,25(OH)(2)vitamin D(3): genomic and non-genomic 
mechanisms. Best practice & researchClinical endocrinology & metabolism 2011, 
25:543-559. 
242. Haussler MR, Haussler CA, Jurutka PW, Thompson PD, Hsieh JC, Remus LS, 
Selznick SH, Whitfield GK: The vitamin D hormone and its nuclear receptor: molecular 
actions and disease states. The Journal of endocrinology 1997, 154 Suppl:57. 
243. Norman AW, Mizwicki MT, Norman DP: Steroid-hormone rapid actions, 
membrane receptors and a conformational ensemble model. Nature reviewsDrug 
discovery 2004, 3:27-41. 
 234 
 
244. Carlberg C: Mechanisms of nuclear signalling by vitamin D3. Interplay with 
retinoid and thyroid hormone signalling. European journal of biochemistry / FEBS 1995, 
231:517-527. 
245. Freedman LP: Transcriptional targets of the vitamin D3 receptor-mediating cell 
cycle arrest and differentiation. The Journal of nutrition 1999, 129:586S. 
246. Palmer HG, Gonzalez-Sancho JM, Espada J, Berciano MT, Puig I, Baulida J, 
Quintanilla M, Cano A, de Herreros AG, Lafarga M, Munoz A: Vitamin D(3) promotes 
the differentiation of colon carcinoma cells by the induction of E-cadherin and the 
inhibition of beta-catenin signaling. The Journal of cell biology 2001, 154:369-387. 
247. Vaquerizas JM, Kummerfeld SK, Teichmann SA, Luscombe NM: A census of 
human transcription factors: function, expression and evolution. Nature reviewsGenetics 
2009, 10:252-263. 
248. Carlberg C, Molnar F: Current status of vitamin D signaling and its therapeutic 
applications. Current topics in medicinal chemistry 2012, 12:528-547. 
249. Banwell CM, O'Neill LP, Uskokovic MR, Campbell MJ: Targeting 1alpha,25-
dihydroxyvitamin D3 antiproliferative insensitivity in breast cancer cells by co-treatment 
with histone deacetylation inhibitors. The Journal of steroid biochemistry and molecular 
biology 2004, 89-90:245-249. 
250. Hendrix I, Anderson P, May B, Morris H: Regulation of gene expression by the 
CYP27B1 promoter-study of a transgenic mouse model. The Journal of steroid 
biochemistry and molecular biology 2004, 89-90:139-142. 
251. Flicek P, Amode MR, Barrell D, Beal K, Billis K, Brent S, Carvalho-Silva D, 
Clapham P, Coates G, Fitzgerald S, et al: Ensembl 2014. Nucleic acids research 2014, 
42:749. 
252. Murayama A, Kim M, Yanagisawa J, Takeyama K, Kato S: Transrepression by a 
liganded nuclear receptor via a bHLH activator through co-regulator switching. The 
EMBO journal 2004, 23:1598-1608. 
253. Takeyama K, Kato S: The vitamin D3 1alpha-hydroxylase gene and its regulation 
by active vitamin D3. Bioscience, biotechnology, and biochemistry 2011, 75:208-213. 
254. Fetahu IS, Hobaus J, Kallay E: Vitamin D and the epigenome. Frontiers in 
physiology 2014, 5:164. 
255. Khorchide M, Lechner D, Cross HS: Epigenetic regulation of vitamin D 
hydroxylase expression and activity in normal and malignant human prostate cells. J 
Steroid Biochem Mol Biol 2005, 93:167-172. 
256. Kawashima H, Torikai S, Kurokawa K: Localization of 25-hydroxyvitamin D3 1 
alpha-hydroxylase and 24-hydroxylase along the rat nephron. Proceedings of the National 
Academy of Sciences of the United States of America 1981, 78:1199-1203. 
257. Pedersen JI, Shobaki HH, Holmberg I, Bergseth S, Bjorkhem I: 25-
Hydroxyvitamin D3-24-hydroxylase in rat kidney mitochondria. The Journal of 
biological chemistry 1983, 258:742-746. 
258. Sakaki T, Sawada N, Komai K, Shiozawa S, Yamada S, Yamamoto K, Ohyama 
Y, Inouye K: Dual metabolic pathway of 25-hydroxyvitamin D3 catalyzed by human 
CYP24. European journal of biochemistry / FEBS 2000, 267:6158-6165. 
259. Novakovic B, Sibson M, Ng HK, Manuelpillai U, Rakyan V, Down T, Beck S, 
Fournier T, Evain-Brion D, Dimitriadis E, et al: Placenta-specific methylation of the 
vitamin D 24-hydroxylase gene: implications for feedback autoregulation of active 
 235 
 
vitamin D levels at the fetomaternal interface. The Journal of biological chemistry 2009, 
284:14838-14848. 
260. Wjst M, Heimbeck I, Kutschke D, Pukelsheim K: Epigenetic regulation of 
vitamin D converting enzymes. The Journal of steroid biochemistry and molecular 
biology 2010, 121:80-83. 
261. Hobaus J, Fetahu IS, Khorchide M, Manhardt T, Kallay E: Epigenetic regulation 
of the 1,25-dihydroxyvitamin D3 24-hydroxylase (CYP24A1) in colon cancer cells. The 
Journal of steroid biochemistry and molecular biology 2013, 136:296-299. 
262. Hobaus J, Hummel DM, Thiem U, Fetahu IS, Aggarwal A, Mullauer L, Heller G, 
Egger G, Mesteri I, Baumgartner-Parzer S, Kallay E: Increased copy-number and not 
DNA hypomethylation causes overexpression of the candidate proto-oncogene CYP24A1 
in colorectal cancer. International journal of cancer 2013, 133:1380-1388. 
263. Norman AW: Intestinal calcium absorption: a vitamin D-hormone-mediated 
adaptive response. Am J Clin Nutr 1990, 51:290-300. 
264. Bolanz KA, Hediger MA, Landowski CP: The role of TRPV6 in breast 
carcinogenesis. Mol Cancer Ther 2008, 7:271-279. 
265. Bolanz KA, Kovacs GG, Landowski CP, Hediger MA: Tamoxifen inhibits 
TRPV6 activity via estrogen receptor-independent pathways in TRPV6-expressing MCF-
7 breast cancer cells. Mol Cancer Res 2009, 7:2000-2010. 
266. Dhennin-Duthille I, Gautier M, Faouzi M, Guilbert A, Brevet M, Vaudry D, 
Ahidouch A, Sevestre H, Ouadid-Ahidouch H: High expression of transient receptor 
potential channels in human breast cancer epithelial cells and tissues: correlation with 
pathological parameters. Cell Physiol Biochem 2011, 28:813-822. 
267. Herr I, Buchler MW: Dietary constituents of broccoli and other cruciferous 
vegetables: implications for prevention and therapy of cancer. Cancer treatment reviews 
2010, 36:377-383. 
268. Gupta SC, Kim JH, Prasad S, Aggarwal BB: Regulation of survival, proliferation, 
invasion, angiogenesis, and metastasis of tumor cells through modulation of 
inflammatory pathways by nutraceuticals. Cancer Metastasis Rev 2010, 29:405-434. 
269. Liska D, Lyon M, Jones DS: Detoxification and biotransformational imbalances. 
Explore (New York, NY) 2006, 2:122-140. 
270. Laso N, Mas S, Lafuente MJ, Llobet JM, Molina R, Ballesta A, Kensler TW, 
Lafuente A: Induction of NAD(P)H quinone oxidoreductase by vegetables widely 
consumed in Catalonia, Spain. Nutrition and cancer 2005, 52:49-58. 
271. Stubbins RE, Hakeem A, Nunez NP: Using components of the Vitamin D 
pathway to prevent/treat colon cancer. Nutrition reviews 2012, 70:721-729. 
272. Garland CF, Comstock GW, Garland FC, Helsing KJ, Shaw EK, Gorham ED: 
Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. Lancet 
(London, England) 1989, 2:1176-1178. 
273. Vandewalle B, Adenis A, Hornez L, Revillion F, Lefebvre J: 1,25-
dihydroxyvitamin D3 receptors in normal and malignant human colorectal tissues. 
Cancer letters 1994, 86:67-73. 
274. Pena C, Garcia JM, Garcia V, Silva J, Dominguez G, Rodriguez R, Maximiano C, 
Garcia de Herreros A, Munoz A, Bonilla F: The expression levels of the transcriptional 
regulators p300 and CtBP modulate the correlations between SNAIL, ZEB1, E-cadherin 
 236 
 
and vitamin D receptor in human colon carcinomas. International journal of cancer 2006, 
119:2098-2104. 
275. Larriba MJ, Martin-Villar E, Garcia JM, Pereira F, Pena C, de Herreros AG, 
Bonilla F, Munoz A: Snail2 cooperates with Snail1 in the repression of vitamin D 
receptor in colon cancer. Carcinogenesis 2009, 30:1459-1468. 
276. Larriba MJ, Valle N, Palmer HG, Ordonez-Moran P, Alvarez-Diaz S, Becker KF, 
Gamallo C, de Herreros AG, Gonzalez-Sancho JM, Munoz A: The inhibition of 
Wnt/beta-catenin signalling by 1alpha,25-dihydroxyvitamin D3 is abrogated by Snail1 in 
human colon cancer cells. Endocrine-related cancer 2007, 14:141-151. 
277. Zhou Y-Q, He C, Chen Y-Q, Wang D, Wang M-H: Altered expression of the 
RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation 
of different splicing RON variants and their oncogenic potential. Oncogene, 22:186-197. 
278. Slattery ML, Wolff RK, Curtin K, Fitzpatrick F, Herrick J, Potter JD, Caan BJ, 
Samowitz WS: Colon tumor mutations and epigenetic changes associated with genetic 
polymorphism: insight into disease pathways. Mutation research 2009, 660:12-21. 
279. Godman CA, Joshi R, Tierney BR, Greenspan E, Rasmussen TP, Wang HW, Shin 
DG, Rosenberg DW, Giardina C: HDAC3 impacts multiple oncogenic pathways in colon 
cancer cells with effects on Wnt and vitamin D signaling. Cancer biology & therapy 
2008, 7:1570-1580. 
280. Malinen M, Saramaki A, Ropponen A, Degenhardt T, Vaisanen S, Carlberg C: 
Distinct HDACs regulate the transcriptional response of human cyclin-dependent kinase 
inhibitor genes to Trichostatin A and 1alpha,25-dihydroxyvitamin D3. Nucleic acids 
research 2008, 36:121-132. 
281. Eisman JA, Martin TJ, MacIntyre I: Presence of 1,25-dihydroxy vitamin D 
receptor in normal and abnormal breast tissue. Progress in biochemical pharmacology 
1980, 17:143-150. 
282. Simboli-Campbell M, Narvaez CJ, van Weelden K, Tenniswood M, Welsh J: 
Comparative effects of 1,25(OH)2D3 and EB1089 on cell cycle kinetics and apoptosis in 
MCF-7 breast cancer cells. Breast cancer research and treatment 1997, 42:31-41. 
283. Marcinkowska E, Wallace GR, Brown G: The Use of 1╬▒,25-Dihydroxyvitamin 
D(3) as an Anticancer Agent. International Journal of Molecular Sciences 2016, 17:729. 
284. James SY, Mackay AG, Binderup L, Colston KW: Effects of a new synthetic 
vitamin D analogue, EB1089, on the oestrogen-responsive growth of human breast 
cancer cells. The Journal of endocrinology 1994, 141:555-563. 
285. Krishnan AV, Swami S, Peng L, Wang J, Moreno J, Feldman D: Tissue-selective 
regulation of aromatase expression by calcitriol: implications for breast cancer therapy. 
Endocrinology 2010, 151:32-42. 
286. Ching S, Kashinkunti S, Niehaus MD, Zinser GM: Mammary Adipocytes 
Bioactivate 25-hydroxyvitamin D(3) and Signal via Vitamin D(3) Receptor, Modulating 
Mammary Epithelial Cell Growth. Journal of cellular biochemistry 2011, 112:3393-3405. 
287. Vaisanen S, Dunlop TW, Sinkkonen L, Frank C, Carlberg C: Spatio-temporal 
activation of chromatin on the human CYP24 gene promoter in the presence of 
1alpha,25-Dihydroxyvitamin D3. Journal of Molecular Biology 2005, 350:65-77. 
288. Jensen SS, Madsen MW, Lukas J, Binderup L, Bartek J: Inhibitory effects of 
1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. Molecular 
endocrinology (Baltimore, Md) 2001, 15:1370-1380. 
 237 
 
289. James SY, Mackay AG, Colston KW: Effects of 1,25 dihydroxyvitamin D3 and 
its analogues on induction of apoptosis in breast cancer cells. The Journal of steroid 
biochemistry and molecular biology 1996, 58:395-401. 
290. Colston KW, Hansen CM: Mechanisms implicated in the growth regulatory 
effects of vitamin D in breast cancer. Endocrine-related cancer 2002, 9:45-59. 
291. Kotepui M: Diet and risk of breast cancer. Contemporary Oncology 2013, 20:13-
19. 
292. Yin TF, Wang M, Qing Y, Lin YM, Wu D: Research progress on 
chemopreventive effects of phytochemicals on colorectal cancer and their mechanisms. 
World J Gastroenterol 2016, 22:7058-7068. 
293. Clarke JD, Hsu A, Williams DE, Dashwood RH, Stevens JF, Ho E: Metabolism 
and tissue distribution of sulforaphane in Nrf2 knockout and wild-type mice. 
Pharmaceutical research 2011, 28:3171-3179. 
294. Yang CS, Smith TJ, Hong JY: Cytochrome P-450 enzymes as targets for 
chemoprevention against chemical carcinogenesis and toxicity: opportunities and 
limitations. Cancer research 1994, 54:1986s. 
295. Zhang Y, Kensler TW, Cho CG, Posner GH, Talalay P: Anticarcinogenic 
activities of sulforaphane and structurally related synthetic norbornyl isothiocyanates. 
Proceedings of the National Academy of Sciences of the United States of America 1994, 
91:3147-3150. 
296. Wang M, Qi YY, Chen S, Liu L, Chen J, Li YQ: The UGT1A, Nrf2 and Keap1 
protein expression and significance in colon tumor. Zhonghua nei ke za zhi 2012, 51:531-
535. 
297. Basten GP, Bao Y, Williamson G: Sulforaphane and its glutathione conjugate but 
not sulforaphane nitrile induce UDP-glucuronosyl transferase (UGT1A1) and glutathione 
transferase (GSTA1) in cultured cells. Carcinogenesis 2002, 23:1399-1404. 
298. Rajendran P, Dashwood WM, Li L, Kang Y, Kim E, Johnson G, Fischer KA, 
LÃ¶hr CV, Williams DE, Ho E, et al: Nrf2 status affects tumor growth, HDAC3 gene 
promoter associations, and the response to sulforaphane in the colon. Clinical Epigenetics 
2015, 7:y. 
299. Jakubikova J, Sedlak J, Mithen R, Bao Y: Role of PI3K/Akt and MEK/ERK 
signaling pathways in sulforaphane- and erucin-induced phase II enzymes and MRP2 
transcription, G2/M arrest and cell death in Caco-2 cells. Biochemical pharmacology 
2005, 69:1543-1552. 
300. Rajendran P, Delage B, Dashwood WM, Yu TW, Wuth B, Williams DE, Ho E, 
Dashwood RH: Histone deacetylase turnover and recovery in sulforaphane-treated colon 
cancer cells: competing actions of 14-3-3 and Pin1 in HDAC3/SMRT corepressor 
complex dissociation/reassembly. Mol Cancer 2011, 10:68. 
301. Shen G, Xu C, Chen C, Hebbar V, Kong AN: p53-independent G1 cell cycle 
arrest of human colon carcinoma cells HT-29 by sulforaphane is associated with 
induction of p21CIP1 and inhibition of expression of cyclin D1. Cancer chemotherapy 
and pharmacology 2006, 57:317-327. 
302. Kim DH, Sung B, Kang YJ, Hwang SY, Kim MJ, Yoon JH, Im E, Kim ND: 
Sulforaphane inhibits hypoxia-induced HIF-1alpha and VEGF expression and migration 
of human colon cancer cells. Int J Oncol 2015, 47:2226-2232. 
 238 
 
303. Erzinger MM, Bovet C, Hecht KM, Senger S, Winiker P, Sobotzki N, Cristea S, 
Beerenwinkel N, Shay JW, Marra G, et al: Sulforaphane Preconditioning Sensitizes 
Human Colon Cancer Cells towards the Bioreductive Anticancer Prodrug PR-104A. 
PLoS One 2016, 11:e0150219. 
304. Schneider Y, Vincent F, Duranton B, Badolo L, Gosse F, Bergmann C, Seiler N, 
Raul F: Anti-proliferative effect of resveratrol, a natural component of grapes and wine, 
on human colonic cancer cells. Cancer letters 2000, 158:85-91. 
305. Wolter F, Ulrich S, Stein J: Molecular mechanisms of the chemopreventive 
effects of resveratrol and its analogs in colorectal cancer: key role of polyamines? The 
Journal of nutrition 2004, 134:3219-3222. 
306. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of 
worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer 
2010, 127:2893-2917. 
307. Latte KP, Appel KE, Lampen A: Health benefits and possible risks of broccoli - 
an overview. Food and chemical toxicology : an international journal published for the 
British Industrial Biological Research Association 2011, 49:3287-3309. 
308. Gupta P, Wright SE, Kim SH, Srivastava SK: Phenethyl isothiocyanate: a 
comprehensive review of anti-cancer mechanisms. Biochimica et biophysica acta 2014, 
1846:405-424. 
309. Zhang Y, Tang L: Discovery and development of sulforaphane as a cancer 
chemopreventive phytochemical. Acta Pharmacologica Sinica 2007, 28:1343-1354. 
310. Dandawate PR, Subramaniam D, Jensen RA, Anant S: Targeting cancer stem 
cells and signaling pathways by phytochemicals: Novel approach for breast cancer 
therapy. Seminars in cancer biology 2016, 40-41:192-208. 
311. Gingras D, Gendron M, Boivin D, Moghrabi A, Theoret Y, Beliveau R: Induction 
of medulloblastoma cell apoptosis by sulforaphane, a dietary anticarcinogen from 
Brassica vegetables. Cancer letters 2004, 203:35-43. 
312. Singh AV, Xiao D, Lew KL, Dhir R, Singh SV: Sulforaphane induces caspase-
mediated apoptosis in cultured PC-3 human prostate cancer cells and retards growth of 
PC-3 xenografts in vivo. Carcinogenesis 2004, 25:83-90. 
313. Fimognari C, Nusse M, Berti F, Iori R, Cantelli-Forti G, Hrelia P: Cyclin D3 and 
p53 mediate sulforaphane-induced cell cycle delay and apoptosis in non-transformed 
human T lymphocytes. Cellular and molecular life sciences : CMLS 2002, 59:2004-2012. 
314. Riedl MA, Saxon A, Diaz-Sanchez D: Oral sulforaphane increases Phase II 
antioxidant enzymes in the human upper airway. Clinical immunology (Orlando, Fla) 
2009, 130:244-251. 
315. Schwab M, Reynders V, Loitsch S, Steinhilber D, Schroder O, Stein J: The 
dietary histone deacetylase inhibitor sulforaphane induces human beta-defensin-2 in 
intestinal epithelial cells. Immunology 2008, 125:241-251. 
316. Anwar-Mohamed A, El-Kadi AOS: Sulforaphane induces CYP1A1 mRNA, 
protein, and catalytic activity levels via an AhR-dependent pathway in murine hepatoma 
Hepa 1c1c7 and human HepG2 cells. Cancer letters 2009, 275:93-101. 
317. Kim SH, Singh SV: D,L-Sulforaphane causes transcriptional repression of 
androgen receptor in human prostate cancer cells. Molecular cancer therapeutics 2009, 
8:1946-1954. 
 239 
 
318. Wang X, Tomso DJ, Chorley BN, Cho HY, Cheung VG, Kleeberger SR, Bell 
DA: Identification of polymorphic antioxidant response elements in the human genome. 
Human molecular genetics 2007, 16:1188-1200. 
319. Dinkova-Kostova AT, Holtzclaw WD, Cole RN, Itoh K, Wakabayashi N, Katoh 
Y, Yamamoto M, Talalay P: Direct evidence that sulfhydryl groups of Keap1 are the 
sensors regulating induction of phase 2 enzymes that protect against carcinogens and 
oxidants. Proceedings of the National Academy of Sciences of the United States of 
America 2002, 99:11908-11913. 
320. Thimmulappa RK, Mai KH, Srisuma S, Kensler TW, Yamamoto M, Biswal S: 
Identification of Nrf2-regulated genes induced by the chemopreventive agent 
sulforaphane by oligonucleotide microarray. Cancer research 2002, 62:5196-5203. 
321. Kwak MK, Kensler TW: Targeting NRF2 signaling for cancer chemoprevention. 
Toxicology and applied pharmacology 2010, 244:66-76. 
 
